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“I am among those who think that science has great beauty. A scientist in his 
laboratory is not only a technician, he is also a child place before natural 
phenomenon, which impress him like a fairy tale.” 
 
 Marie Skłodowska Curie, Nobel Prize in Physics (1903) and Chemistry (1911). 
 
“Science and everyday life cannot and should not be separated” 
 
Rosalind Franklin, Nobel Prize in Chemistry (1982). 
 
“For a research worker the unforgotten moments of his life are those rare ones which 
come after years of plodding work, when the veil over natures secret seems suddenly 
to lift and when what was dark and chaotic appears in a clear and beautiful light and 
pattern.”  
Gerty Cori, Nobel Prize in in Physiology or Medicine (1947). 
 
 
“The first telescope opened the heavens; the first microscope opened the world of the 
microbes; radioisotopic methodology, as examplified by RIA [radioimmunoassay], has 
shown the potential for opening new vistas in science and medicine” 
   
 Rosalyn Yalow, Nobel Prize in Physiology or Medicine (1977).  
 
“Young people, especially young women, often ask me for advice. Here it is, valeat 
quantum. Do not undertake a scientific career in quest of fame or money. There are 
easier and better ways to reach them. Undertake it only if nothing else will satisfy 
you; for nothing else is probably what you will receive. Your reward will be the 
widening of the horizon as you climb. And if you achieve that reward you will ask no 
other.” 
 
Cecilia Payne-Gaposchkin, Henry Norris Russell Lectureship of the American 
Astronomical Society (1976). 
 
“It is imperfection - not perfection - that is the end result of the program written into 
that formidably complex engine that is the human brain, and of the influences 
exerted upon us by the environment and whoever takes care of us during the long 
years of our physical, psychological and intellectual development.” 
 
 Rita Levi-Montalcini, Nobel Prize in Medicine (1986). 
 
 
    “Different and diverse points of view make science stronger” 
 
 
Donna Strickland, Nobel Prize in Physics (2018). 
 
  
 
First quote included in the previous page belongs to Marie Skłodowska Curie - a 
researcher who gives her name to the prestigious scholarship that I have been able 
to enjoy. I felt that I need to include a bit of her knowledge in this work. She has 
been an example for me and was one out of very few women researchers that are 
recognized worldwide and throughout history excelled in science, technology, 
mathematics or engineering, leaving an important legacy. Many of them have 
remained in shade and battled against people who did not allow them to freely 
access education, to publish their research, people who prohibited them from 
obtaining funding or even those that allowed them to work in precarious conditions 
and without any support, because they were women. They had to fight against 
stereotypes to develop their research career. They have also contributed to 
numerous and important advances in science and their names are not well known. 
For this reason, this research work is especially dedicated to THEM, TO ALL THOSE 
WOMEN RESEARCHERS. Also, to those that will come, courageous and determined 
to take their rightful place in science and society. FOR WOMEN IN SCIENCE!
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ABSTRACT 
 
Introduction 
 
Dry eye disease (DED) is a multifactorial disease of the ocular surface considered 
one of the most frequently encountered ocular conditions seen by eye care 
practitioners. Nowadays, DED is estimated to affect between 5 − 50% of the worldwide 
population. Furthermore, the prevalence of DED increases linearly with age which makes 
DED a growing public health concern as the global population of older people is 
expected to be more than double its current amount by 2050. According to DED 
classification, the aqueous deficient dry eye (ADDE) and evaporative dry eye (EDE) are 
the two major DED types and are considered to exist on a continuum rather than as 
separate entities. Despite this, according to the current DED understanding, an 
evaporative component is more common than an ADDE component. Currently, the 
Meibomian gland dysfunction (MGD) is considered the leading cause of EDE. This 
condition may result in alteration of the tear film, symptoms of eye irritation, clinically 
apparent inflammation and ocular surface disease. Therefore, any change that occurs in 
the morphology of the MG or in its secretion has an important clinical impact.  
Recently, the non-contact infrared meibography (NIM) has become the most 
widely used tool for both researchers and clinicians for the assessment of the MG 
structure. Many studies have confirmed the use of this technology for diagnosis and 
management of MGD. Indeed, NIM allows the detection of MG abnormalities such as 
meibomian gland loss (MGL), shortening, dilation and distortion. The MGL or dropout 
refers to the partial or total loss of acinar tissue and it is one of the most common MG 
features reported in the literature.  Currently, there is no gold standard in the 
classification of MG assessed by NIM but most of them are based on the MGL. Previous 
studies found significant correlations between MGL and some tear film parameters 
(such as tear film break-up time (TBUT), non-invasive break-up time (NIBUT), lipid layer 
thickness (LLT), Schirmer test, MG expressibility and corneal staining) and subjective 
symptomatology (Ocular surface disease index questionnaire (OSDI) and McMonnies 
questionnaire), suggesting its possible diagnostic value. However, other studies 
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concluded that asses the MGL alone as clinical parameter has not enough DED 
diagnostic value, and it should be interpreted jointly with other clinical parameters.  
 Additionally, the multifactorial nature of the DED makes difficult for eye care 
practitioners to carry out a correct diagnosis and monitoring. For this reason, more 
objective, less invasive and more repeatable methods and technologies have been 
developed in order to obtain more valuable information for DED diagnosis.  
This dissertation is an in-depth work focused on the study of the MG structure 
revealed by NIM.  The main research goals of this work were: to assess the effect of 
ageing on the ocular surface parameters since it has been reported to be a risk and 
relevant factor for MG and the ocular surface. Also, to study the relationship between 
the MGL revealed by NIM and the ocular surface parameters in order to update MGD 
classification based on the MG structure. In addition, to study the relationship between 
new objective MG morphology parameters and the ocular surface parameters. Finally, 
to study and compare the thermal characteristics of DED and healthy subjects using 
infrared thermography.  
 
 Material and Methods 
 
In order to accomplish these objectives, a clinical protocol was designed that 
included a complete assessment of the ocular surface with classical tests both invasive 
and non-invasive, as well as some new technology for the ocular surface assessment. 
The following measurements were included: a clinical anamnesis; tear film osmolarity by 
TearLab Osmolarity System; automated measurements with the Keratograph 5M (K5M); 
ocular surface temperature (OST) using a non-contact infrared thermography camera; a 
slit lamp biomicroscope with ´10 magnification, cobalt blue illumination, a Wratten 12 
yellow-barrier filter and fluorescein sodium ophthalmic sterile strips were used to 
observe ocular surface staining and TBUT. Lissamine Green strips were used to assess lid 
wiper and the conjunctival staining. Additionally, an assessment of the eyelid was 
carried out. Furthermore, a meibography image of each eyelid was obtained using the 
K5M. Finally, the Schirmer test was performed with topical anaesthesia with the eye 
closed and after 5 minutes the length of the wetting was measured.  
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 Results 
This experimental work is organized into four independent studies. In the first 
study the clinical protocol explained above was applied monocularly to a total of 110 
participants (mean age; 44 ± 19 years, 70 females and 40 males) in order to study the 
first objective of this work. The main results of this study showed elderly population 
present ocular surface changes when compare to a young population. Although the 
majority of the ocular surface parameters studied presented a fair correlation with age, 
these results give us relevant information of the ageing of the ocular surface and how it 
could affect the DED diagnosis. Additionally, females from this study showed more 
changes due to ageing than males who presented better ocular surface conditions than 
those of their age- matched female group. 
In the second study a total of 161 participants were included (mean age; 42 ± 17 
years, 91 females and 70 males) whom were grouped according to the MGL graded 
using the subjective scale meiboscore introduced by Reiko Arita et al.2008. These groups 
were compared and the relationships between MGL and several ocular surface 
parameters were evaluated. In addition, age was included as covariant in the 
relationship between MGL and the ocular surface parameters since the mean age of the 
participants in this study was higher in those groups with higher MGL. The findings of 
this study suggest that a MGL higher than 50% is accompanied by signs of increased 
osmolarity, redness and staining of the ocular surface. Despite this, when age was 
included as a covariant only the corneal staining was correlated with MGL, emphasizing 
the influence of ageing on the MG morphology and also on several ocular surface 
parameters. Overall, these findings suggest that age-matched groups should be 
compared in order to know the contribution of the MGL on the ocular surface as well as 
establish a valid cut-off values for DED diagnosis.  
The third study of this doctoral thesis consisted of the use of an automated 
algorithm that analyses infrared images of the MG using image processing techniques 
(developed by the Department of Biomedical Engineering, Wroclaw University of Science 
and Technology, Wroclaw, Poland) to obtain objective information about the MG 
morphology. Several objective MG parameters such as the MGL, gland length, gland 
width and the gland irregularity (also named as tortuosity or MG distortion) were 
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extracted of a total of 149 meibography images from the everted upper eyelids (UL) 
from the second study of this work. The main results of this study showed that the 
majority of the objective MG morphology parameter, which were obtained with the 
automated algorithm (Objective MGL, length and width of the gland) are highly 
influenced by age. Therefore, their influence on the ocular surface should be assessed by 
comparing age-matched groups as previously described in the second study. Regarding 
MG irregularity, its role as a clinical parameter is not clear according to the findings of 
this study. Instead, it could be a prodromal sign of gland loss. Therefore, as long as the 
gland is not atrophied it will be functioning and the ocular surface will not be affected. 
The latest study involved the assessment of the OST of 86 participants (48 
healthy and 38 DED eyes, mean age; 39 ± 12 and 49 ± 19 years, respectively) using an 
infrared thermography camera. The OST of both groups was registered for 40 seconds, 
allowing subjects to blink naturally. Several OST metrics were proposed in order to study 
the OST changes during the recording, assessing the first and last complete interblink 
interval (IBI). The main results of this work showed slightly thermal differences between 
DED and healthy eyes as well as ADDE and EDE. These differences were not statistically 
significant when the complete thermal recording was assessed. Indeed, this could be 
explained since the OST could be regulated by the warming effect provided by the eyelid 
in each blink. These findings show that the evaluation of the thermal behaviour during 
the IBI could provide useful information about the thermal changes of the ocular surface 
in DED and healthy eyes.  
 
 Conclusions 
Summarizing, this research work provides a new knowledge about the MG 
morphology and its relationship with several important ocular surface parameters. This 
could help eye care professional to interpret and carry out a better the DED diagnosis. At 
the same time, the clinical utility of the infrared thermography to study the tear film 
dynamics has been used for the study of the tear film dynamics, especially in DED.  
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RESUMEN  
Introducción 
 
 
El ojo seco o síndrome de ojo seco (SOS) es una enfermedad multifactorial de la 
superficie ocular considerada como una de las afecciones oculares más frecuentes 
observadas por los profesionales de la visión en la práctica clínica. Hoy en día, se estima 
que el SOS afecta al 5-50% de la población mundial. Además, su prevalencia aumenta 
linealmente con la edad, lo que hace que el SOS sea un problema de salud pública 
creciente, ya que se espera un aumento del doble de la población mundial de personas 
ancianas para 2050. Según la clasificación del SOS, se pueden distinguir principalmente 
dos tipos: el ojo seco acuodeficiente, caracterizado por un déficit en la capa acuosa de la 
película lagrimal y el ojo seco evaporativo, el cual se caracteriza por una alteración en la 
evaporación de esta. A pesar de esta diferenciación, recientemente se ha observado que 
ambos tipos de SOS pueden coexistir simultáneamente, aunque el componente 
evaporativo tiende a ser el más común. Actualmente, la disfunción de las glándulas de 
meibomio (DGM) se considera la causa principal de la SOS evaporativo. Esta condición 
puede provocar alteración de la película lagrimal, síntomas de irritación ocular, 
inflamación clínicamente aparente y enfermedad de la superficie ocular. Por lo tanto, 
cualquier cambio que se produzca en la morfología o en la secreción de las glándulas 
puede tener un impacto clínico importante. 
Actualmente, la meibografía infrarroja se ha convertido en la herramienta más 
utilizada por investigadores y por clínicos para la evaluación in vivo de la estructura de 
las glándulas de meibomio. Muchos estudios han confirmado el uso de esta tecnología 
para el diagnóstico y manejo de la DGM. De hecho, la meibografía infrarroja permite la 
detección y evaluación de diferentes anomalías de las glándulas de meibomio, como la 
pérdida del tejido glandular (o también comúnmente denominado como dropout), el 
acortamiento, dilatación y la tortuosidad de estas. Concretamente, el dropout se refiere 
a la pérdida parcial o total del tejido glandular y es una de las características 
morfológicas más evaluada en la literatura científica relacionada con el diagnóstico de 
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SOS y DGM. En la actualidad, no existe un método de cuantificación de referencia y/o 
clasificación del dropout basada en la meibografía infrarroja, pudiendo realizarse de 
forma subjetiva utilizando diferentes escalas, semiautomáticamente con la ayuda de un 
software para delimitar el área deseada o en algunos casos, de forma automática 
mediante softwares basados en análisis y procesado de imagen. Estudios previos han 
encontrado que el dropout se correlaciona de forma significativa con algunos 
parámetros de la película lagrimal como el tiempo de ruptura de la película lagrimal 
invasiva y no invasiva, el espesor de la capa lipídica, el test de Schirmer, la expresividad 
de las glándulas, la tinción corneal e incluso con la sintomatología subjetiva 
(cuestionarios comúnmente utilizados como el Ocular surface disease index (OSDI) y el 
cuestionario McMonnies), lo que sugiere su posible valor diagnóstico. Sin embargo, 
otros estudios concluyen que el área de dropout solo como parámetro clínico no tiene 
suficiente valor diagnóstico y debe interpretarse junto con otros parámetros clínicos. 
Además, la naturaleza multifactorial del SOS dificulta a los profesionales de la visión 
realizar un correcto diagnóstico y manejo de esta condición. Por esta razón, se han 
desarrollado nuevos métodos y tecnologías más objetivas, menos invasivas y más 
repetibles para obtener información válida para el diagnóstico de SOS. 
Este trabajo de investigación esta centrado en el estudio de la estructura de las 
glándulas de meibomio mediante la utilización de meibografía infrarroja. Los principales 
objetivos son los siguientes: el primer objetivo pasa por evaluar el efecto del 
envejecimiento en los parámetros de la superficie ocular, ya que se ha reportado que es 
un factor relevante tanto para las glándulas de meibomio como para la superficie ocular. 
El segundo objetivo consiste en estudiar la relación entre el área de dropout (observada 
mediante meibografía infrarroja y cuantificada subjetivamente) y los parámetros de la 
superficie ocular. El tercer objetivo consiste en estudiar la relación entre los nuevos 
parámetros morfológicos de las glándulas de meibomio (como el área de dropout 
objetivo, longitud, anchura e irregularidad de la glándula) y los parámetros de la 
superficie ocular. Finalmente, el cuarto objetivo consiste en estudiar y comparar las 
características térmicas de ojos sanos y ojos que sufren de SOS mediante el uso de 
termografía infrarroja. 
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Material y Métodos 
 
Para llevar a cabo estos objetivos, se diseñó un protocolo clínico que incluía una 
evaluación completa de la superficie ocular y sus componentes, incluyendo pruebas de 
diagnóstico clásicas y también nuevas tecnologías para la evaluación de la superficie 
ocular tanto invasivas como no invasivas. Se procedió a realizar las siguientes medidas 
(de menos invasivo a más invasivo): elaboración y análisis de la historia clínica del 
participante; osmolaridad de la película lagrimal medida con el dispositivo TearLab; 
medidas no invasivas de la superficie ocular con el dispositivo Keratograph 5M (K5M); 
temperatura de la superficie ocular (TSO) utilizando una cámara termográfica; 
evaluación completa de los diferentes componentes de la superficie ocular mediante 
biomicroscopía. Para ello, la lámpara fue configurada con un aumento de ´10 con luz 
difusa para una observación general y aumentos más altos para observar con más 
detalle partes como por ejemplo el borde del párpado y los orificios glandulares. 
También se utilizó la iluminación azul cobalto, filtro amarillo Wratten 12 y tiras de 
fluoresceína y verde lisamina para observar la integridad de la córnea, conjuntiva, 
párpados y la estabilidad de la película lagrimal. Posteriormente a esta evaluación, se 
obtuvo una imagen de meibografía de cada párpado utilizando la cámara infrarroja 
incorporada en el K5M. Finalmente, la prueba de Schirmer se realizó con anestesia 
tópica durante 5 minutos con el ojo cerrado. 
 
Resultados 
 
Este trabajo experimental está organizado en cuatro estudios de investigación 
independientes. Para llevar a cabo el primer objetivo, el protocolo clínico mencionado 
anteriormente fue aplicado monocularmente a un total de 110 participantes (edad 
media; 44 ± 19 años, 70 mujeres y 40 hombres). Los principales resultados de este 
estudio mostraron que la población anciana presenta cambios en la superficie ocular en 
comparación con una población joven. Aunque la mayoría de los parámetros de la 
superficie ocular estudiados presentaron una justa correlación con la edad, estos 
resultados nos brindan información relevante sobre el envejecimiento de la superficie 
ocular y cómo podría afectar al diagnóstico de SOS. Además, las mujeres de este estudio 
 XII 
 
mostraron más cambios debido al envejecimiento en comparación a los hombres, los 
cuales presentaron una mejor condición de la superficie ocular.  
En el segundo estudio se incluyeron un total de 161 participantes (edad media; 
42±17 años, 91 mujeres y 70 hombres) que se agruparon en cinco grupos según el área 
de dropout mostrado (total meiboscore) de acuerdo con la escala de cuantificación 
subjetiva introducida por Reiko Arita y colaboradores en 2008. Estos grupos se 
compararon y se evaluó la relación entre el área de dropout y varios parámetros 
relevantes de la superficie ocular. Posteriormente, la edad se incluyó como covariante 
en esta relación ya que la edad media de los participantes de este estudio fue mayor en 
aquellos grupos con mayor área de dropout. Los hallazgos de este estudio sugieren que 
un área de dropout superior al 50% se acompaña de signos en la superficie ocular, como 
por ejemplo un incremento en la osmolaridad, enrojecimiento ocular y tinción corneal y 
conjuntival. A pesar de ello, cuando la edad fue incluida como covariante, solo la tinción 
corneal se correlacionó con el área de dropout, enfatizando la influencia del 
envejecimiento en la morfología de las glándulas de meibomio, pero también en varios 
parámetros de la superficie ocular. En general, estos hallazgos sugieren que para 
conocer la contribución o influencia del área de dropout como parámetro para el 
diagnóstico de SOS es necesario la comparación entre grupos de la misma edad para 
poder establecer valores de corte válidos para el diagnóstico.  
Para el tercer estudio de esta tesis doctoral, fue utilizado un nuevo algoritmo 
basado en procesado de imagen (desarrollado por el Departamento de Ingeniería 
Biomédica, Wroclaw University of Science and Technology, Wroclaw (Polonia)) que 
analiza de forma automática las meibografías para obtener información objetiva sobre la 
morfología de las glándulas de meibomio. Se extrajeron varios parámetros objetivos de 
la glándula como el área de dropout objetivo, la longitud, la anchura y la irregularidad de 
la glándula (también llamada tortuosidad o distorsión) de un total de 149 meibografías 
del párpado superior obtenidas previamente. Los principales resultados de este estudio 
mostraron que la mayoría de los parámetros morfológicos objetivos de las glándulas de 
meibomio obtenidos con el algoritmo están también influenciados por la edad y, por 
tanto, su influencia en la superficie ocular debe evaluarse comparando grupos de la 
misma edad tal como se ha mencionado previamente en el segundo estudio. En relación 
con la irregularidad de la glándula como parámetro, este estudio sugiere que podría 
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representar la etapa prodrómica antes de perder la glándula. Por lo tanto, significa que 
mientras la glándula esté todavía presente, esta seguirá funcionando y solo en presencia 
de una gran cantidad de dropout, la superficie ocular se verá realmente afectada. 
El último estudio de esta tesis se llevó a cabo la evaluación de la TSO de 86 
participantes (48 ojos sanos y 38 SOS, edad media; 39±12 y 49±19 años, 
respectivamente) utilizando una cámara termográfica. La TSO de ambos grupos se 
registró durante 40 segundos mientras los participantes parpadeaban de forma natural 
mirando a la cámara. Varias métricas de temperatura fueron extraídas para estudiar los 
cambios de la TSO durante los 40 segundos completos de grabación térmica pero 
también en el primer y último intervalo completo de parpadeo. Los principales 
resultados de este trabajo mostraron que los ojos con SOS y los ojos sanos, así como los 
participantes con ojo seco acuodeficientes y evaporativo presentaban ligeras diferencias 
térmicas, aunque estas no fueron estadísticamente significativas. Esto podría deberse a 
la regulación térmica ejercida por el párpado en cada parpadeo. A la luz de estos 
hallazgos, la evaluación del comportamiento térmico durante el intervalo de parpadeo 
podría proporcionar información útil sobre los cambios térmicos de la superficie ocular 
en SOS y en ojos sanos. 
 
Conclusiones 
 
En resumen, este trabajo de investigación proporciona nuevos conocimientos 
sobre la morfología de las glándulas de meibomio y su relación con parámetros 
relevantes de la superficie ocular que podrían ayudar al profesional de la visión a 
interpretar y llevar a cabo un mejor diagnóstico del SOS. Al mismo tiempo, en este 
estudio se ha demostrado la utilidad clínica de la termografía infrarroja para el estudio 
de la dinámica de la película lagrimal y en especial en esta condición multifactorial.   
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ABSTRAKT 
 
Zespół suchego oka (ZSO) jest wieloczynnikowym schorzeniem powierzchni 
ocznej i jedną z najczęściej obserwowanych w praktyce klinicznej dolegliwości 
okulistycznych. Obecnie szacuje się, że ZSO dotyka od 5 do 50% światowej populacji. 
Ponadto, zachorowalność na ZSO wzrasta liniowo z wiekiem. Szacuje się, iż populacja 
osób starszych ulegnie do 2050 roku podwojeniu, przez co ZSO może stać się znaczącym 
problem zdrowia publicznego. Zgodnie z przyjętą ogólnie klasyfikacją, podtyp ZSO 
związany z niedostatecznym wydzielaniem warstwy wodnej filmu łzowego (ang. aqueous 
deficient) oraz podtyp związany z nadmiernym jego parowaniem (ang. evaporative) są 
dwoma najbardziej powszechnymi rodzajami ZSO, które nierzadko są współistniejące. 
Badania naukowe pokazują, że ZSO spowodowane zwiększonym parowaniem łez 
występuje częściej niż pozostałe typy. Obecnie uważa się, że za ten podtyp odpowiada w 
dużej mierze dysfunkcja gruczołów Meiboma (ang. Meibomian gland dysfunction, MGD). 
Dysfunkcja ta powoduje zaburzenia filmu łzowego, podrażnienie, stan zapalny i chorobę 
powierzchni oka. Stąd też, każda zmiana zachodząca w morfologii gruczołów Meiboma 
lub w ich zdolności wydzielniczej ma duże znaczenie kliniczne. 
Bezkontaktowa meibografia w świetle podczerwonym (ang. non-contact infrared 
meibography, NIM) jest najczęściej używaną techniką oceny i wizualizacji gruczołów 
Meiboma. Badania naukowe potwierdzają przydatność tej metody w diagnostyce i 
ocenie postępów terapii MGD. NIM pozwala na wykrywanie anomalii gruczołów 
Meiboma tj. ubytki (ang. Meibomian gland loss, MGL), ich skrócenie, rozszerzenie lub 
zniekształcenie. MGL spowodowane jest zanikiem (częściowym lub całkowitym) tkanki 
gruczołowej i jest najczęściej raportowaną w literaturze zmianą zachodzącą w tych 
gruczołach. Obecnie nie ma ustandaryzowanej metody klasyfikacji MG przy pomocy 
NIM, jednakże większość prezentowanych w literaturze skali opiera się na parametrze 
MGL. Poprzednie badania wykazały znaczące korelacje między MGL i parametrami 
określającymi jakość filmu łzowego, tj. czas przerwania filmu łzowego mierzony 
nieinwazyjnie i z użyciem fluoresceiny, grubość warstwy lipidowej filmu łzowego, wynik 
testu Schirmera, wysięk z gruczołów Meiboma, czy uszkodzenie nabłonka rogówki, a 
także między subiektywnymi wrażeniami pacjentów (mierzonymi przy pomocy 
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kwestionariuszy OSDI lub McMonnies’a). Wszystkie te korelacje sugerują diagnostyczną 
wartość parametru MGL. Mimo to, badania naukowe pokazują, iż samo MGL nie 
wystarczy jako kliniczny marker ZSO i musi być zawsze interpretowane w oparciu o inne 
zmienne. Dodatkowo, wieloczynnikowa natura ZSO utrudnia specjalistom ochrony 
wzroku szybką i poprawną diagnostykę i monitorowanie przebiegu choroby. Z tego 
powodu istnieje zapotrzebowanie na obiektywne, mniej inwazyjne i bardziej 
powtarzalne metody pomiaru. Nowe technologie powstają by sprostać temu 
zapotrzebowaniu. 
Niniejsza praca doktorska opiera się na obserwacji gruczołów Meiboma przy 
pomocy NIM, a jej głównym celem jest: 
• ocena wpływu starzenia na powierzchnię oka w kontekście gruczołów 
Meiboma; 
• ocena zależności pomiędzy nowymi, obiektywnymi metodami oceny 
morfologii gruczołów Meiboma a innymi klinicznymi parametrami 
opisującymi powierzchnię oka; 
• ocena i porównanie charakterystyk termalnych powierzchni oka u 
pacjentów z ZSO i zdrowych pacjentów przy pomocy termografii 
podczerwonej.   
W tym celu przygotowano protokół kliniczny zawierający pełną procedurę oceny 
powierzchni oka, uzupełnioną o nowe metody. Protokół ten zawiera: wywiad lekarski; 
pomiar osmolarności łez przy pomocy osmometru TearLab Osmolarity System; 
automatyczne pomiary jakości filmu łzowego przy pomocy wielofunkcyjnego keratografu 
Keratograph 5M (K5M); pomiar temperatury powierzchni oka przy pomocy 
bezkontaktowej termografii podczerwonej; ocena powierzchni oka przy pomocy 
biomikroskopu z lampą szczelinową; pomiary barwienia rogówki i spojówki oraz czasu 
przerwania filmu łzowego przy użyciu fluorescein oraz barwienie powierzchni oka i 
tarczki powiekowej zielenią lizaminową. Dodatkowo przeprowadzono ocenę zdrowia 
powiek. Dla każdej powieki wykonano też NIM przy pomocy K5M. Na koniec wykonano 
5-minutowy test Schirmera w znieczuleniu miejscowym i przy zamkniętych oczach. 
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Część eksperymentalna niniejszej pracy podzielona została na cztery niezależne badania.  
W pierwszym z nich zastosowano przedstawiony powyżej protokół kliniczny, zaś udział w 
badaniu wzięło 110 uczestników (70 kobiet i 40 mężczyzn) w wieku (średnia ± odchylenie 
standardowe) 44 ± 19 lat. Pomiary wykonano na jednym oku u każdego z pacjentów. 
Niniejszy eksperyment pokazuje, iż w populacji osób starszych występuje więcej 
negatywnych zmian na powierzchni oka niż w grupie osób młodych. Większość 
parametrów wykazała silną korelację z wiekiem. Niniejszy eksperyment pokazuje wpływ 
wieku na powierzchnię oka i jej związek z ZSO. Dodatkowo, grupa kobiet wykazała więcej 
zmian na powierzchni oka spowodowanych wiekiem niż odpowiadająca im grupa 
mężczyzn. 
W drugim badaniu wzięło udział 161 uczestników (91 kobiet i 70 mężczyzn) w 
wieku (średnia ± odchylenie standardowe) 42 ± 17 lat, którzy zostali pogrupowaniu 
według parametru MGL, mierzonego skalą meiboscore zaproponowaną przez Reiko Arita 
et al. w 2008 roku. Dokonano porównania pomiędzy wyróżnionymi grupami oraz 
obserwowano korelacje klinicznych miar zdrowia powierzchni oka z MGL. Grupę o 
wyższym MGL cechowała wyższa średnia wiekowa, toteż w analizie uwzględniono wiek 
uczestników. Wyniki niniejszego badania wskazują, iż parametrowi MGL wyższemu niż 
50% towarzyszy zwiększona osmolarność, zaczerwienienie oraz mierzalne uszkodzenie 
nabłonka powierzchni ocznej. Zauważono także, iż określając ubytki MGL i ich wpływ na 
powierzchnię oka, a także przy ustalaniu wartości odcięcia w diagnostyce ZSO, powinno 
się uwzględniać różne grupy wiekowe.  
W eksperymencie trzecim użyto automatycznego algorytmu do analizy obrazów 
zarejestrowanych przy pomocy NIM. Algorytm ten został opracowany w Katedrze 
Inżynierii Biomedycznej Politechniki Wrocławskiej w celu obiektywnej oceny morfologii 
gruczołów Meiboma. Uwzględniono w nim kilka różnych obiektywnych miar, tj. MGL, 
długość i szerokość gruczołów oraz nieregularność ich kształtu. W badaniu 
przeanalizowano 149 obrazów przedstawiających wywinięte powieki górne uczestników 
poprzedniego eksperymentu. Niniejsze badanie pokazuje, iż większość parametrów 
zmierzona automatycznym algorytmem jest silnie skorelowana z wiekiem, zatem ich 
wpływ na powierzchnię oka powinien być zawsze rozpatrywany w oparciu o wiek. W 
niniejszych badaniach wykazano także, że nieregularność gruczołów Meiboma może być 
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prodromem MGL. Gruczoł Meiboma będzie dalej funkcjonował niezależnie od kształtu, a 
dopiero znaczny wzrost MGL będzie miał wpływ na powierzchnię oka. 
W ostatnim z przeprowadzonych eksperymentów wzięło udział 86 uczestników: 
48 oczu zdrowych i 38 oczu z ZSO, w średnim wieku odpowiednio (średnia ± odchylenie 
standardowe) 39 ± 12 lat oraz 49 ± 19 lat. W eksperymencie zmierzono temperaturę 
powierzchni oka przy pomocy termografii podczerwonej. Temperatura rejestrowana 
była przez okres 40 sekund, w trakcie których uczestnicy mogli swobodnie mrugać. 
Niniejsze badanie nie wykazało różnic w rozkładzie termalnym powierzchni oka na 
przestrzeni 40 sekund pomiędzy osobami zdrowymi i z ZSO oraz pomiędzy osobami z 
dwoma podtypami ZSO. Niniejsze zjawisko da się wytłumaczyć w oparciu o wpływ 
ciepłoty powiek na temperaturę powierzchni oka podczas mrugania.  W oparciu o te 
wyniki można zauważyć, że pomiary temperatury powierzchni ocznej pomiędzy 
mrugnięciami będą miały większe znaczenie kliniczne w diagnozie ZSO. 
 Podsumowując, niniejsza praca doktorska przyczynia się do poszerza stanu 
wiedzy na temat morfologii gruczołów Meiboma i jej związku ze zdrowiem powierzchni 
oka. Parametry je określające są niezwykle przydatne w diagnostyce i prowadzeniu 
terapii ZSO. Dodatkowo, w niniejszej pracy, wykazano kliniczną przydatność termografii 
podczerwonej. 
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ABBREVIATIONS 
 
o AC: Allergic Conjunctivitis 
o ADDE: Aqueous Deficient Dry Eye 
o BR: Bulbar Redness 
o CCD: Charge Coupled Device 
o CL: Contact Lens 
o CLAC: Contact Lens Related Allergic Conjunctivitis 
o CLD: Contact Lens Discomfort 
o DED: Dry Eye Disease 
o DEQ: Dry Eye Questionnaire 
o DEQ-5: Dry Eye Questionnaire (short-version) 
o DEQS: Dry Eye-Related Quality-of-Life Score 
o DEWS I: First International Dry Eye Workshop (2007) 
o DEWS II: Second International Dry Eye Workshop (2017) 
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Chapter 1 
Introduction 
 
 
 
The purpose of this introduction is to provide a wide background about several aspects of 
the ocular surface. 
 
 
1.1 THE OCULAR SURFACE 
 
 
The ocular surface is considered a well-integrated unit composed by the cornea, 
conjunctiva, lacrimal glands and eyelids that are interconnected [1]. It was first defined 
by Thoft et al.[2] in 1978 but its description was extended by Gipson [3] in 2007 in her 
Friendenwald lecture as: “the ocular surface…includes the surface and glandular 
epithelia of the cornea, conjunctiva, lacrimal gland, accessory lacrimal glands, 
meibomian glands and their apical (tears) and basal (connective tissue) matrices; the 
eyelashes with their associated glands of Moll and Zeiss; those components of the eyelids 
responsible for the blink and the nasolacrimal duct”. In the same year, the International 
Dry Eye WorkShop (DEWS I) included the term of Lacrimal Functional Unit (LFU) 
introduced by Stern et al.[4] in 1998 as “an integrated system comprising the lacrimal 
glands, ocular surface (cornea, conjunctiva and meibomian glands), lids, and the sensory 
and motor nerves that connect them”. 
 The principal function of the LFU is to preserve the integrity of the tear film, ensure 
the transparency of the cornea and also the quality of the image that will be projected 
onto the retina[4–6].The components of the LFU are directly exposed to the outside 
world, therefore any damage to any of these components could lead to a destabilization 
of the tear film resulting in an ocular surface disease termed as dry eye disease (DED).  
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1.2 DRY EYE DISEASE  
 
Historically, the definition of DED has been modified and adapted several times 
along the years as the understanding of the condition increased. Furthermore, several 
difficulties were found in establish a widely-accepted definition due to a lack of 
understanding about the processes involved in DED. 
The first formal DED definition was presented in 1995 at the National Eye Institute 
(NEI)/Industry Dry Eye Workshop[7] as “Dry eye is a disorder of the tear film due to tear 
deficiency or excessive tear evaporation which causes damage to the interpalpebral 
ocular surface and is associated with symptoms of ocular discomfort”. This definition 
highlighted that the DED could be caused by aqueous tear deficiency but also by 
excessive tear film evaporation giving equal relevance to the change of quality and 
quantity of the tear film with respect to their normative values as a cause of DED. On the 
other hand, the term “disorder” was included in this definition instead of “disease” 
which may not reflect the true relevance of DED. In addition, the term DED is considered 
as synonymous with the term keratoconjunctivitis sicca (KCS). Later on, in 2006, a Delphi 
consensus group proposed “dysfunctional tear syndrome” as a new name to define DED, 
suggesting that this name reflects the pathophysiology events associated with this 
condition and also reflected the importance of both tear film quantity and quality[8]. 
Moreover, the experts involved in the panel concluded that treatment strategies should 
rely on symptoms and signs and a severity-based treatment algorithm was suggested for 
this purpose[8].  
The following year, in 2007, the first International Dry Eye Workshop (DEWS I)[9] 
elaborated by the Tear Film and Ocular Surface Society (TFOS) proposed a DED definition 
centered on the clinical effects and associated signs, which was: “a multifactorial disease 
of the tears and ocular surface that results in symptoms of discomfort, visual disturbance 
and tear film instability with potential damage to the ocular surface. It is accompanied 
by increased osmolarity of the tear film and inflammation of the ocular surface”. For the 
first time, the definition acknowledges the DED as a disease with a multifactorial nature. 
Discomfort symptoms were still relevant, but symptoms of transient visual disturbance 
were also included in this definition. On the contrary, a statement regarding the 
mechanism or aetiology of DED was not included. 
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After a decade of advances in the DED field, TFOS proposed an evidence-based 
definition included in the second International Dry Eye Workshop (DEWS II) 
[10]published in 2017. It was described as follow: “Dry eye is a multifactorial disease of 
the ocular surface characterized by a loss of homeostasis of the tear film, and 
accompanied by ocular symptoms, in which tear film instability and hyperosmolarity, 
ocular surface inflammation and damage, and neurosensory abnormalities play 
etiological roles”. 
This new definition still highlights the multifactorial nature of the DED but as a 
novelty, the loss of homeostasis of the tear film was included as a unifying element that 
describes the essential process in the development of DED. Regarding ocular symptoms, 
these remained as relevant DED feature. Furthermore, the neurosensory abnormalities 
(not included in last versions) have been reported to play an important role in the 
etiology together with the tear hyperosmolarity, tear film instability and ocular surface 
inflammation as reflected in the definition. Futures advances in the DED knowledge may 
lead to a new definition of the DED. 
 
1.3 DED EPIDEMIOLOGY  
 
The epidemiology data provides an essential information about the frequencies and 
types of diseases in a population and the factors that influence its distribution. 
Nowadays, the magnitude of the DED problem worldwide is better understood thanks to 
all the information compiled from the last thirty years of DED research. Despite this, the 
epidemiological studies need to face several challenges that complicate the 
interpretation of the epidemiological data. This could be the lack of a validated 
diagnostic test for DED diagnosis or even the lack of standardization in the DED 
definition and classification [11]. Both DEWS I & II reports published to date, which 
contribute a valuable information about this relevant issue.  
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1.3.1 DED PREVALENCE 
 
DED is considered one of the most frequently encountered ocular morbidities seen 
by eye care practitioners. Additionally, it has been reported that the 25% of patients 
who visit ophthalmic clinics report symptoms of DED, making it a growing public health 
problem[12]. The prevalence in DED vary due to the definition of DED used and the 
characteristics of the population studied, resulting in large differences in the reported 
prevalence data. In 2007, according to the  DEWS I Epidemiology report, the prevalence 
of DED ranged from 5 to 30% in individuals over the age of 50[13]. Currently, according 
to the Epidemiology report from the DEWS II [11], the prevalence rate varies depending 
on the diagnostic criteria applied. Indeed, in studies that involve symptoms (with or 
without signs), the prevalence ranged from 5 to 50% revealing that they are more 
consistent than the prevalence rates including signs (which it raises up to 75% in certain 
populations) [11]. 
According to the Women’s Health Study (WHS) criteria, the prevalence of DED based 
on symptoms ranged between 14.4 and 24.4%[14–16] but the majority of the 
conducted studies, which applied this criterion, were performed in Asia. In addition, 
other studies carried out in China [17]and Japan[16] have reported that between 21 to 24% of high school students reported DED symptoms, showing higher rates than in 
adults. On the other hand, a study conducted in American males applying this criterion 
reported the lowest age adjusted prevalence of 4.3% [18]. Despite this, women showed 
higher prevalence than men in all studies stratified by gender. 
        Regarding symptomatic DED (Figure 1), it has been observed that it is more 
common in women than men, being from 1.33 to 1.74 times higher in women[19–21]. 
Despite this, other studies have found no significant sex difference[22,23]. Also, the 
symptomatic DED has been reported to be more common in Asian than Caucasian 
populations[11]. The highest prevalence rates of symptomatic DED have been shown on 
studies conducted in South East Asia, ranging from 20.0 to 52.4%[19,22,24]. The 
diagnostic criteria applied to these studies was based on the frequency of symptoms, 
having at least one of several symptoms of DED or all at the same time (such as dryness, 
irritation, foreign body sensation, itching, or burning). However, although applying the 
same diagnostic criteria, the prevalence rates reported in Spain[25], USA[26] and UK[27] 
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were lower (18.4%, 14.5% and 20,8%, respectively).	 	 On the other hand, studies 
conducted in France[28] and Iran[29] using  the OSDI cut-off value above 22 as 
diagnostic criteria, the prevalence rates reported were very different (39.2% and 18.3%, respectively).  
 
 
 
Figure 1. Prevalence map of symptomatic DED. The prevalence percentage is detailed in the 
legend and the red square cover the area with higher prevalence rates worldwide. 
Based on “Epidemiology report” (DEWS II)[11]. 
 
 
When the diagnosis is only based on DED signs, the prevalence rates are variable. 
In addition, depending on the study, a single clinical sign or a combination of them is 
chosen. For example, the prevalence of DED vary between studies, from 15.6 to  85.6% 
for TBUT£	10 seconds whereas for the Schirmer test £	5	mm varies between 19.9 and 37%	[22,23,25]. The differences in the prevalence rates reside in the characteristics of 
the population studied, poor repeatability of the tests, lack of establishing cut-off values 
and the different techniques used. It is important to highlight that the signs may also not 
always be an intrinsic feature of the DED and may reflect normal ageing or conditions 
other than DED. Indeed, studies previously have been found an association between 
ageing and an increase in positive DED signs has been found[22,23]. This increase being 
a factor of 10 times greater with clinical DED signs as compared with symptoms. 
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Currently, it is not clear how the pathological thresholds from different clinical signs 
could be adjusted to age. Despite this, DEWS II Diagnostic report suggest a cut-off at ± 2 
standard deviations from the mean value [30].  
On the other hand, when the diagnosis is performed based on a combination of 
symptoms and signs, the prevalence of DED ranges from 8.7 to 30.1%	[25,27,28]. 
Nevertheless, different criteria were applied in each of the studies which makes it 
difficult to draw clear conclusions.   
Finally, as suggested previously[13], it has been demonstrated that there is a lack of 
association between the prevalence of symptomatic DED and the prevalence of signs 
which implies that a considerable proportion of subjects are asymptomatic.  
 
1.3.2 IMPACT OF DED ON QUALITY OF LIFE AND ECONOMY 
 
 
Given the high prevalence worldwide, DED is considered to have a significant impact 
on the quality of life (QoL) of affected patients[31,32]. The several symptoms of 
discomfort and the decreased visual function associated to DED can lead to a reduction 
in physical functioning, loss of leisure time and deterioration of general health[33]. 
Indeed, DED patients present worse perception of their health and vitality in comparison 
to the general population, being worse when the severity is increased[34]. The QoL of 
DED patients is considered similar to that experienced by patients with mild psoriasis, 
moderate-to-severe angina or even those who undergo hospital dialysis[35–37]. Daily 
activities such as reading, watching television, carrying out a professional work, driving 
or viewing a computer screen can be limited by the blurred vision reported in DED 
patients. These patients are three times more likely to report difficulties in performing 
these activities[33].  Furthermore, it is important to mention that DED has an adverse 
impact on psychological health. DED patients have reported to be more anxious, 
depressed, psychologically stressed and showed lower scores for mental health 
compared to patients without DED [38,39]. Depression has been especially associated 
with increased severity of DED symptoms[40]. Sleep and mood seem to be affected by 
DED since the prevalence of sleep and mood disorders are significantly higher in patients 
who suffer from DED compared with those encountered with other ocular conditions as 
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glaucoma, retinal disease or cataracts[41]. In addition, sleep disturbance has been 
associated with DED being equal for men and women[42].  
Apart from the impact on QoL, the direct medical care spending and the loss of 
productivity contribute to the DED has economic burden[43–45]. The management of 
DED involve the utilization of several healthcare resources such as follow-up visits with 
physicians, pharmalogical and non pharmalogical therapies available and surgical 
procedures. The global cost of the DED is difficult to address because of healthcare 
systems differing from country to country. For example, in the United States, the annual 
cost in DED management is around 3.84 billion dollarts (USD) [45] while in Singapore it is  
0.15 USD millions [46]. In addition, the DED annual costs vary across Europe ranging 
from 0.27 million USD in France to 1.10 million USD in the United Kingdom [47]. As well 
as the global cost, the DED treatment cost varies by country according to the different 
treatment options available in each one and even in the same geographical location [48–
50]. 
The impact of indirect costs due to absenteeism (early leaving or work absent) and 
presenteeism (productivity loss when employees are not fully productive during working 
hours) are also relevant in the economic framework. Actually, it has been reported that 
DED is associated to decreased productivity and days missed from work [43,44,51,52]. 
Future strategies should be focus on the improvement of the QoL of the DED patients 
leading to a reduction of the economic burden.  
 
1.3.3 RISK FACTORS OF DED 
 
The multifactorial nature of DED is well-recognized. For this reason, the knowledge 
about the risk factors provide relevant and valuable information about the 
pathophysiological mechanisms involved, allowing advances in diagnostic methodology 
and therapeutic perspectives [11]. Ageing [18,25,29,53] and female sex [14,19,27,54] 
have been confirmed as the most consistent risk factors for DED according to large 
epidemiologic studies. Asian race [14,55], meibomian gland dysfunction (MGD) [56,57], 
connective tissue diseases and Sjögren syndrome (SS) are the risk factors that have been 
proven to increase the risk of DED. In the DEWS II report, all risk factors have been 
classified by the level of evidence (consistent, probable and inconclusive) and into “non-
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modifiable” and “modifiable” in order to help on the DED management (for more details  
see Figure 3 of Epidemiology report” (DEWS II) [11]). 
1.4 DED CLASSIFICATION 
 
As well as the DED definition, the DED classification has been adapted according to 
the understanding of the disease. The classification schemes are useful to guide 
diagnosis and as a result, improve patient care applying the appropriate treatment in 
each particular case [10]. 
The NEI/Industry Workshop classification proposed in 1995 was useful and durable 
for over a decade. This report presented tear-deficient and evaporative as primary 
categories of DED and also proposed several intrinsic and extrinsic etiological factors 
within each category, that could contribute to DED [7]. Despite this, this classification 
needed to be updated because it did not reflect different aspects regarding  effects on 
vision, pathophysiological mechanisms and the importance of the severity assessment 
[9]. 
 In 2003, the Committee from the 14th Congress of the European Society of 
Ophthalmology proposed the “triple classification”[58]. Later on, in 2005, it was updated 
and presented in three separate schemes based on the etiopathogenesis, the glands and 
tissues targeted in DED and disease severity [59]. This approach was considered 
attractive to DEWS committee who took many conceptual aspects derived from this 
scheme for the next classification scheme that was proposed later in 2007. 
Nevertheless, from the Delphi Panel report, the DEWS committee considered the 
severity grading [8]. Therefore, the classification scheme [9] presented in the DEWS I 
report in 2007 (Figure 2) was the result of the knowledge obtained from the reports 
presented at the 14th Congress of the European Society of Ophthalmology together with 
the Delphi panel report. 
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Figure 2. Dry eye classification from DEWS I report published in 2007. Based on “Definition 
and Classification report” (DEWS II)[10]. 
 
 
The etiopathogenic classification developed and presented in the DEWS I preserved 
the two DED major categories as “aqueous deficient dry eye” (new term for “tear 
deficient”) (ADDE) and “evaporative dry eye” (EDE). Suffering from any of these DED 
types lead to an alteration of the quality and/or the composition of the tear film, which 
result in a reduction of the tear stability and an increase of tear film osmolarity. 
Furthermore, it has been reported that these DED types are not mutually exclusive, 
being possible that these entities could co-exist at the same time [10]. 
ADDE is characterized by a failure of lacrimal tear secretion that can be caused by 
lacrimal acinar cells destruction or dysfunction [60,61]. As a result of it, the tear 
osmolarity increase leading to a stimulation of inflammatory mediators. Furthermore, 
ADDE is subdivided into Sjögren syndrome (SS) and non-Sjögren syndrome (non-SS). The 
SS is described as an exocrinopathy in which the lacrimal and salivary glands are 
targeted by an autoimmune process. In addition, other organs are also affected by the 
SS. Both lacrimal and salivary glands are infiltrated by activated T-cells, which cause 
acinar and ductular cell death and hyposecretion of the tears or saliva [62].  
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On the other hand, non-SS is a form of ADDE developed by several causes as the 
reduction of the reflex lacrimal secretion, deficiencies in the main and secondary 
lacrimal gland and obstruction of the lacrimal gland ducts [62].  
EDE is characterized by an excessive water loss from the exposed ocular surface 
in the presence of normal lacrimal secretory function [62]. As observed in Figure 2, the 
causes that lead to EDE have been described as intrinsic (drug actions, MGD, low blink 
rate, etc) which affect lid structures or dynamics and extrinsic (vitamin A deficiency, 
topical drugs preservatives, etc) where ocular surface disease occurs due to some 
extrinsic exposure [62]. 
As well, DED can be categorized as episodic or chronic. The episodic DED occurs 
when environmental or visual tasks with reduced blinking overwhelm the stability of the 
tear and produce symptomatic DED. On the other hand, chronic DED persists 
continuously with symptoms and possible damage to the ocular surface [63]. 
The current DED classification scheme published in the DEWS II is showed in Figure 3. 
 
 
     Figure 3. Current DED classification. Based on “Definition and Classification report” (DEWS II) [10]. 
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This new classification considers that ADDE and EDE exist on a continuum rather 
than as separate entities [10]. Triaging elements have been included in order to avoid 
misdiagnosis of DED in the presence of other ocular surface diseases. Accuracy in DED 
diagnosis is critical since it increases the chance of establishing a successful treatment. 
For this reason, a clinical decision algorithm based on the DED pathophysiology has been 
incorporated. In addition, this classification considers the cases where patients present 
marked signs without DED symptoms and those who experience DED symptoms without 
DED signs [64,65]. 
It is important to highlight that this classification is based on the predominant 
aetiologies ADDE and EDE. Despite that, EDE cover a large area on the diagram, 
according to the current understanding, an evaporative component to DED is more 
common than an ADDE component. Indeed, MGD has been  considered the most 
common cause of DED in both clinic and population based studies [56,66,67]. 
 
1.5 THE PATHOLOGY OF DED AND THE VICIOUS CIRCLE 
 
As confirmed previously in the DEWS I, the core mechanisms of DED are the tear film 
hyperosmolarity along with tear instability. It is well-known that tear hyperosmolarity is 
caused due to reduced lacrimal secretion (ADDE) or excessive evaporation of tears from 
the ocular surface (EDE).  It has been shown that these two DED subtypes may co-exist 
but despite this, the progression of any form of DED may lead to additional evaporative 
features. The pathological process starts when the tear hyperosmolarity generates a 
cascade of events that lead to ocular surface damage by the release of inflammatory 
mediators and proteases. Tear hyperosmolarity together with the inflammatory 
mediators can cause goblet cell and epithelial cell loss and damage to the epithelial 
glycocalyx. Additionally, these mediators reinforce the ocular surface damage leading to 
punctate epitheliopathy of DED together with tear film instability which leads to early 
tear film break-up. As well, the tear break-up aggravates and magnifies tear 
hyperosmolarity and it completes the so-called Vicious Circle (Figure 4) of events that 
lead to ocular surface damage, perpetuating the disease [68]. 
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Figure 4.  Representation of the vicious circle of DED. The cycle of events is shown at the centre of 
the figure where the core driver of DED is tear film hyperosmolarity. Based on “Pathophysiology 
report” (DEWS II) [68]. 
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1.6 DED DIAGNOSIS 
 
An accurate clinical diagnosis is necessary in order to distinguish DED from other 
ocular conditions which may share several characteristics (such as signs and symptoms) 
with DED. In addition, according to the diagnosis, the adequate treatment is applied, 
therefore, performing a correct diagnosis is a key to success.   
The combination of different diagnostic tests [62,69]has been used in order to assess 
both symptoms and signs since most of the tests show poor repeatability as well as low 
sensitivity and specificity.  
       The DED experts that participated in the Diagnostic report (DEWS II)[30] recommend 
performing the diagnosis evaluating at least the “homeostatic marker” tests after 
performing a screening questionnaire. On the other hand, in order to identify the DED 
subtype or specific aspects (such as inflammatory markers or environmental triggers), it 
is suggested to perform additional DED metrics.   
 
TFO: Tear film osmolarity (mOsms/L); TMH: Tear meniscus height (mm); NIBUT: non-invasive tear film break-up time (seconds); MGD: 
Meibomian gland dysfunction; TBUT: Tear break-up time(seconds); OSDI: The Ocular-surface-disease-index (scores);  
DEQ-5: Dry Eye Questionnaire (scores) 
Figure 5.  DED diagnostic test battery proposed by TFOS. Based on “Diagnostic report 
(DEWSII)”[30]. 
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As observed in the Figure 5, symptoms and at least one positive result of the 
markers of homeostasis should constitute the diagnosis of DED. Also, it is always 
recommended that the tests should be performed from the least to the most invasive.  
The clinical procedural is detailed as follows: 
 
1.6.1 SYMPTOMS ASSESSMENT 
 
The questionnaires are useful screening tools for DED diagnosis. Furthermore, these 
are relevant for monitoring the progression of the DED and response to treatments [12]. 
Indeed, the questionnaires allow the evaluation of different aspects of DED 
symptomatology, including severity, ocular surface discomfort, vision symptoms, health-
related QoL or even their effect on daily activities. For this reason, it is highly 
recommended that at the beginning of the clinical examination the eye care practitioner 
administers a validated DED questionnaire. Table 1 gives a summary of the most 
frequently used and validated DED questionnaires in the clinical studies and practice. 
Table  1. Most used DED questionnaires in the clinical studies and practice. 
 
Questionnaire Year Description Other 
comments 
McMonnies (MQ) 
[70,71] 
1986 -  14 items. 
- DED screening and assess risk factors. 
- Items include age, sex, contact lens wear, 
previous diagnosis of DED and triggers. 
- It assesses the frequency of symptoms 
dryness, grittiness, soreness, redness, 
tiredness and medications used. 
Clinical studies 
Ocular Surface Disease 
Index (OSDI) [72] 
2000 - 12 items (0-4) 
- Measures frequency of symptoms, 
environmental triggers and vision related 
quality of life. 
 
Clinical studies 
Dry Eye Questionnaire 
(DEQ) [73,74] 
2002 - 21 items  
- It includes categorical scales of prevalence, 
frequency, diurnal severity and intrusiveness 
of symptoms in a typical day over a one-week 
recall period.  
Epidemiological 
and clinical studies 
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Women's Health 
Study (WHS) 
questionnaire [37] 
2003 - It consists of only 3 questions. 
 
1) Previous diagnosis of dry eye from 
clinician? (yes or no). 
2) How often eyes feel dry (not wet enough)? 
(constantly, often, sometimes, or never) 
3) How often eyes feel irritated? (constantly, 
often, sometimes, or 
never) 
 
The person is considered positive for DED 
with reported rates of disease based on 
symptoms of dryness and irritation at least 
often and/or a physician's diagnosis of DED, 
as reported by the participant. 
 
 
 
It has been 
reported to have 
similar sensitivity 
and specificity as a 
16-item 
instrument 
Epidemiological 
studies 
 
Standard Patient 
Evaluation of Eye 
Dryness (SPEED) [75] 
2005 - 4-question survey to assess the frequency 
and severity of patient DED symptoms.  
- It monitors diurnal and longer-term 
symptom changes over the course of three 
months.  
It has been shown 
to exhibit good 
validity, 
unidimensionality, 
objectivity and 
consistency when 
compared with the 
DEQ, MQ 
questionnaire, 
OSDI and SESoD 
questionnaire. 
Epidemiological 
studies and clinical 
practice. 
Symptom Assessment 
in Dry Eye (SANDE) 
[76] 
2007 - 2 questions 
- Short and intuitive based on a visual analog 
scale that quantifies both severity and 
frequency of DED symptoms. 
Clinical practice 
Subjective Evaluation 
of Symptom of 
Dryness (SESoD) [77] 
2008 - 3- items 
- Evaluate a patient's perception of ocular 
discomfort related to dryness  
 
It has been 
validated against 
the SPEED, OSDI, 
DEQ, and MQ 
Clinical practice 
Dry Eye Questionnaire 
(DEQ-5) [78] 
2010 - 5 questions related to visual disturbance, 
including the frequency of visual changes, 
how noticeable the visual disturbance is in 
the morning and at night, as well as how 
much the visual fluctuation bothers the 
respondent. 
 
 
It is sensitive to 
disease severity 
and is one of two 
instruments 
recommended by 
the TFOS DEWS II 
diagnostic 
methodology 
report. 
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Impact of Dry Eye on 
Everyday Living 
(IDEEL) [79] 
2011 - 57 questions evaluating DED symptom 
bother, impact on daily life and treatment 
satisfaction 
Epidemiological 
and clinical studies 
Dry Eye-Related 
Quality-of-Life Score 
(DEQS) [80] 
2013 - 15 items 
- An overall summary scale and 2 multi-item 
subscales: impact on daily life and 
bothersome ocular symptoms  
Clinical practice 
 
 
Currently, the OSDI is the most widely used DED questionnaire and has been 
accepted by the Food and Drugs Administration (FDA, USA) for its use in clinical trials. 
This questionnaire was developed by the Outcomes Research Group (Allergan Inc) in 
1997 and consists in 12-item which assess DED symptoms and also the effects on vision-
related function in the past week of the patient’s life. It has shown good specificity 
(0.83	%)and a moderate sensitivity (0.60%) when differentiating between patients with 
DED and normal subjects [72]. The questionnaire has 3 categories related to ocular 
symptoms, vision-related function, and environmental triggers that the patients can rate 
with a 0 (none of the time) to 4 (all of the time) scale.  The final OSDI score range from 0 
to 100 where scores 0 to 12 representing normal, 13 to 22 representing mild DED 23 to 
32 representing moderate DED, and greater than 33 representing severe DED.  
The SANDE is a short questionnaire which quantifies both severity (from “very 
mild” to “very severe”) and frequency (from “rarely” to “all of the time”) of DED 
symptoms through 2 questions that use 100-mm horizontal linear visual analog scale. 
Furthermore, the questionnaire has demonstrated to have good test reliability 
(Interclass Correlation Coefficient (ICC) 0.53 − 0.76) when repeated assessments were 
done, suggesting that it is useful in detecting changes in symptoms over time (SANDE 
version II) [76]. 
The SPEED questionnaire has been developed to evaluate symptoms and monitor both 
diurnal and longer-term symptom changes over the course of 3 months [75,81]. The 
score of the SPEED questionnaire is derived by summing the scores from the 8 items 
that assess frequency and severity (from 0 to 28). Symptoms such as dryness, 
scratchiness, grittiness, irritation, burning, watering, soreness, and eye fatigue are 
included in the questionnaire. This questionnaire has shown a good sensitivity (0.90%) 
and specificity (0.80%) [82]. 
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MQ questionnaire is one of the most commonly used DED questionnaires to 
screen and to assess DED risk factors. It is composed of 14 questions that include DED 
risk factors such as age, gender, previous DED treatments, DED-related symptoms (both 
primary and secondary to environmental triggers), and systemic conditions associated 
with DED (dryness of mucous membranes, arthritis, thyroid disease, and medication 
use). Previously, several studies have reported different values of sensitivity (34– 98%) 
and specificity (36– 97%) for the McMonnies questionnaire [70,83]. 
The DEQ-5 is the short version of the DEQ questionnaire comprising 5 questions 
only. It has been shown that it is sensitive to disease severity, being one of the two tools 
recommended by the TFOS (DEWS II). Four questions of the questionnaire are related to 
visual disturbance which includes the frequency of visual changes, how noticeable the 
visual disturbance is in the morning and at night, together with how much the visual 
fluctuation bothers the patient [78]. 
 
1.6.2 TEAR FILM STABILITY 
 
The tear film instability has been included in the new revised definition of DED and 
its assessment is fundamental for DED diagnosis [10,84]. The measurement of the tear 
film stability can be performed invasively or non-invasively. Traditionally, the tear film 
stability has been assessed through the tear film break-up time (TBUT). This method 
previously described by Norn[85] consists of the instillation of unpreserved fluorescein 
drops in the eye and measure the time to the first break-up of the tear film after a 
complete blink using a slit-lamp with a cobalt blue filter. Any ocular damage should be 
avoided by instilling the fluorescein at the outer canthus. In addition, in order to reduce 
the variability of the test and obtain more reliable data, three repeated measurements 
are recommended. Also,  TBUT should be evaluated between 1-3 minutes after the 
instillation in order to obtain optimal results [86]. Normal TBUT values are found 
between 20 and 30 seconds while the values for DED ranges from a cut-off time of less 
than 10 seconds and less than 5 seconds when smaller [87,88]. Despite this, other 
studies have found that the average in healthy middle-aged patients is lower than 10 
seconds [89]. In the case of individuals with SS, the sensitivity and specificity reported 
were 72.2% and 61.6	%, respectively [90]. One of the most important limitation of this 
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method is the fact that the instillation of fluorescein itself provoke tear film instability. 
For this reason, it is recommended to control the amount in order to obtain more 
repeatable results [91]. Despite the limitations of this method, TBUT remains as one of 
the most widely used diagnostic tests for DED in a clinical practice [92,93]. 
Indeed, in order to overcome the drawbacks associated with TBUT, Mengher et 
al.[94] described the non-invasive tear film break-up time (NIBUT).  Its measurement has 
become more relevant in both clinical practice and research along the years. It involves 
the measurement of the time between a complete blink and the first deformation of the 
image obtained from the specular reflection of an illuminated grid pattern from the tear 
film [95]. Currently, several corneal topography systems allow the NIBUT measurement 
through observation of the placido rings reflected on the ocular surface [96]. In addition, 
there are also commercial software available assessing the NIBUT automatically. Indeed, 
the NIBUT values obtained with automated systems have found to be shorter than those 
obtained subjectively [97,98]. For this reason, it is important to establish a standardized 
methodology when conducting NIBUT measurements [99]. Normal NIBUT values have 
been found to range between 10 and 15 seconds, being indicative of DED a cut-off value 
of less than or equal to 10 seconds [100]. Depending on the technique used, the 
sensitivity and specificity of the NIBUT oscillate between 82 − 84% and 76 − 94%, 
respectively[101,102].   
 
1.6.3 TEAR FILM OSMOLARITY 
 
The tear film osmolarity (TFO) has been widely studied in clinical settings since it has 
been considered as the single best metric to diagnose and classify DED [103]. 
Furthermore, TFO has shown the highest correlation to disease severity of clinical DED 
diagnosis tests [104]. Tear hyperosmolarity is one of the central events in the vicious 
circle of DED and one of its core mechanisms, leading to reduced cell volume and 
increased concentration of solutes [105].In the past, the systems used to measure the 
TFO have been limited to research laboratories and only trained technicians could 
obtain the samples[106].  Clifton and vapor pressure osmometers are examples of 
techniques usually used to measure the TFO which showed high sensitivity and 
specificity as well as accuracy [107]. Despite this, a new handheld instrument developed 
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by TearLab was introduced to perform the TFO measurement in an easy way, allowing 
its use on the clinical setting [108]. This device analyses around 50 nl of tear film and in a 
few seconds provides the TFO reading.  
Mean TFO values in normal subjects range from 270 to 315 mOsm/L (average of 300 
mOsm/L) [108–110]. In addition, the normal variation between both eyes is around 6.9 ± 
5.9 mOsm/L [111]. On the other hand, taking into account different degrees of DED 
severity and aetiologies, the mean values range between 297 and 337 mOsm/L (average 
of 315 mOsm/L). TFO has been reported to increase with disease severity [112], 
therefore it is possible to be classified as normal (302.2 ± 8.3 mOsm/L), mild-to-
moderate (315.0 ± 11.4 mOsm/L) and severe (336.4 ± 22.3 mOsm/L). In the case of 
subjects affected severely, both TFO average, variability between eyes and visits are 
increased [113].  
TFO readings have been seen to be highly variable and it is believed it is due to 
compromised homeostasis of the DED tear film. For this reason, these differences 
between TFO readings can be considered a marker for tear film instability [110,111,113]. 
In the current literature about TFO several cut-off values for DED have been proposed. 
The sensitivity and specificity of TFO for cut-off values from 305 mOsm/L [109] to 316 
mOsm/L oscillate between 64 − 91% [114–116] and 78 − 96%	[109,117], respectively. 
Besides, positive predictive values using this range oscillate from 85% to	98.4%	[108]. 
Regarding these findings, a cut-off value of 316 mOsm/L is established to better 
differentiate moderate to severe DED when used in parallel with other specific tests. On 
the other hand, the 308 mOsm/L cut-off has become a widely accepted value for use in 
the clinical practice to help diagnose mild to moderate subjects [110,114]. 
 
1.6.4 OCULAR SURFACE INTEGRITY 
 
The ocular surface integrity assessment is performed using a slit-lamp biomicroscopy 
and vital dyes such as fluorescein and lissamine green which are extensively used in the 
diagnosis and management of DED. Fluorescein is the most commonly used dye since it 
is a hydro-soluble colorant that allows the observation of both the tear film and 
epithelial erosions in the conjunctiva and cornea [118]. Fluorescein should be instilled 
with a strip wetted with saline, but the excess saline should be shaken off to instil a 
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minimal volume. The optimal fluorescein staining is evaluated between 1 and 3 minutes 
after instillation[86], considering a positive result > 5 corneal spots [119].  The lissamine 
green allows the assessment of the conjunctival and lid margin damage. This dye is less 
toxic than the rose bengal and better tolerated [120]. In addition, under lissamine green 
the blood vessels and haemorrhages can be observed with greater contrast [121]. 
Lissamine green dye should be instilled in a similar way as fluorescein but the saline 
drop should be retained on the strip for at least 5 seconds to elute the dye. The optimal 
lissamine staining is evaluated between 1 and 4 minutes after instillation [86], 
considering a positive result > 9 conjunctival spots [119]. The assessment of both 
corneal and conjunctival staining is considered an important aspect in the clinical 
assessment of DED severity [104], using several grading systems such as the 
standardized version of the NEI/ Industry Workshop [7], Efron scales [122], Van 
Bijsterveld system [123], the Oxford Scheme [124], etc. It is recommended to use the 
same grading system during the clinical follow-up since they cannot be used 
interchangeably [125]. 
 
1.6.5 SUBTYPE CLASSIFICATION TESTS  
 
These tests are performed to identify the subtype of DED according to the DED 
classification as well as to categorize their severity in order to help on the management 
of DED. 
 
1.6.5. 1 TEAR FILM VOLUME 
 
The tear volume is also relevant for maintaining the ocular surface balance. 
Therefore, its assessment is also important for DED diagnosis. Currently, the quantitative 
evaluation of the tear meniscus is the most direct approach to assess the tear film 
volume. It refers to the tear fluid accumulated within the menisci, lying at the junctions 
of the bulbar conjunctiva and the margins of both eyelids [126]. Tear meniscus 
characteristics such as height (TMH), width,  radius curvature (TMR), and cross sectional 
area (TMA) have been widely used in clinical practice and have shown good diagnostic 
accuracy and correlations with other DED tests [127,128]. Traditionally, the assessment 
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has been performed using a slit-lamp biomicroscope equipped with a graded ocular but 
this technique showed numerous drawbacks. For this reason, optical coherence 
tomography (OCT) has been used extensively in the last ten years to measure tear 
volume since it is an objective and non-invasive technology. The most common tear 
meniscus parameters obtained with this technology are the upper and lower TMH, TMA, 
TMR and tear meniscus depth [97,129]. Normal TMH ranges between 0.1 and 0.3 mm 
and values below 0.1	mm are associated to DED [130]. Despite this, the range of both 
normal and DED values depends on the technique used to perform the measurement 
[131]. 
The Schirmer test allows the measurement of the tear secretion by placing a paper 
strip (5x35 mm) into the conjunctival sac of the temporal third of the lower eyelid. After 
5 minutes, the length of the wetted part of the strip is measured [30].  The Schirmer test 
was described by Otto Schirmer[132] and has been widely used along the years for DED 
diagnosis. In addition, there are several versions of this test. The more common is the 
Schirmer test I performed without anesthesia which provide an estimation of stimulated 
reflex tear flow. Depending on the authors, the cut-off values proposed oscillate 
between 5 and 15 mm [117,133]. For example, a cut-off of 5mm [62] showed a 
sensitivity of 77% and specificity of 70% [90] while using 10 mm [134] the sensitivity 
and specificity were 85% and 83% [123], respectively. The Schirmer test II is performed 
instilling topical anesthesia and it measures the function of the basal lacrimal secretion. 
For this reason, it is believed that it is more objective and reliable than the Schirmer test 
I in DED detection[135] but there is a lack of high-level evidence data on repeatability, 
sensitivity and specificity [136]. The cut-off value for Schirmer test version II has been 
set in 5mm /5 minutes. Both version of Schirmer test should be performed with the 
patient's eyes closed in order to minimize variability and prevent influencing factors as 
vertical gaze position and eye movements [30]. 
 
1.6.5. 2 EVAPORATIVE DED COMPONENT  
 
       The evaporative component type can be assessed in the clinical setting through 
interferometry (by measuring the tear film thickness) and the meibography (by assessing 
the Meibomian gland morphology).  
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INTERFEROMETRY 
 
It is possible to measure the thickness of the lipid layer of the tear film (LLT) using 
interferometry technique based on the interferometric patterns. The thickness of tear 
film ranges from 15 to 160 nm with the mean of 42 nm and the most feasible value close 
to 30 nm [137]. It has been suggested that the evaluation of the lipid layer of the tear 
film by interferometry enables monitoring of the function of meibomian glands [138]. 
There are many devices on the market such as the Tearscope Plus (Keeler, Windsor, 
United Kingdom) [139] and  LipiView (TearScience, Morrisville, NC) [140] that allow the 
assessment of the LLT. The LipiView interferometer has been considered the first 
clinically available device that allow automated measurement of the LLT. Using this 
device, the cut-off value of 75 nm has shown a sensitivity of 65.8% and a specificity of 63.4% for detection of MGD. Despite this, its diagnostic contribution to DED has not 
been established yet [140]. A study conducted by Eom et al.[141] found a negative 
correlation between the remaining meibomian gland area assessed by meibography and 
the LLT measured with LipiView. On the other hand, a study conducted by Finis et 
al.[140] with 110 DED patients found that the number of functional Meibomian glands 
are significantly related to the LLT [140]. 
 
MEIBOGRAPHY  
 
Detailed information is provided in Section 1.7.3.  
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1.7 EVAPORATIVE DRY EYE 
 
As previously described, the EDE is characterized by an excessive water loss from the 
exposed ocular surface in the presence of normal lacrimal secretory function [62]. The 
lipid layer of the tear film (Figure 6) has relevant functions such as reducing the surface 
tension of the tear film to help the tear spreading over the ocular surface, provision of a 
smooth optical surface, and prevention of water evaporation [142]. Its role in the tear 
film stabilization is crucial because any alteration of its composition, distribution and 
thickness is related to DED [143,144].  
 
Figure 6.  (A) Scheme of the tear film structure and (B) Scheme of the lipid layer structure. 
Based on “Tear film lipid layer: A molecular level view” by Lukasz Cwiklik.[142] Biochim 
Biophys Acta. 2016. 
 
1.7.1 MEIBOMIAN GLANDS 
 
Historically, these glands were named as “meibomian glands” in honour to the 
German physician and anatomist Heinrich Meibom. In 1666 he published the first 
detailed description and drawing of the oil glands inside the tarsus of the eyelid [145]. 
Despite this, it is believed that Galenus was the first who mentioned them in 200 AD 
[146].  
Meibomian glands (MG) are modified, holocrine, sebaceous glands that are located in 
the tarsal plate of both upper (UL) and lower (LL) eyelids (Figure 7). The principal 
function of these glands is to secrete actively lipids and proteins that are spread over the 
tear film surface. This oil matter is named meibum and provide lubrication, promote the 
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stability of the tear film in order to obtain a clear optical surface and as well, to prevent 
its evaporation [147].  
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 7 . Illustration representing the MG within the tarsal plates of the upper and 
lower eyelids.  
  
 
The number of MG in the UL and LL is in median, 31 and 26, respectively. These 
are arranged in parallel in a single row throughout the length of the tarsal plates [148]. It 
has been reported that the MG from the UL are longer than the MG from LL but the 
latter are wider. Furthermore, the MG from the UL produces higher volume of secretion 
(around 26 µl) than their UL counterparts [149]. 
 
The structure of a single Meibomian gland includes clusters of secretory acini 
(which contain secretory cells termed as meibocytes), lateral ductules, a central duct, 
and a terminal excretory duct that opens at the posterior lid margin (Figure 8A). 
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Figure 8.  Progressive structural alterations of the MG in obstructive MGD. (A) Normal MG 
produces meibum constantly within the secretory acini which is transferred to the central duct 
and, with the help of the pretarsal orbicularis muscle and the marginal muscle of Riolan, comes out 
and is spread over the ocular surface. (B) The meibum delivery is reduced due to the obstruction 
and MG structure start to be dilated due to the increased pressure exerted by the meibum 
accumulated within the ductal system. (C) After a while, the pressure starts to affect the rest parts 
of the MG structure and the ductal epithelium turns cornified in the last stages. Based on The 
International Workshop on Meibomian Gland Dysfunction: Report of the subcommittee on 
anatomy, physiology, and pathophysiology of the meibomian gland [145]. 
 
The meibum is synthesized within the secretory acini which is constantly 
producing oily meibum. This production generates a continuous force that allows the 
transportation of the meibum pushing it into the ductal system and the posterior 
delivery of the oily meibum onto the lid margin and the tear film [145]. In addition, the 
action of the pretarsal orbicularis muscle and the marginal muscle of Riolan during a 
blink contribute to the meibum delivery [145]. 
The function of the MG is regulated by androgens, estrogens, progestins, retinoic 
acid, growth factors and possibly by neurotransmitters since they are richly innervated 
with sensory, sympathetic and parasympathetic nerves [145,150,151].  
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1.7.2 MEIBOMIAN GLAND DYSFUNCTION  
 
The Meibomian gland dysfunction (MGD) is considered the leading cause of EDE 
which is the most common subtype of DED. This term was first used by Korb and 
Henriquez [152] in the early 1980s as it was considered suitable for describing the 
functional abnormalities of the MG. In the scientific literature MGD and posterior 
blepharitis are used as synonymous [153,154] but these terms are not interchangeable. 
The definition of this condition was established when a committee of experts from 
TFOS launched in 2011 the International Workshop on Meibomian Gland Dysfunction 
which collected all the available knowledge about MGD. The MGD was defined as “a 
chronic, diffuse abnormality of the meibomian glands, commonly characterized by 
terminal duct obstruction and/or qualitative/quantitative changes in the glandular 
secretion. It may result in alteration of the tear film, symptoms of eye irritation, clinically 
apparent inflammation, and ocular surface disease” 
The prevalence rate of MGD based on clinical signs in populations over the age of 
40 ranges from 38 to 68% as reported by several population-based studies [19,20,155]. 
Furthermore, the prevalence has been seen to be higher in Asians [57] compared with 
Caucasians [155]. The impact of sex and age on MGD is not yet well-known [11]. 
Historically, more than five different MGD classifications have been proposed 
[153,156,157]. Currently, the MGD is classified into two major categories based MG 
secretion [158]: low and high delivery state, respectively.  As observed in the Figure 9, 
the high delivery state is characterized by the release of a large amount of MG secretion 
in response to a pressure exerted on the tarsus. On the other hand, the low delivery 
state is sub classified into hyposecretory and obstructive. The first one is characterized 
by reduced MG secretion without obstruction while the second show reduced secretion 
due to an obstruction of the gland, being the most common form of MGD [152,159]. On 
the other hand, MGD may be primary when it appears without known disease 
association or secondary when it has associated with another disease, for example, the 
rosacea or psoriasis.  
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Figure 9. Classification system proposed by The International Workshop on MGD. Based on The 
International Workshop on Meibomian Gland Dysfunction: Report of the definition and 
classification subcommittee [158]. 
 
 
It is suggested that the pathology starts with an obstruction of the orifice of the 
gland due to a hyperkeratinisation of the epithelium or increased viscosity of the 
meibum leading to a reduced or completely inhibited secretion. During the obstruction, 
the meibum is accumulated within the ductal system due to the constant production 
carried out by the secretory acini.  The amount of meibum within the gland exerts a 
pressure leading to a widening of the ductal system. If this situation persists for a long 
time, the secretory acini will suffer the consequences of the pressure and the acini 
undergo atrophic changes which are visible as MG loss (or dropout) through infrared 
meibography [145] (Figure 8A,8B and 8C). 
MGD is considered a symptomatic condition whose symptoms result from lid 
involvement and ocular surface inflammation in the absence of increased evaporation 
[160]. 
Nevertheless, the degree and extent of obstruction developed with the progression 
of disease result in a reduced delivery of meibum to the tear film [161] that lead to a 
deficiency in the lipid layer of the tear film [162], which makes lose its barrier function 
[144]. Changes in the lipid composition, reduced spread time and instability of the lipid 
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layer also contribute to the increased evaporation that finally leads to EDE [163,164]. 
Additionally, an asymptomatic form of MGD termed as non-obvious MGD has been 
described [165]. It is characterized by normal lid margin appearances at the slit-lamp 
but, in this case, due to the absence of signs the diagnosis must be based on the 
assessment of the quality of the expressed secretions [68]. 
Diagnosing MGD, it can be problematic. There is a problem in distinguishing which 
symptoms are related to MGD and which are related to DED since there are no specific 
symptoms related to this disease. Indeed, MGD is part of the vicious circle of DED 
[147,166] and therefore, it is not known whether MGD may lead to DED through a 
process of events that involves inflammation or on the contrary, the inflammation of the 
eyelid margin in DED may affect MG morphology and function [167]. Actually, MGD 
diagnosis is mainly based on slit-lamp assessment of the lid margin and ocular surface 
integrity, TBUT, MG expressibility and secretion quality[166]. Despite this, there is no 
unanimity concerning the tests that are needing to be performed for MGD diagnosis and 
monitoring of the treatment response. Most of the proposed tests are invasive and 
imply modification of the natural conditions of the ocular surface. On the other hand, 
they are subjective which lead to the introduction of significant observer bias because of 
a low degree of standardization [168]. In order to overcome these drawbacks, 
automated and non-invasive tests have been developed to help in MGD and DED 
diagnosis as NIBUT, TFO, LLT measured by interferometry and non-contact infrared 
meibography. 
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1.7.3 ASSESSMENT OF THE MEIBOMIAN GLAND STRUCTURE 
 
1.7.3.1 IMAGING TECHNIQUES: MEIBOGRAPHY  
 
The meibography has become the most widely used tool for both researchers 
and clinicians for the assessment of the MG structure. It comprises of photographic 
documentation of the MG under different illuminations techniques[169]. The 
meibography technique has evolved over the last decades in order to improve MGD and 
DED diagnosis providing more information about MG morphology by detecting 
abnormalities such as Meibomian gland loss (MGL) or dropout, shortening, dilation and 
distortion [170]. 
The first attempt of MG visualization was performed by transillumination of the 
everted lid. This technique was described by Tapie in 1977 [171] and it involved the use 
of an illumination probe (normally used during vitreous surgery) with a red light filter to 
transilluminate the lid and to observe it under the slit-lamp microscope (Figure 10A). At 
that time, it was the only way to observe the silhouette of the MG and obtain 
information about their morphology, but this technique showed several drawbacks. On 
one hand, the probe tip provokes heat discomfort and pain to the patient and on the 
other hand, the small observation area makes it difficult to capture the images of the lid.  
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Figure 10.  Different Meibography techniques (A) Transillumination performed in a lower 
eyelid with white light observed with red filter (normal vs DED). (B) Infrared transillumination in a 
lower eyelid (normal vs DED). Based on (A) Eyelid Transillumination. Townsend WD. Cont Lens 
Spect. 2007 Jan;22(1):23. (B) University of Iowa Health Care (Ophthalmology and Vision 
Science). 
 
Later on, Tapie’s technique was improved by Jester et al.[172] adapting the 
biomicroscopic and photographic techniques. This study was carried out in rabbits and 
the morphologic changes in the MG were registered by using transillumination with a 
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Zeiss photo-slit lamp microscope that incorporated a high-speed IR KODAK film (HIE 135-
20).[172] After that, also Robin et al.[173] also used this improved technique to evaluate 
MGD in human which reinforced its usefulness for the MG observation.  
Since IR film was expensive, the developing was time-consuming, and the results 
were only available after the measurement was made.  Also,  it was not possible to 
control the quality of the image [169,174], another alternative method was proposed to 
perform meibography. It was in 1994 when Mathers et al.[175] improved this technique 
developing a video-meibography system that allowed observing of the MG structure (by 
transillumination) in real time. Visual records of the MG from the patients were 
recorded using a super VHS recorder and individual frames were extracted for analysis 
[175]. The quality of the video images obtained was higher in comparison to IR films. 
Despite the advantages obtained with this technique, it is still required multiple image 
acquisitions in order to obtain the entire length of the lid.  
In 2005, Nichols et al.[176] used digital video meibography imaging for the 
evaluation of the MG. They evaluated the lower eyelid using a Dolan-Jenner 
transilluminator and a fiber-optic guide using near-IR light and the images from the 
central lid were recorded using a Hitachi KP-M2R near-IR 1 chip CCD camera. This study 
mentioned the use of the IR light source for the first time. Later on, Yokoi et al.[177] 
described the use of IR light. They developed a new IR probe for meibography to 
enhance participant comfort and provide optimal transillumination (Figure 10B). The 
images of this study were registered by an IR CCD camera and digital video recorder. 
Besides, an imaging software was used to combine the MG images and with this, 
reduced also the number of photos also reduced that were needed for the observation 
of the entire eyelid.  
A relevant improvement in meibography was introduced by Arita et al.[178] in 2008. 
They developed the non-contact infrared meibography (NIM) which consisted in a slit-
lamp microscope equipped with an IR CCD video camera and an IR transmitting filter. 
This technique provides one image that covers the entire area of the MG from both 
eyelids and increase patient comfort, making it more suitable for the use in the clinical 
setting. With this system, the MG are detected as areas of high reflectivity and lost 
portions as areas of low reflectivity (Figure 11). 
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Figure 11. Meibography images from the upper and lower eyelid performed with 
Keratograph 5M (A and B) Normal subject with normal MG morphology (C and D) DED subject 
who show shortening of the MG and areas of MGL. 
 
 
Few years later, Pult et al.[179]  developed a novel NIM system named Portable 
Non-Contact Meibography which was based on modified IR security camera (pixel: PAL: 
628(H) 582(V), 1⁄4 CCD Sensor, 802CHA CCD; Shenzhen LYD Technology Co. Ltd, 
Shenzhan, China). In addition, the system included a near focus adaptation by mounting 
a +20 diopter lens in front of the camera, allowing the visualization of the MG without 
using a slit-lamp. Nowadays, there are several commercially available instruments on 
the market that incorporate this technology for the assessment of the MG in the clinical 
setting. 
 
 
 
 
 
 
 
 
 
A 
B 
C 
D 
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1.7.3.2 MEIBOMIAN GLAND MORPHOLOGY  
 
As aforementioned, NIM allows the detection of MG abnormalities such as MGL, 
shortening, dilation and distortion/ tortuosity of the gland. Indeed, many studies have 
confirmed the use of NIM for the diagnosis and evaluation of MGD [176,180,181]. The 
MGL or dropout refers to the partial or total loss of acinar tissue and it is one of the most 
common MG features reported in the literature [166]. Currently, there is no gold 
standard in the classification of MG assessed by NIM. Several scoring systems have been 
developed for quantification of MG features (Table 2). Nevertheless, there is no 
agreement on the number of increments that should be included in a grading scale. 
Regarding this, Bailey et al.[182] have suggested that a scale of fine clinical sensitivity 
should not exceed one-third of the standard deviation of the discrepancy indicating the 
use of scales with smaller increments to increase the ability to detect clinical changes. 
Traditionally, the quantification of the assessment has been done manually but in the 
last few years, semi-automatic and automatic approaches have emerged in order to 
obtain more reliable data.  
 
Table  2. Grading systems developed for MG morphology assessment by meibography 
technique. 
 
Author (year) MG 
feature 
Scoring system Method 
Mathers and Billborough [183] 
(1992) 
MGL Number of whole or partial MG missing from the 
central two thirds of the lower lid 
 
Manual, 
counting 
Shimazaki et al. [160]  
(1995) 
MGL Grade 0: No loss of MG 
Grade 1: Lost area 50% or less than the observed 
area  
Grade 2: Lost area more than 50% of the observed 
area  
 
*lower eyelid 
Manual, 
counting 
Pflugfelder et al.[184]  
(1998) 
 
MGL Grade 0: No gland dropout  
Grade 1: 33% gland dropout  
Grade 2: 34% - 66% gland dropout  
Grade 3: More than 66% gland dropout  
 
*lower eyelid 
Manual, 
counting 
De Paiva et al.[185]  
(2003) 
MGL Grade 0: No gland dropout  
Grade 1: ≤ 25% dropout  
Grade 2: ≤ 50% dropout  
Grade 3: ≤ 75% dropout  
Grade 4: ≤ 100% dropout  
 
Manual, 
counting 
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McCann et al.[186] 
 (2003) 
MGL Total number of absent MGs, half MG were 
counted as 0,5 
 
Manual, 
counting 
McCulley et al.[187]  
(2003) 
MGL Only the seven central MG were examined. 
 Each gland is given a score from 0 to 4, where 0= 
no dropout and 4= complete dropout of that single 
gland.  
The score from each gland is summed up as a total 
out of 28.  
 
*lower eyelid 
Manual, 
counting 
Nichols et al.[176]  
(2005) 
MGL Number of whole MG, no credit was given for 
partial MG of the lower lid  
 
Grade 1: No partial glands  
Grade 2: Less than 25%of the image contains 
partial glands  
Grade 3: Between 25% and 75% of the image 
contains partial glands  
Grade 4: More than 75% of the image contains 
partial gland 
 
Within-reader reliability: ICC (0.92) 
Between-reader reliability: ICC (0.75) 
Manual, 
counting 
Arita et al.[178]  
(2008) 
MGL 
(meiboscore) 
Grade 0: No loss of MG 
Grade 1: Lost area was less than 33% of the total 
MG area  
Grade 2: Lost area was between 33% and 67% of 
the total MG area  
Grade 3: Lost area was over 67% of the total MG 
area  
 
Meiboscore for the upper and lower eyelids were 
summed to obtain a score from 0 through 6 for 
each eye.  
 
Interobserver mean difference: 0.08 (±0.55) on 
day 1 and 0.13 (±0.50) on day 2. Concordance 
correlation coefficient: 0.79 and 0.81 on days 1 
and 2, respectively.  
Intraobserver mean difference: 0.04 (±0.54) and 
Concordance correlation coefficient: 0.79 for 
observer. Intraobserver mean difference: -0.09 
(±0.60) and concordance correlation coefficient:  
0.74 for observer 2. 
 
 
Manual, 
counting 
Pult and Riede- Pult. [188] 
(2012) 
MGL Grade 0: 0%(no partial glands)  
Grade 1: ≤ 25% partial meibomian glands  
Grade 2: between 26% and 50% partial meibomian 
lands  
Grade 3: between 51% and 75% partial meibomian 
glands  
Grade 4: > 75% partial meibomian glands  
 
 
Intra-observer agreement: 1ºobserver: κ statistics 
= 0.80, p < 0.001; 2º observer: κ = 0.40, p = 0.009; 
3º observer: κ = 0.81, p < 0.001.  
Inter-observer agreement: 1ºobserver-2º 
observer: ±1.49; 1º observer-3º observer: ±0.91 
and 2ºobserver-3º observer: ±1.20 
Manual 
and semi-
automatic 
(ImageJ) 
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Pult et al.[190]  
(2012) 
MGL 
Distortion 
Width 
 
Total MGL, most bent MG from both eyelid and 
MG width of most predominant MG. 
Semi-
automatic 
(ImageJ) 
Ban et al. [191] 
(2012) 
MGL Mean value for length of the 5 central glands and 
proportion of MG coverage of a central area  
 
*upper eyelid 
Semi-
automatic 
(ImageJ) 
Koh  et al.[192] 
(2012) 
Width 
Length 
Imaging processing used for MG width and length 
detection  
 
MG features accurately differentiate between 
healthy (specificity 96.1%) and unhealthy 
(sensitivity 97.9%) meibography images. 
 
*upper eyelid 
Semi-
automatic, 
software 
developed 
Arita et al. [193] 
(2014) 
MGL The ratio of the total MG area relative to the total 
analysis area for the upper and lower eyelid. 
The intra-examiner coefficients of variation for the 
objective analysis of upper/lower meibomian 
gland area in normal controls and in patients with 
MGD were0.59±0.26%/0.40±0.20% and 
0.47±0.45%/0.44±0.31%, respectively.  
Automatic, 
software 
developed 
Ngo et al.[189]  
(2014) 
MGL Grade 0: 0% dropout  
Grade 0.5: 1%-16% dropout 
Grade 1: 17-33% dropout  
Grade 2: 51%-67% dropout  
Grade 3: 68%-84% dropout 
Grade 4: 85%-100% dropout  
 
Interobserver mean difference: 0.05 (±0.45), 
concordance correlation coefficient: 0.89 on day 1, 
and interobserver mean difference: 0.01 (±0.41), 
concordance correlation coefficient: 0.91 on day 2. 
 
Manual 
and semi-
automatic 
(ImageJ) 
Koproswki et al. [194,195] 
(2016) 
MGL The percentage area occupied by MG is analysed 
in relation to the whole surface of the eyelid.  
 
The algorithm described shows a sensitivity of 
99.3% and specificity of 97.5% in the diagnosis of 
meibomian glands and is insensitive to parameter 
changes. 
Fully 
automatic, 
software 
developed 
    
 MG: Meibomian glands, MGL: Meibomian gland loss or dropout 
*preferred eyelid in the study 
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1.7.3.2.1 CHANGES TO MEIBOMINA GLANDS IN VARIOUS CONDITIONS REVEALED BY 
NIM 
 
1.7.3.2.1.1 AGE 
 
It has been well-documented that MGL increases with age in normal subjects 
[178,191,196] and it is not necessarily in response to the presence of obstructive MGD 
[197]. Indeed, significant positive correlation between age and the MGL was detected, 
indicating that the number of MG declines with age [178]. These findings remark that 
ageing is a relevant risk factor for the development of MGD.  
 
1.7.3.2.1.2 CONTACT LENS 
 
The MG morphology has been assessed in contact lens (CL) wearers. Several 
studies have shown that CL wear negatively affects the condition of the glands [198–
200] (Figure 12) whereas other studies have found no relation [201,202]. A study 
conducted by Arita et al.[199] found higher meiboscore in CL wearers compared to 
control subjects and as well, the duration of the CL wear was significantly correlated 
with the meiboscore. A multivariate analysis found that the meiboscore was correlated 
with age in the CL wearers [201]. Another study conducted by Alghamdi et al.[203] 
found that the morphology and function of the MG were related to the duration of the 
CL wear. As well, they observed that the MG did not deteriorate after 2 years of CL wear 
and despite their discontinuation, the MG morphology did not improve. 
Tang et al.[204] after assessing 60 eyes from 60 CL wearers and 21 control eyes 
found that CL wear longer than 3 years was associated with MGL. The possible 
hypothesis behind the MGL observed in CL wearers could be the chronic friction 
provoked by the CL [199]. In addition, MG distortion was also observed in 57 of 58 
subjects who used overnight orthokeratology and also developed papillary hypertrophy 
[205]. Further studies are needed regarding overnight CL wear and its impact on MG 
morphology.  
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Figure 12. Representative meibography images obtained from (A) A non-CL wearer with 
total meiboscore of 0 (B) Soft CL wearer with total meiboscore of 1 and (C) Rigid gas-permeable 
CL wearer with total meiboscore of 4. Based on “Meibomian Gland Dysfunction and Contact 
Lens Discomfort”. Arita et al.[206]. Eye Contact Lens. 2017 
 
 
1.7.3.2.1.3 PATHOLOGIES 
 
Both meibometry and NIM have revealed morphological changes in glaucoma 
patients, leading to DED [207]. MGL and low secretion expressibility are some of the 
most common features in glaucoma patients that use preserved anti-glaucoma drugs 
[208]. Arita et al.[209] found that the meiboscore was significantly higher in the eye 
which was under glaucoma treatment. On the other hand, a study conducted by Agnifili 
et al.[210] assessed the MG features in medically controlled glaucoma treated with 
preserved or preservative-free drugs. Their study showed a significant reduction of the 
mean acinar density and area, a greater secretion reflectivity, and a higher interstice 
inhomogeneity in patients who used preserved prostaglandin analogues (PGA). 
Furthermore, a recent clinical study found the association between PGA and MGD [211]. 
The prevalence of MGD found in this study was higher in patients treated with PGA 
(92.0%) compared with those receiving non-PGA therapy (58.3%). Besides, patients 
treated with PGA showed the obstructive MGD (95.7%) [211]. 
 
MG distortion (Figure 13) has been found in higher frequency in patients with 
perennial allergic conjunctivitis (AC) (45%) than in control subjects (8%) [212]. In 
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addition, the MG function of those patients have shown to be impaired. It is believed 
that inflammatory changes in the conjunctival tissue might induce pressure on the MG 
in the tarsus [145,213]. 
 
 
 
Figure 13.  Distortion of 
the MG from the UL 
obtained from a patient 
with allergic conjunctivitis 
by NIM. Based on 
“Functional Morphology of 
the Lipid Layer of the Tear 
Film”. Arita et al. [138]. 
Cornea. 2017 
 
 
Additionally, changes have been observed  in the MG morphology of patients 
with other pathologies such as chalazion [214,215] rosacea [216,217], ocular graft-
versus-host disease [218], phlyctenular keratitis [219], granular corneal dystrhophy type 
2[220], vitiligio  [221]and diabetes mellitus (type 2) [222]. Moreover, it has been 
reported that the radiotherapy [223] and chemotherapy [224] treatments affect the MG 
morphology.  
 
1.7.3.2.2 DIAGNOSTIC VALUE OF MEIBOMIAN GLAND LOSS 
 
Previously, Arita et al.[180] found that the MGL was significantly higher in 
obstructive MGD patients compared to controls. In addition, they showed that the 
symptoms, lid margin abnormalities and the meiboscore were valuable for distinguishing 
MGD patients and normal patients (with a sensitivity of 84.9% and specificity of 96.7%	for MGD diagnosis). Another study found that the level of MGL was also able to 
differentiate MGD subjects from subjects with ADDE [225]. Previous studies found 
significant correlations between MGL and some tear film parameters (such as TBUT 
[191,226,227], non-invasive tear film break-up time (NIBUT)[190], lipid layer thickness 
(LLT) [141], Schirmer test [228], MG expressibility [226], corneal staining [227]) and 
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subjective symptomatology (OSDI [179]and McMonnies[229]), suggesting its possible 
diagnostic value [167]. However, others studies concluded that assessing the MGL alone 
as clinical parameter has not enough DED diagnostic value, and it should be interpreted 
jointly with other clinical parameters [66,180,226]. Currently, the diagnostic value of 
meibography in DED need further study [30]. Other MG morphology features are being 
studied in order to obtain more information to improve DED and MGD diagnosis.  
 
1.7.3.2.3 MEIBOGRAPHY LIMITATIONS 
 
Despite all advantages that this technology can provide, it is important to point 
out some limitations. The short wavelength IR used by the commercial IR meibography 
systems do not allow the penetration of the palpebral conjunctiva and in some cases, 
the assessment of MG could be difficult. For example, MGD patients normally show 
thicker palpebral compared to healthy patients [230], therefore it may affect the MG 
evaluation. In addition, the images do not have in depth information because they are 
two-dimensional. Also, different contrasts in the image obtained with different devices 
could introduce errors in the evaluation of the MGL [189]. 
 
1.7.3.2.4 OTHER TECHNOLOGIES FOR MG MORPHOLOGY ASSESSMENT.  
 
In the last few years, several methods have been used for the observation of the MG 
structure despite the fact that they not being designed for MG assessment particularly. 
For example, the confocal laser microscopy allows the in vivo assessment of the 
histopathology of many ocular surface conditions [231,232] and recently has been useful 
as a supplementary diagnostic tool. The confocal laser is an invasive method and 
requires the instillation of topical anaesthetic. This method was first applied to the 
palpebral conjunctiva to observe the MG structure in 2005 [231,233] and it 
demonstrated that it is able to provide images of the MG acini. MG parameters such as 
MG acinar unit density (MGAUD), MG acinar longest and shortest diameter (MGALD, 
MGALSD) and periglandular inflammatory cell density (ICD) have been extracted from 
the observation through confocal laser microscopy. These parameters have been well 
correlated with the MGD severity, demonstrating to be useful for MGD assessment 
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[234]. The sensitivity and specificity values of these parameters for the cut- off values 
established were 90% and 81% for MGALD, 86% and 96% for MGASD, 100% and 100%	for ICD, 81% and 81% for MGAUD [89]. Furthermore, this technology has 
provided information about morphological changes in patients with SS [232], effect of 
the ageing [235], differences in MG morphology in CL wearers [198] or even the 
effectiveness of MGD treatment [236]. 
Another method, the OCT has been used to obtain 3D and volumetric images of the 
MG structure [237] (Figure 14). This technology allows the visualizing deeper regions of 
the MG due to its longer-wavelength light which improves imaging depth [238]. The OCT 
provides images of  the acini, ducts and MG lesions that are observed in the deeper 
layer but the observation is limited, requiring a long time to obtain the entire area of the 
MG [230,238]. The OCT recently has been used for histologic examination, also named 
as optical coherence microscopy (OCM) [239], which provides high-resolution transverse 
imaging and large field-of-view. This technology may provide more insight about the 
pathophysiology based on structural changes.  
 
Figure 14. Images of the MG obtained with NIM and OCT (A) Normal MG (B) Increased 
atrophy of the MG (white). Based on “Morphological evaluation for diagnosis of dry eye 
related to meibomian gland dysfunction” Yoo YS et al.[238]. Exp Eye Res. 2017 
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Nevertheless, these methods mentioned above present some limitations. One of 
these limitations, in the case of the confocal laser microscopy, is its high cost that 
prevents introducing it in clinical practice. In addition, it has a small field of view, thus 
the image obtained is from a very small area. Also, this technology requires prolonged 
assessments in order to achieve the images and it would require placing the patients in 
very uncomfortable situations (since it is requires the instillation of topical anaesthetic 
and remain with the eyelid everted and the ocular surface exposed for a long period of 
time) [240]. Regarding OCT, the scan depth is limited to approximately 1–2 mm due to 
scattering and absorption of light by biological tissue. OCM method is usually performed 
in a research context since it allows the cellular imaging in human tissues without the 
use of extrinsic contrast agents or obtain images from a novel materials [241]. 
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1.8 NEW TECHNIQUE FOR OCULAR SURFACE ASSESSMENT 
 
Currently, the DED diagnosis and monitoring are still challenging tasks for 
clinicians[242] due to the multifactorial nature of DED. Most of the clinical tests used for 
its diagnosis show some limitations such as: semi-invasive, subjective, show insufficient 
sensitivity and specificity and low repeatability [62]. Additionally, there is a lack of 
agreement between clinical signs and severity of DED symptoms making the DED 
diagnosis more difficult [243,244]. Thus, more objective, less invasive, repeatable 
methods and technologies have been developed in order to obtain more valuable 
information for DED diagnosis.  
 
1.8.1 THE ROLE OF THE TEMPERTURE IN CLINICAL DIAGNOSIS 
 
Traditionally, the temperature has been used for clinical diagnosis since it has 
proved to be a good indicator of general health [245,246]. The human body is capable of 
maintaining the constant temperature through a physiological process called 
thermoregulation[247]. This regulation is vital for the normal performance in the human 
body, therefore changes of temperature by a few degrees could be considered as a clear 
sign of a possible disorder[248]. Historically, the temperature as a scientific indicator of 
illness was established in 1868 where the range between 36.3 and 37.5°C was 
considered as normal temperature and temperatures beyond this were considered as an 
indication of illness[249].  
The measurement of the temperature has evolved through time with the 
advancement of the technology and discoveries related to the light. One step forward 
was the discovery of infrared radiation in 1800 which opened new horizons in the field 
of temperature measurement[245]. The diagnostic importance of temperature 
measurement by infrared (IR) thermography was mentioned in 1934 [250] and it was 
the start point to the application of this technique in the medical field. The several 
advantages of the IR thermography such as speed, real-time imaging, no harmful effects, 
non-contact and non-invasive which makes it an attractive diagnostic tool[251]. Indeed, 
this technique has been widely used in the medical environment for breast cancer 
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detection [252], dentistry[253], dermatology[254], diagnosis of rheumatologic 
diseases[255] and vascular disorder[256], among others.  
 
1.8.2 INFRARED THERMOGRAPHY FOR TEAR FILM DYNAMIC 
ASSESSMENT 
 
As previously mentioned, the IR thermography has been proposed as a diagnostic 
tool to detect pathological and physiological changes in the eye [257] allowing the study 
of the ocular surface temperature (OST) [258] increasing accuracy, resolution, and 
speed[259,260]. The OST changes registered using  IR thermography reveal the nature of 
the tear film and its stability [261,262]. As reported by TFOS, the assessment of the tear 
film stability helps to identify the loss of homeostasis that is crucial in the development 
of DED [30]. Therefore, this technology allows the DED assessment [263,264]. Different 
approaches have been proposed for DED evaluation such as the measurement of the 
temperature of the geometric center of the cornea (GCC)[259,261], the mean ocular 
surface temperature (MOST) [264], relative differences in temperature across the ocular 
surface[263], nasal and temporal conjunctiva temperature[259], temporal and nasal 
limbus temperature[265] and maximum and minimum temperature of the region of the 
studied area [265]. The evidence in the current literature shows that the cooling rate of 
the ocular surface is faster in subjects with DED than in normal eyes, which is assumed 
to be a result of a greater rate of tear film evaporation (Figure 15). 
 
  
Figure 15. Examples of thermal images of (Left) An eye showing normal temperature of the 
ocular surface (Right) An eye showing a cooling of the ocular surface due to a higher evaporation 
of the tear film. 
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The quality and the stability of the tear film can be evaluated by tear evaporimetry. 
The rate of water loss of the aqueous phase or the evaporation rate (TER) from the 
exposed ocular surface has been widely studied in tear dynamics [266]. Several research 
studies have found increased TER in subjects with DED (both ADDE and EDE) [267,268] 
and MGD [234,269] while others did not find differences [270]. As well, blinking is 
considered an essential function of the eye because is responsible for spreading tears, 
mucin, and lipids over the ocular surface, maintaining the eye’s moisture and its 
protection from the external environment. The interblink interval (IBI) has been 
demonstrated that together with other parameters related to the blink, to be useful for 
distinguishing between healthy subjects and patients with DED [88,271,272]. Currently, 
there is an emerging interest in the analysis of the OST through IR thermography as a 
non-invasive technology due to its high potential for DED diagnosis.  
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1.9 JUSTIFICATION, HYPOTHESES AND OBJECTIVES 
 
 
This research work belongs to the working package of the EDEN project entitled 
“Objective non-invasive diagnostic tools”. The general aim of this working package is to 
develop new metrics to objectively and precisely assess and analyse the LFU.  
 
1.9.1 JUSTIFICATION 
 
            For completeness, some aspects related to the motivation behind the doctoral 
work is reiterated. As previously explained, DED is a multifactorial disease of the ocular 
surface considered one of the most frequently encountered ocular conditions seen by 
eye care practitioners. Nowadays, DED is estimated to affect between 5 − 50% of the 
worldwide population [11]. Furthermore, the prevalence of DED increases linearly with 
age which makes DED a growing public health concern as the global population of older 
people is expected to be more than double its current amount by 2050. According to 
DED classification, ADDE and EDE are the two major DED types and are considered to 
exist on a continuum rather than as separate entities [10]. Despite this, according to the 
current DED understanding, an evaporative component is more common than an ADDE 
component. Currently, the MGD is considered the leading cause of EDE. This condition 
has been may result in alteration of the tear film, symptoms of eye irritation, clinically 
apparent inflammation and ocular surface disease. Therefore, any change that occurs in 
the morphology of the MG or in the secretion of these glands has an important clinical 
impact. Currently, the NIM has become the most widely used tool for both researchers 
and clinicians for the assessment of the MG structure. Many studies have confirmed the 
use of this technology for diagnosis and management of MGD [176,180,181]. Indeed, 
NIM allows the detection of MG abnormalities such as MGL, shortening, dilation and 
distortion of the glands. The MGL or dropout refers to the partial or total loss of acinar 
tissue and it is one of the most common MG features reported in the literature [166] 
Currently, there is no gold standard in the classification of MG assessed by NIM but most 
of the classification are based on the MGL. Previous studies found significant 
correlations between MGL and some tear film parameters (such as TBUT [191,226,227], 
NIBUT [190], LLT [141], Schirmer test [228], MG expressibility [226], corneal staining 
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[227]), subjective symptomatology (OSDI [179] and McMonnies [229]), suggesting its 
possible diagnostic value [167]. However, other studies concluded that assessing the 
MGL alone as clinical parameter has not enough DED diagnostic value, and it should be 
interpreted together with other clinical parameters [66,180,226].  
            Additionally, the multifactorial nature of the DED makes it difficult for the eye 
care practitioners to carry out a correct diagnosis and monitoring [242]. For this reason, 
more objective, less invasive, and more repeatable methods and technologies have been 
developed in order to obtain valuable information for DED diagnosis.  
 
1.9.2 HYPOTHESES 
 
The hypotheses of this research work are:  
 
v Information revealed by NIM can be used for assessing changes in the 
morphology of the MG (such as loss of glandular tissue, shortening and distortion 
of the glands) related to DED.  
v Changes in MG structure can affect the ocular surface integrity. 
 
1.9.3 OBJECTIVES 
 
The following objectives were established:  
Objective 1 (Main) 
To study the relationship between the MGL revealed by NIM and the ocular surface 
parameters. 
Objective 2 (Secondary) 
To assess the effect of ageing on the ocular surface parameters and to study its role on 
the DED diagnosis.  
Objective 3 (Secondary) 
To study the relationship between new objective MG morphology parameters and the 
ocular surface parameters.  
Objective 4 (Secondary) 
To study and compare the thermal characteristics of DED and healthy subjects using 
non-contact IR thermography.   
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1.9.3.1 EXPECTED RESULTS 
 
 
The expected outcomes are as follow:  
• Understanding the impact of ageing in the ocular surface and to know the ocular 
surface characteristics of different age groups. 
• Understanding the role of the MG in the DED. 
• Verifying the classification based on MGL.  
• To know the impact of other MG morphology parameters apart from MGL on the 
ocular surface. 
• Gaining knowledge about the tear film stability through ocular surface 
temperature assessment using a non-contact infrared thermography camera.  
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Chapter 2 
Material and Methods 
 
The present chapter describes the clinical protocol, methodology, material and the 
statistical analysis conducted for each study included in this doctoral thesis. 
 
The present prospective clinical study was reviewed and approved by the Ethics 
Committee of San Carlos University Hospital (Madrid) and adhered to the tenets of the 
Declaration of Helsinki (see Annex 1). Written informed consent was obtained from all 
included participants after explanation of the purpose and consequences of the study 
(see Annex 2). 
 
The study was carried out in the Optometry Clinic of the Faculty of Optics and 
Optometry at Complutense University of Madrid (UCM, Madrid, Spain). Participants 
were recruited via email notices sent to the institutional e-mails from the UCM academic 
community and advertisements placed on noticeboards in the Faculty of Optics and 
Optometry. 
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2.1 CLINICAL PROTOCOL 
 
The research work undertaken in this doctoral thesis required designing a clinical 
protocol which is described in detail in Figure 16. Only the right eye (RE) of each 
participant was assessed. One eye was chosen in order to avoid a possible bias since 
DED affect equally both eyes and both are assessed under the same conditions. The 
design of this clinical protocol was elaborated with the objective of performing a 
comprehensive assessment of the health state and integrity of each component of the 
ocular surface. In order to obtain reliable information, all the clinical measurements 
were performed from the least to the most invasive in order to minimize the effect of 
the previous measurements. Therefore, the clinical examination starts with a medical 
interview, allowing the researcher to have a start point about the general ocular state of 
the participant. The tear film osmolarity is performed following the medical interview 
because, this way, it is possible to obtain more reliable readings before performing the 
Keratograph 5M measurements. Despite non-invasive measurements by Keratograph 
5M, tear film test involves maintaining the eye open for almost 24 seconds. This usually 
leads to an excessive tear production of the eye in order to compensate for the dryness 
during the recording. Therefore, the excessive water content may change the osmolarity 
of the tear film, obtaining false results. After Keratograph 5M measurements, are 
performed the thermal registration of the ocular surface is measured. Before that, the 
participant rests for 5-10 minutes in order to allow tear film to recover from the last 
measurements and obtain more reliable data. This resting time is used for the 
participants to fill in some of the DED questionnaires. In addition, the thermal recording 
is recommended to be performed after 20 minutes [273]when the participant is 
acclimated to the room and to the surrounding environmental conditions. Once the 
thermal registration is performed, the biomicroscopic general assessment is carried out 
with diffuse illumination to carefully observe the features of the eyelids manually by 
touching the eye. At this point, the invasive measurements are performed. After the 
overall ocular surface is assessed and fluorescein dye is applied in order to evaluate the 
tear film stability as well as the corneal staining. The staining is assessed two minutes 
after the application of the dye, in order to observe the tear film when the fluorescein is 
on its higher peak of brightness and also, when the participant’s eye has filtered or 
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absorbed some quantity of dye through their lacrimal system. Excessive fluorescein dye 
and water in the eye could lead to less reliable readings. Following the application of the 
dye, lissamine green is applied to assess the conjunctival integrity and the eyelid margin. 
After this, meibography is performed of both eyelids using K5M. The action of the eyelid 
eversion is normally uncomfortable for the participant, therefore it is performed 
carefully and also in the minimal time. Due to the invasiveness of the last test, the 
participant rest again for 10-15 minutes in order to allow tear film system to recover. As 
previously mentioned, this resting time is used for the participants to fill in the DED 
questionnaires. Besides, the application of the DED questionnaires at different times 
during the examination visit ensure the reliability of the information obtained by the 
questionnaires since they usually show similar results related to DED.  Finally, a drop of 
topical anaesthesia is instilled and the Schirmer test is performed for 5 minutes with the 
eyes closed. At the end of the visit, if the participant has a DED symptoms caused by the 
measurements, artificial eye drops is provided to relieve their symptoms. 
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RE: Right eye; LE: Left eye; NIKBUT-fr: First break-up of the tear film; NIKBUT-avg: Average time of all tear film breakup incidents; TBUT: Tear 
break-up time; MGD: Meibomian Gland Dysfunction 
 
Figure 16. Flow diagram of study protocol. 
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2.1.1 Participant Selection 
 
Participants were required to be 18 years of age or older, be able to complete the 
questionnaires, understand the procedures and obtain an evaluable meibography image 
of the UL and LL. They were excluded if they had a history of any active ocular disease(s) 
different from DED and MGD (e.g., corneal ulcers, herpes simplex keratitis, etc), 
uncontrolled severe systemic disease that may have affected the eye (e.g.,SS, diabetes 
type II, dermatological diseases, etc), ocular surgery or trauma that could affect the tear 
distribution, eyelid margin abnormality and/or use of contact lens wear within the week 
before performing the clinical examinations. 
 
2.1.2 Medical Interview 
 
 
Before starting the study, a detailed medical interview was carried out in order to 
obtain the relevant information of each participant.  Information about age, gender, 
general health state (systemic history), ocular history, ocular family history, current and 
past medication or treatments and additional information were registered in the clinical 
evaluation sheet (see Annex 3). 
 
2.1.3 Tear Film Osmolarity 
 
TFO was measured using the TearLab Osmolarity System (TearLab Corp, San Diego, 
CA, USA) in both eyes of each participant according to the manufacturer’s instructions. It 
was conducted as a first test in order to avoid reflex tearing or the instillation of any dye 
that could affect the results. The device was calibrated before each measurement using 
the check cards provided by the manufacturer. The participant was seated with the chin 
tilted upward and eyes directed towards the ceiling. In order to proceed with the tear 
collection, the device pen was positioned just above the lower eyelid avoiding contact 
with the globe during the measurement (Figure 17). Afterwards, the device is returned 
to the electronic base to obtain the osmolarity reading. One measurement per eye was 
performed (based on Tomlinson et al.[274]) but only the RE and the difference between 
the eyes (inter-eye variability) of each patient were included in the analysis.  
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Figure 17. A) TearLab device and and TFO scale. Image courtesy of Edouard Laffosse. 
B) The researcher performing the TFO test. 
 
 
 
2.1.4 Keratograph 5M Automated Measurements 
 
Automated measurements were performed using the Keratograph 5M (K5M; Oculus 
GmbH, Wetzlar, Germany) equipped with a modified tear film scanning function. Three 
measurements of the tear meniscus height (TMHk), first break-up of the tear film 
(NIKBUT-first), the average time of all tear film breakup incidents (NIKBUT-avg), bulbar 
redness (BR) and limbal redness (LR) were obtained automatically by K5M software 
according to the manufacturer’s instructions (Figure 18). All the K5M measurements 
were performed under dimly lit room conditions.  
 
 
 
 
 
 
 
 
A 
B 
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Figure 18. A) Keratograph 5M device and components B) Researcher performing K5M tests. 
 
 
 
 
 
 
 
 
 
 
 
A 
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2.1.4.1 Tear Film Meniscus Height  
 
During tear meniscus height measurement with K5M (TMHk), participants were 
instructed to blink naturally while looking at the target in the device. Once the images 
were registered by the researcher, the inferior TMHk was measured perpendicularly to 
the lid margin at the central point relative to the pupil center using an integrated ruler. 
Three reading were obtained and averaged for analysis (Figure 19). 
 
 
Figure 19. Representative output of TMHk performed with the K5M (blue callipers). 
 
 
2.1.4.2 Ocular Redness 
 
During ocular redness measurement, participants were instructed to look at the light 
target maintaining the eye open for few seconds (Figure 20A). The K5M system scanned 
automatically the image of the exposed conjunctiva automatically and generated a score 
based on the area percentage ratio between blood vessels and the bulbar conjunctiva 
(precise to 0.1 unit). The degree of redness, nasal and temporal, is based on the JENVIS 
grading scale (Figure 20B). Three images were obtained and the redness scores from the 
nasal, temporal and total conjunctiva were averaged for the analysis. 
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Figure 20. A) Representative output of the ocular redness performed with the K5M  
B) JENVIS grading scale. 
 
 
 
 
 
 
 
 
A 
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2.1.4.3 Lipid Layer Assessment 
 
During lipid layer assessment, participants were instructed to look at the light 
target and blink naturally while a digital video was recorded. The lipid layer 
interferometric patterns (LLP) were observed and assessed in real time between 
multiple blinks (Figure 21). The lipid layer of each participant was classified subjectively 
based upon its appearance as described by Guillon [275] (0= None or not visible; 1= 
Meshwork (open/tight); 2 = Wave (Meshwork and Wave); 3 = Amorphous (Wave and 
Amorphous) and 4 = Colours (Wave and Colours/ Amorphous and Colours and Colours) 
(Figure 22). 
 
 
Figure 21.  Representative output of the LLP assessment performed with the K5M. 
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Figure 22. Examples of different LLP observed with the white lamp incorporated in the K5M: A.1) 
Not visible: 13-30 nm, A.2) Meshwork: 30-50 nm, A.3) Wave: 50-80 nm, A.4) Amorphous: 80-90 
nm and A.5) Colours: 90-180 nm. 
 
 
 
 
 
 
A.1 A.2 
A.3 A.4 
A.5 
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2.1.4.4 Tear Film Stability 
 
 
During tear film stability measurement, participants were instructed to look at the 
target and blink twice normally. After the second blink, they supressed the blink for as 
long as they could. The K5M software detected the break-up areas and measured the 
NIKBUT-first and NIKBUT-avg automatically. Three measurements were obtained, and 
the time values were averaged for the analysis. (Figure 23 and Figure 24) 
 
 
Figure 23.  Representative output of tear film stability performed with the K5M. Color-
coded map, break-up characteristics map, and classification are included in the software 
analysis. 
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Figure 24.  Color-
coded map of the NIKBUT 
measurements during the 
recording. 
 
 
2.1.5 Infrared Thermography 
 
 
An IR thermography camera (FLIR A325; FLIR Systems Inc., USA) was used to register 
the temperature of the ocular surface (Figure 25A). This thermal camera has an image 
resolution of 3201240 pixels, a sensitivity of 50	mK and an accuracy of ±	2%. It can 
detect temperatures that range from -20°3 to 120°3. Data acquisitions were done with 
a frame rate of 30 Hz and tear emissivity was set to 0.98 [276]. 
The camera incorporates a macro-lens in order to obtain a clear image of the eye 
and it was aligned with respect to the GCC. The participants were instructed to maintain 
a stable head position on the chin- and forehead rest, close their eyes for 3 seconds and 
afterwards, open and blink naturally for 40 seconds looking straight (Figure 26A). This 
procedure was established with the purpose of assessing the tear film during the natural 
blinking of each participant. The body temperature for all participants was measured 
using a digital thermometer (Citizen Digital Thermometer CTA303, Citizen System, 
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Japan) and subjects with body temperature ³	37°	3 were excluded. The air-conditioning 
system was used to maintain both temperature and humidity stable that were 
registered using a portable weather station (ThermoPro TP-50, Thermo Hygrometre, 
USA) (22	±	2°3 and 30±	5%, respectively) (Figure 26B). Participants were adapted to 
the room at least for 20 minutes [273] before the evaluation in order to stabilize the eye 
temperature and minimize the experimental error. 
  
 
 
 
 
 
 
Figure 25.  A) Non-contact IR thermography camera and macro-lens integrated. B) 
Representative output of ResearchIR software showing the thermal data obtained from the eye. 
 
The thermal recording was performed in a control group and a group with DED. The 
inclusion criteria established for the DED subjects were the diagnostic criteria described 
previously in the DEWS II [30] : subjects must show an OSDI score ³13 and present at 
A 
B 
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least one sign regarding homeostasis markers (tear film stability, TFO and ocular surface 
staining). To diagnose the subtype of DED according to the DEWS II, the MGD features, 
lipid dynamics and tear volume was assessed. The control group was composed of 
subjects who reported no subjective DED symptoms and lacked DED signs. 
  
 
Figure 26. A) Participant undergoing the thermal measurement with the non-contact IR 
camera. B) Weather station used to obtain the humidity and the ambient temperature of the 
room. 
 
In order to obtain the different OST metrics, the software which provided by the 
manufacturer was used (Figure 25B). Next, the temperature data of the sequences were 
exported and analysed off line to extract metrics of interest. Those frames affected by 
blinks were detected and removed for the following analysis. The region of interest (ROI) 
was manually determined by a single examiner and kept constant for each sequence 
(Figure 27).   
A B 
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Figure 27.  ROI marking on 
ocular surface in order to obtain 
OST metrics with the custom 
algorithm. 
 
 
A custom algorithm developed in Matlab (MathWorks Inc., Natick, USA) by Clara 
Llorens Quintana (EDEN fellow in the Department of Biomedical Engineering, Wroclaw 
University of Science and Technology, Wroclaw, Poland) and was used to analyse OST 
data. The TER was computed according to the approach proposed by Tan et al.[266].  
3.1.5. 1 Ocular Surface Temperature (OST) metrics 
 
In order to characterize the thermal changes, several OST metrics were generated 
after image analysis. Because the established the OST recording process was established 
based on the natural blinking, the first and the last complete IBIs were taken in order to 
study the temporal OST changes. As reported by Johnston et al. [271], the IBI 
assessment can reveal a substantial amount of information for a given sample compare 
to the blink rate. In this study, the first IBI was chosen in order to assess the OST just 
after opening the eye and the last complete IBI in order to assess the OST after a period 
of time. Six OST metrics were generated as shown in Table 3.  
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Table  3. The six OST metrics studied. 
 
 
 
 
MOST: Mean OST of the ROI (°C). GAP: OST difference between the end of one IBI and the beginning of the next IBI (°C). GAP 
recovery: OST difference between the beginning of two consecutive IBIs in the ROI. 
Figure 28.  Example of OST output generated by the custom algorithm. The illustration 
represents the OST metrics GAP (red) and the GAP recovery (green), respectively. 
 
OST 
metrics 
Description 
TER Tear Evaporation Rate (g/cm2/s) 
MOST Mean OST of the ROI (°C). 
GAP OST difference between the end of one IBI and the beginning of the 
next IBI (°C). (Figure 28) 
GAP 
recovery 
OST difference between the beginnings of two consecutive IBIs in the 
ROI (°C). (Figure 28)  
MIN Minimum temperature in the ROI (°C). 
MAX Maximum temperature in the ROI (°C). 
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2.1.6 Slit-Lamp Examination 
 
The ocular surface examination was performed with a slit-lamp biomicroscopy 
(Topcon SL-D4, Tokyo, Japan). The cornea, conjunctiva and adnexa were observed under 
diffuse illumination using ´10 – ´16 magnification (Figure 29). 
 
Corneal integrity was assessed by instilling fluorescein in the eye using a fluorescein 
strip (Tiedra Laboratories, Madrid, Spain) that was previously wetted with saline solution 
(Saline solution, AVIZOR, Madrid, Spain) (Figure 30). Two minutes after the instillation, 
the corneal staining was graded using the Oxford scoring scheme [124] (0-5 score; Figure 
31A and 31C). The evaluation was performed using a cobalt blue filter incorporated in 
the illumination system together with a yellow Wratten #12 filter. Conjunctival integrity 
was assessed under diffuse white illumination using lissamine green strips (Tiedra 
Laboratories, Madrid, Spain) and graded using the Oxford scoring scheme (Figure 31B 
and 31C). 
  
Figure 29.  Ocular surface assessment performed by the researcher using the slit-lamp 
biomicroscopy. 
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Figure 30. Clinical set used to 
perform the ocular surface 
examination (saline solution, topical 
anaesthesia, fluorescein and 
lissamine green strips and Schirmer 
strip, respectively). 
 
 
A few minutes before the corneal staining assessment, the TBUT was assessed asking 
the participants to blink a couple of times and then to maintain their eyes open. The 
appearance of the first dry spot considered as the TBUT, it was measured three times 
with a stopwatch and averaged in order to obtain a reliable value.  
 
  
 
 
 
 
 
Figure 31. A) Inferior corneal staining observed with fluorescein dye B) Conjunctival staining 
with lissamine green C) Oxford scoring scheme (0-5 scores) used for corneal and conjunctival 
staining grading. 
 
C 
A B 
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2.1.6.1 Eyelid Features 
 
The examination of the eyelids was performed under diffuse white illumination using 
´10 – ´16 magnification. Before fluorescein instillation, lid abnormalities and MG 
grading were observed and scored according to Foulks/Bron scoring [181] as 
recommended by the Diagnosis Subcommittee from International Workshop on 
Meibomian Gland Dysfunction [166]. Lid margin abnormality scores from both eyelids 
were 0 (absent) or 1 (present) for the following parameters: irregularity of the lid 
margin, lid margin telangiectasia, lash loss, trichiasis, malposition, plugging, capping, 
orifice narrowing, orifice vascular invasion, loss of cuffing definition and foam secretion. 
The eyelid margin thickness was assessed on a scale from 1 to 5: 1-2=thin; 3=normal; 
4-5= thick. The meibum quality from the central 8 MG was assessed on a scale from 0 to 
3: 0 = clear meibum readily expressed; 1= cloudy meibum expressed with mild pressure; 
2= cloudy meibum expressed with more than moderate pressure; 3= meibum could not 
be expressed even with strong pressure. The number of functional MGs was assessed on 
a scale from 0 to 3: 0= more than 5 glands expressible; 1= 3 to 4 glands expressible; 2 = 1 
to 2 glands expressible; 3 = no glands expressible. Lid wiper epitheliopathy (LWE) of the 
UL and LL was assessed using a combination of fluorescein and lissamine green (Korb 
Protocol B). The higher of the final fluorescein or lissamine green staining were used as 
LWE severity grade (0 = absent, 1 = mild, 2 = moderate and 3 = severe) [277] (Figure 32). 
 
  
 
Figure 32.  Lid wiper epitheliopathy of the UL and LL observed with lissamine green. 
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2.1.7 Non-contact Infrared Meibography  
 
NIM was performed to observe MG structure from the UL and LL of each participant 
(Figure 33). UL and LL  of each participant were everted carefully and IR images were 
obtained using the infrared camera integrated in the K5M. Afterwards, MGL of the UL 
and LL was graded subjectively using the meiboscore (grade 0 = no gland loss; grade 1 = 
area of gland loss <33%; grade 2 = area of gland loss 33%–67%; and grade 3= area of 
gland loss >67%) [178].  The meiboscore for each eyelid was summed to give a total 
score of 0 to 6 (Figure 34). 
  
Figure 33. Meibography images from the LL and UL of a normal participant. 
 
 
 
Figure 34. Different grades of MGL in the UL and LL obtained by NIM (K5M). A.1 and A.2) 
Participants without MGL in the UL and LL (total meiboscore 0; = 0%). B.1 and B.2) Participants 
with slight MGL in the UL and LL (total meiboscore 1; < 33%). C.1 and C.2) Participants with 
moderate MGL in the UL and LL (total meiboscore 2; 33-66%).  D.1 and D.2) Participant with 
severe MGL in the UL and LL (total meiboscore 3; >66%). 
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2.1.8 Tear Film Volume 
 
 
Schirmer’s test was carried out as the final test and performed with topical 
anaesthesia (Colirio Anestésico Doble®, Alcon Laboratories, Spain). One drop of topical 
anaesthesia was instilled on the conjunctival lower fornix of the chosen eye, five 
minutes prior to the test. Afterwards, the Schirmer strip (35-mm Whatman filter paper; 
Tiedra Laboratories, Spain) was placed into the lower conjunctival sac at the junction of 
the lateral and middle thirds (avoiding contact with the cornea) and the length of 
wetting was recorded after 5 minutes (Figure 35B). Participants were seated at rest and 
their eyes closed during the test (Figure 35A). 
 
  
Figure 35. (A) A participant performing Schirmer test (B) Schirmer test strip wetting 
during measurement (the red line indicates the wetting measurement). 
 
2.1.9 Symptomatology Assessment 
 
During the clinical examination, participants were required to complete five of the 
most common DED questionnaires used in the clinical setting: OSDI [72], MQ[83], 
SPEED[82], SANDE[76] and the DEQ-5[78] (Annex 4).  
In order to ensure the reliability of the information obtained by DED questionnaires 
and also to avoid interference between measurements, the questionnaires were 
completed by the participants throughout the examination, randomly. For example, 
B A 
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some of the questionnaires were performed at the end of K5M measurements and 
before the thermography recording in order to allow tear film to recover from the last 
measurements (5-10 minutes). Questionnaires were also completed by the participants 
after the conjunctival staining and before the Schirmer test with the same objective.  
 
2.1.10 Automatic Algorithm for Meibomian Gland Assessment  
 
An automated algorithm that analyses infrared images of the MG using image 
processing techniques has been developed by Clara Llorens Quintana (EDEN fellow in 
the Department of Biomedical Engineering, Wroclaw University of Science and 
Technology, Wroclaw, Poland) and used to obtain objective information about the MG 
morphology (Figure 36 and Annex 6). The morphometric parameters obtained were: 
MGL, gland length, gland width and gland irregularity (also named as tortuosity or MG 
distortion) extracted from a total of 149 meibography images (out of 161) from the 
everted UL of the present study.    
 
 
Figure 36. Summary of the methodology performed for meibomian gland analysis. More 
detailed in Annex 6 (Image courtesy of Clara Llorens Quintana, ESR fellow). 
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Automated and objective analysis of the glands was carried out in a batch mode 
with no user input. Manual adjustment consisting of ROI selection was necessary in 9 of 
the images (6.04%). In 6 of those cases, the images were not acquired properly while in 
the remaining 3 images, a pre-processing problem was encountered.  Acquisition 
problem can be due to an unfocused image, off center image with part of the tarsal 
conjunctiva out of the frame or because the lower boundary of the upper eyelid is 
attached to the lower eyelid (Figure 37). Despite this, it is worth to mention that the 
algorithm never failed in the steps after the ROI selection.  
 
 
 
Figure 37.  Example of three images where the algorithm was unable to detect the correct ROI 
due to a problem during the acquisition A) unfocused image (focus is at the eyelashes), B) out 
of frame image and C) image where the upper eyelid is attached to the lower eyelid. 
(Image courtesy of Clara Llorens Quintana, ESR fellow). 
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2.1.11 Statistical Analysis  
 
2.1.11.1 Sample Size Calculation. 
 
The study evaluates numerous parameters related to the lacrimal function, then a 
correct estimation of the sample size is considered several measured parameters 
measured (thus obtaining an n for each parameter studied), to consider the highest 
value of 4	for the study, since this will achieve a greater statistical power. The 
calculations made for the sample size estimation make use of the expression of a normal 
distribution with a level of statistical significance of 5% (6	 = 	0.05), the minimum 
sample size necessary to reach a statistical power of 80% (1 − 9	 = 	0.8). For the 
calculation of the sample size it is necessary to establish the minimum detectable 
change (or clinically significant difference) in the variable to be studied, as well as the 
expected standard deviation. These two variables can be set by some criterion or 
extracted from the published literature on the subject studied. 
Meibography:  
Based on the qualitative analysis of the meibography images, the grading scale 
for MGL assessment consist of 4 degrees, then the minimum clinically detectable change 
using this scale would be 1 degree. From the study carried out by Heiko and Britta [188], 
0.9 can be considered as the standard deviation for meibography.  
The minimum sample size necessary for this data is  :	 = 	;<. 
TBUT: 
Considering the data from the research work performed by Paschides et al.[278], 
TBUT = 13 seconds can be considered normal for subjects, and TBUT = 7 seconds for 
subjects with DED, then the difference between groups would be 6 seconds. In addition, 
this study has reported a standard deviation of 6 seconds. 
Regarding the data provided, the minimum sample size necessary is :	 = 	;= 
Schirmer test: 
From the study conducted by Kashkouli et al.[279],  the Schirmer value for 
normal subjects was 26.76 mm in 5 minutes and 13.15 mm for DED subjects, considering 
16.61 mm as the significant change. In addition, the same study reported 16.7 mm as 
standard deviation of Schirmer test. 
According to data provided, the minimum sample size necessary is :	 = 	;< 
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After analysing each variable, it was finally decided to set  4 ≥ 17 in each group 
to achieve a correct statistical power for this study. 
 
 
2.1.11.2 General Statistical Analysis Description.  
 
Statistical analysis was performed using (SPSS Version 25; SPSS, Chicago, IL). 
Normality of the data distribution was tested using the Kolmogorov–Smirnov test and 
was rejected for ? < 0.05. Paired samples t-test (if normality of the data was assumed) 
and Wilcoxon test (if normality of the data was rejected) were used. Also, independent 
t-test (if normality of the data was assumed) and Mann-Whitney test (if normality of the 
data was rejected) were used. Post hoc tests were performed for multiple comparisons 
(Duncan’s Test for ANOVA and Bonferroni for Kruskal- Wallis). Correlations among 
variables were assessed through Pearson and Spearman coefficients. The correlations 
were considered strong if > 0.80, moderately strong if between 0.5 and 0.8, fair within 
the range of 0.3 and 0.5 and poor if < 	0.30 [280]. The values are expressed as 
mean±SD/ median (IQR). The significance level was set ? < 	0.05	with > 	95% of 
confidence level. 
Additionally, in the second study, Cohen’s kappa coefficient (weighted kappa value- 95% of confidence) was calculated and classified as follow: 0.00 (poor), 0.00 − 0.20 
(slight), 0.21 − 0.40	(fair), 0.41 − 0.60 (moderate),0.61 − 0.80 (substantial) and 0.80 −1.0 (close to perfect) [281]. Associations between incidence of changes in the eyelid and 
MGL were assessed using Chi-squared (B2). 
In addition, In the third study, in order to classify the irregularity in groups according 
to the degree of irregularity (low, medium and high), the data has been clustered in 
three classes and their intra-class variance was minimal using Otsu’s classification 
algorithm [282]. 
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   Chapter 3 
Results  
Study I 
 
The effect of ageing on the ocular surface parameters 
 
A total of 110 participants were enrolled in the study (70 females and 40 males). The 
mean age of the participants was 44 ± 19 years (ranging from 19 to 88 years).  
A negative correlation was observed between TBUT and NIKBUT (first and average) with 
age (fair; D	 = 	−0.394, ? < 	0.0001; poor; D	 = 	−0.245, ? = 	0.010; poor; D	 =	−0.210, ? = 	0.029, respectively) (see Figures 38A, 38B and 38C).  
 
 
 
 
 
 
 
 
 
 
 
A
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TBUT: Tear break-up time(seconds); NIKBUT-first: first rupture non-invasive Keratograph tear film break-up time (seconds); 
NIKBUT-avg: average of non-invasive Keratograph tear film break-up time (seconds). 
Figure 38. Correlations between Age and A) TBUT measured using fluorescein dye; B) NIKBUT-
first measured with the K5M and C) NIKBUT-avg measured with the K5M. 
(r, Pearson correlation coefficient). 
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As it is shown in Figures 39A and 39B, TFO from RE and TFO inter-eye difference 
showed no significant correlation with age (poor; D	 = 	0.150, ?	 = 	0.216 and poor; D	 = 	−0.030, ?	 = 	0.808, respectively). 
 
 
 
TFO: Tear film osmolarity (mOsms/L) and Inter-eye difference.RE: Right eye 
Figure 39. Correlations between Age and A) TFO from RE measured with TearLab 
Osmolarity System B) Inter-eye difference.  
(r, Pearson correlation coefficient) 
 
A 
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Schirmer test (see Figure 40A) showed a negative correlation with age (fair; D	 =	−0.344, ? < 	0.001). While TMHk showed a positive correlation with age (fair; D	 =0.336, ? < 		0.001) (see Figure 40B). 
 
 
 
TMHk: Tear meniscus height (mm) 
Figure 40.  Correlations between Age and A) Schirmer test performed with 
topical anaesthesia and B) TMHk measured with the K5M.  
(r, Pearson correlation coefficient). 
 
 
A 
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Regarding ocular staining and redness, significant positive correlations were 
observed between corneal and conjunctival staining score with age (fair; D	 =	0.400, ? < 	0.0001	and moderately strong; D	 = 	0.638, ? < 	0.0001, respectively) (see 
Figures 41A and 41B) and also between BR and LR with age (moderately strong; D	 =0.619, ? < 	0.0001 and D	 = 0.659, ? < 	0.0001, respectively) (see Figures 42A and 
42B). 
 
 
 
 
Figure 41.  Correlations between Age and A) Corneal staining graded the Oxford scoring 
scheme; B) Conjunctival staining graded the Oxford scoring scheme;  
(r, Spearman correlation coefficient). 
 
A 
B 
 80 
 
 
 
 
 
Figure 42. Correlations between Age and A) Bulbar Redness measured with the K5M and B) 
Limbal Redness measured with the K5M.  
(r, Pearson correlation coefficient). 
 
 
 
 
 
 
 
 
A 
B 
 81 
 
Figures 43, 44 and 45 show the lid margin and MG features assessed, 
respectively. Significant correlations were observed between age and every lid 
margin/MG features (MGL (see Figure 43A), quality of the secretion expressed (see 
Figure 43B), eyelid margin thickness(see Figure 44A), number of functional MG (see 
Figure 44B) and LWE from the UL and LL (see Figure 45A and 45B)(moderately strong D = 	0.522, ? < 	0.0001; D	 = 	0.599, ?	 < 	0.0001; D	 = 0.650, ?	 < 	0.0001; D	 =0.651, ?	 < 	0.0001; fair; D = 	0.305	? = 	0.0015; and D = 	0.393	? < 	0.0001; 
respectively).  
 
 
 
MGL: Meibomian gland loss graded with meiboscore scale; NIM: Non-contact meibography; MG: Meibomian glands 
 
Figure 43.  Correlations between Age and A) MGL observed by NIM; B) Quality of expressed 
MG secretion.  
(r, Spearman correlation coefficient). 
A 
B 
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MG: Meibomian glands 
Figure 44. Correlations between Age and A) Number of functional MG and B) Eyelid 
margin thickness assessed by slit-lamp. 
(r, Spearman correlation coefficient). 
 
 
 
 
 
 
B 
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LWE: Lid wiper ephiteliopathy (score).  
 
Figure 45. Correlations between Age and A) LWE from the UL and B) LWE from the LL 
assessed by slit lamp.  
(r, Spearman correlation coefficient). 
 
 
 
 
 
 
A 
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Concerning symptomatology, both OSDI and MQ questionnaires (Figure 46A and 
46B) showed a weak correlation with age (fair; D	 = 	0.254, ? = 0.01 and D	 =	0.241, ? = 	0.01, respectively). On the other hand, no significant correlations were 
observed between SPEED, DEQ-5 (Figure 47A and 47B) and SANDE (Figure 48) with age 
(poor; D	 = 	0.110, ? = 	0.256; D	 = 	0.041, ? = 	0.698 and D	 = 	0.025, ? = 	0.798, 
respectively). 
 
 
OSDI: The Ocular-surface-disease-index (scores) 
Figure 46. Correlations between Age and A) OSDI questionnaire and B) McMonnies 
questionnaire.  
(r, Pearson correlation coefficient). 
 
 
E 
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Standard Patient Evaluation of Eye Dryness(scores); DEQ-5: Dry Eye Questionnaire (scores) 
Figure 47. Correlations between Age and A) SPEED questionnaire and B) DEQ-5 questionnaire  
(r, Pearson correlation coefficient). 
 
 
A 
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SANDE: Symptom Assessment in Dry Eye (scores). 
Figure 48. Correlations between Age and SANDE questionnaire. 
(r, Pearson correlation coefficient). 
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Demographic information, clinical parameters and symptomatology scores classified by 
age groups are shown in Table 4. The ocular surface differences between females and 
males was also analysed (see Table 5). 
 
Table  4. Demographic information and comparison of the clinical parameters among 
age groups. Results expressed in mean±standard deviation (in bold) and median (IQR) 
for each parameter. 
 
 Classified by AGE 
  A. <42 B. 42 to 65 C. >65 
PARTICIPANTS (N)  61 24 24 
AGE (years)  28±6 
27(8) 
55±8 
56(11) 
72±5 
70(8) 
Female/Male  35/26 19/5 15/9 
TFO RE 311±17 
309(17) 
319±21 
315(20) 
314±18 
306(12) 
 LE 307±15 
305(18) 
314±12 
309(23) 
308±12 
308(14) 
 Inter-eye Diff -4±14 
-1(13) 
-6±16 
-5(16) 
-6±16 
-1(16) 
Keratograph K5M TMHk 0.24±0.06*† 
0.23(0.08) 
0.28±0.06 
0.26(0.09) 
0.29±0.10 
0.28(0.12) 
 BR Total 0.80±0.31*† 
0.23(0.08) 
1.37±0.67 
1.23(0.59) 
1.50±0.37 
1.52(0.38) 
 LR 0.40±0.23*† 
0.40(0.25) 
0.80±0.40§ 
0.75(0.43) 
0.99±0.37 
0.99(0.44) 
 NIKBUT-first 10.22±5.99 
8.73(7.45) 
7.31±4.20 
6.31(3.20) 
7.34±5.36 
5.46(3.87) 
 NIKBUT-avg 13.14±5.42 
13.51(7.61) 
10.47±4.55 
10.88(5.96) 
10.86±5.80 
9.77(8.13) 
 MGL 1.26±0.87*† 
1.00(1.00) 
2.45±1.56 
2.00(1.25) 
2.71±1.27 
3.00(2.00) 
Slit Lamp Assessment Corneal Staining 
(Oxford score) 
 
0.61±0.76*† 
0.00(1.00) 
1.46±0.97 
1.00(1.00) 
1.25±1.03 
1.00(1.00) 
 Conjunctival Staining 
(Oxford score) 
 
1.07±0.89*† 
1.00(2.00) 
1.83±0.70 
2.00(0.25) 
2.54±0.88 
2.00(1.00) 
 TBUT 5.11±2.71*† 
4.13(2.49) 
3.52±1.03 
3.35(1.02) 
3.30±1.43 
2.84(1.42) 
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Lid Margin 
Assessment 
and MG grading 
Lid margin thickness 3.41±0.58 
3.00(1.00) 
4.17±0.76 
4.00(1.00) 
4.71±0.75 
5.00(0.00) 
 Quality of the 
secretion expressed 
 
0.61±0.67*† 
1.00(1.00) 
1.26±0.69 
1.00(1.00) 
1.58±0.71 
2.00(1.00) 
 Number of 
functional MGs 
 
0.21±0.41*† 
0.00(0.00) 
0.82±0.71 
1.00(1.00) 
1.21±0.72 
1.00(1.00) 
 LWE UL 0.83±0.74† 
1.00(1.00) 
1.13±0.54 
1.00(0.00) 
1.33±0.58 
1.00(1.00) 
  
LWE LL 
 
1.38±0.78† 
1.00(1.00) 
 
1.71±0.86 
2.00(1.00) 
 
2.04±0.88 
2.00(0.00) 
Schirmer test  14±9*† 
12(6) 
9± 3 
9(3) 
9±6 
8(6) 
 
Symptomatology OSDI 
(0-100) 
15.34±14.50† 
12.50(16.91) 
20.53±21.00 
12.50(23.96) 
25.31±16.91 
23.83(20.21) 
 MQ 
(0-45) 
9.67±3.96 
10.00(5.00) 
11.46±6.93 
11.00(7.25) 
12.00±5.24 
12.00(7.75) 
 DEQ-5 
(0-20) 
7±5 
6(7) 
8±5 
10(8) 
6±4 
7(6) 
 SPEED 
(0-28) 
7±5 
7(6) 
8±6 
8(10) 
8±4 
8(6) 
 SANDE 
(0-100) 
29.93±21.72 
24.73(39.36) 
39.87±27.96 
38.52(43.22) 
23.55±19.88 
18.63(29.55) 
TFO: Tear film osmolarity (mOsms/L); RE: Right Eye; LE: Left Eye; TMHk: Tear meniscus height (mm); Bulbar and limbal redness (BR and LR) 
were graded automatically by K5M software; NIKBUT-first: first rupture non-invasive Keratograph tear film break-up time (seconds); NIKBUT-
avg: average of non-invasive Keratograph tear film break-up time (seconds); MGL: Meibomian gland loss graded with meiboscore scale; TBUT: 
Tear break-up time(seconds); LWE: Lid wiper ephiteliopathy (score). OSDI: The Ocular-surface-disease-index (scores); MQ: Mcmonnies 
(scores); DEQ-5: Dry Eye Questionnaire (scores); SPEED: Standard Patient Evaluation of Eye Dryness(scores) SANDE: Symptom Assessment in 
Dry Eye (scores). 
 
*Indicates a statistically significant difference between groups A and B with p-value<0.05. 
† Indicates a statistically significant difference between groups A and C with p-value<0.05. 
§ Indicates a statistically significant difference between groups B and C with p-value<0.05. 
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Table  5.  Comparison of the clinical parameters between females and males. Results 
expressed in mean±standard deviation (in bold) and median (IQR) for each parameter. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Classified by SEX  
  Male    Female  
PARTICIPANTS (N)  40 70 p-value 
AGE (years)  41±19 
32(36) 
45±19 
41(37) 
 
TFO RE 313±16 
309(19) 
314±19 
312(15) 
0.702 
 LE 307±13 
307(18) 
310±14 
306(18) 
0.374 
 Inter-eye Diff -5±16 
0(18) 
-4±15 
-1(16) 
0.729 
Keratograph K5M TMHk 0.26±0.08 
0.25(0.07) 
0.25±0.08 
0.24(0.10) 
0.219 
 BR Total 1.17±0.51 
1.07(0.70) 
1.03±0.54 
0.90(0.63) 
0.160 
 LR 0.74±0.42 
0.53(0.53) 
0.70±0.40 
0.63(0.40) 
0.604 
 NIKBUT-first 11.93±6.64 
10.94(9.96) 
7.21±4.07 
5.86(4.72) 
0.0001* 
 NIKBUT-avg 14.99±5.66 
14.64(8.15) 
10.29±4.45 
9.56(6.54) 
<0.0001* 
 MGL 1.75±1.17 
1.50(2.00) 
1.92±1.41 
2.00(1.00) 
0.734 
Slit Lamp Assessment Corneal Staining 
(Oxford score) 
Conjunctival Staining 
(Oxford score) 
TBUT 
0.58±0.64 
0.50(1.00) 
1.28±1.04 
1.00(1.25) 
5.30±3.34 
3.88(2.99) 
1.17±1.05 
1.00(1.50) 
1.73±1.00 
2.00(1.00) 
3.81±1.30 
3.53(1.38) 
0.002* 
 
0.018* 
 
0.010* 
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TFO: Tear film osmolarity (mOsms/L); RE: Right Eye; LE: Left Eye; TMHk: Tear meniscus height (mm); Bulbar and limbal redness (BR 
and LR) were graded automatically by K5M software; NIKBUT-first: first rupture non-invasive Keratograph tear film break-up time 
(seconds); NIKBUT-avg: average of non-invasive Keratograph tear film break-up time (seconds); MGL: Meibomian gland loss graded 
with meiboscore scale; TBUT: Tear break-up time(seconds); LWE: Lid wiper ephiteliopathy in upper and lower eyelid(score). OSDI: 
The Ocular-surface-disease-index; MQ: Mcmonnies; DEQ-5: Dry Eye Questionnaire SPEED: Standard Patient Evaluation of Eye 
Dryness. SANDE: Symptom Assessment in Dry Eye. 
 
*statistically significant differences between groups; p-value<0.05.  
 
 
 
 
 
 
 
 
Lid Margin Assessment 
and MG grading 
Lid margin thickness 3.93±0.86 
4.00(2.00) 
3.81±0.86 
4.00(1.75) 
0.504 
 Quality of the 
secretion expressed 
 
1.08±0.83 
1.00(2.00) 
0.93±0.81 
1.00(1.00) 
0.310 
 Number of functional 
MG 
 
0.57±0.71 
0.00(1.00) 
0.58±0.72 
0.00(1.00) 
0.986 
 LWE UL 0.92±0.79 
1.00(1.75) 
 
1.04±0.63 
2.00(1.00) 
0.397 
 LWE LL 1.43±0.81 
1.00(1.00) 
1.71±0.78 
2.00(1.00) 
0.085 
Schirmer test  13±9 
11(8) 
10.87±6.96 
10.00(6.75) 
0.160 
Symptomatology OSDI 
(0-100) 
12.44±12.52 
8.33(12.45) 
22.34±18.15 
20.45(18.70) 
0.001* 
 MQ 
(0-45) 
9.10±4.03 
8.50(7.00) 
11.61±5.58 
11.50(6.75) 
0.007* 
 DEQ-5 
(0-20) 
5±4 
5(6) 
8±4 
9(7) 
0.0007* 
 SPEED 
(0-28) 
6±4 
5(7) 
8±5 
8(7) 
0.025* 
 SANDE 
(0-100) 
22.27±19.25 
16.33(27.20) 
35.91±24.08 
32.35(36.66) 
0.007* 
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Study II 
 
Relationship between MGL assessed by NIM and the ocular surface 
parameters and symptomatology 
 
     The characteristics of the participants are summarized in Table 6. A total of 161 
participants (mean age; 42 ± 17 years, 91 females and 70 males) were recruited for this 
study. 
Table  6.  Demographic data from the participants of the study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N 161 
AGE 
(years) 
42±17 
40(29) 
AGE RANGE 
(years) 
19 to 88 
Male/ Female 
(%)  
43/57 
TFO 309±17 
309(19) 
TMHk 0.26±0.08 
0.25(0.09) 
LR 0.70±0.37 
0.57(0.43) 
BR 1.11±0.49 
1.05(0.67) 
NIKBUT- fr 9.05±5.41 
7.01(6.81) 
NIKBUT- avg 12.02±5.26 
11.37(8.04) 
TBUT 4.36±2.07 
3.85(1.97) 
SCHIRMER TEST 11.83±7.14 
11.00(7.00) 
OSDI 17.47±15.65 
14.58(18.75) 
SPEED 7±5 
6(6) 
TFO: tear film osmolarity(mOsms/L); TMHk: tear meniscus 
height (mm); Bulbar and limbal redness (BR and LR) were 
graded automatically by K5M software; NIKBUT-first: first 
rupture non-invasive Keratograph tear film break-up time 
(seconds); NIKBUT-avg: average of non-invasive Keratograph 
tear film break-up time (seconds); Schirmer test (mm); OSDI: 
The Ocular-surface-disease-index; SPEED: Standard Patient 
Evaluation of Eye Dryness. 
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3.2.1 Association and correlation between UL and LL 
 
 
       A contingency table was used to compare MGL between UL and LL (see Table 7) in 
order to know if it is necessary to evaluate the MGL in one eyelid or in both. Weighted 
kappa statistics showed no statistically significant agreement (EFGHℎJFK L	MNOPF =	0.2; ? = 0.3; range 0.099 − 0.353, 95% confidence limit) indicating no association 
between both eyelids. Despite it, a fair and statistically significant correlation was found 
between UL and LL (Spearman: D = 	0.3; ? < 0.001). For this reason, both eyelids 
should be assessed in order to know the overall condition of MG and its possible 
influence on the ocular surface state.  
Table  7. Association between UL and LL according to MGL.  
 
  Upper Eyelid (UL)  
 
 
 
 
 
 
Lower 
Eyelid 
(LL) 
Total 
Meiboscore* 
0 1 2 3 Row  
Totals  
0 21 
44.68% 
36.84% 
22 
46.81% 
32.84% 
4 
8.51% 
16.00% 
0 
0% 
0% 
47 
1 33 
39.76% 
57.89% 
36 
43.37% 
53.73% 
 
12 
14.46% 
48.00% 
2 
2.41% 
28.51% 
83 
2 3 
13.04% 
5.26% 
8 
34.78% 
11.94% 
9 
39.13% 
36.00% 
3 
13.04% 
42.86% 
23 
3 0 
0% 
0% 
1 
33.33% 
1.49% 
0 
0% 
0% 
2 
66.67% 
28.57% 
3 
 Column 
Totals  
57  67 25 7 156 
*The total meiboscore is the sum of the meiboscore of both eyelids (0-6). Grade 0, no gland loss; grade 1, area of gland loss <33% 
of the total gland area; grade 2, area of gland loss 33%–67%; and grade 3, area of gland loss >67% 
 
 
According to these findings, the participants of this study were divided by groups 
according to the total meiboscore (0-6), as proposed by Arita et al.[178]. Therefore, the 
group 1 was constituted by participants who presented a total meiboscore of 0; group 2 
by participants who showed a total meiboscore of 1; group 3 by participants who 
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showed a total meiboscore of 2; group 4 by participants who showed a total meiboscore 
of 3  and group 5 by participants who showed a total meiboscore of 4,5 or 6. According 
to the groups established groups, the percentage range of MGL was 0, 0-16.6, 16.5-
33,33-49.5 and >50, for groups 1, 2, 3, 4 and 5 respectively. Table 8 shows the 
distribution of the sample as a function of the total meiboscore, and its demographic 
characteristics. 
 
Table  8. Characteristics and distribution of the sample according the MGL grade 
(total meiboscore). Results expressed in mean±standard deviation (in bold) and median 
(IQR) for each parameter. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total Group 1 Group 2 Group 3 Group 4 Group 5 
Meiboscore* 
 
0 
(reference) 
1 
 
2 
 
3 
 
4+5+6 
MGL (%) 
 
0 0-16.5 16.5-33 33-49.5 >50 
N (%) 21 
(13.04%) 
59 
(36.65%) 
44 
(27.33%) 
20 
(12.42%) 
17 
(10.55%) 
AGE 
(years) 
34±11 
32(18) 
37±15 
32(19) 
46±17 
44(25) 
50±18 
53(34) 
60±18 
64(18) 
 
Female (%) 
 
      9/91 
9.9% 
33/91 
36.3% 
27/91 
29.7% 
8/91 
8.8% 
12/91 
13.2% 
 
Male (%) 
 
     12/70 
17.1% 
 
25/70 
35.7% 
 
17/70 
24.3% 
 
12/70 
17.1% 
 
4/70 
5.7% 
 
*The total meiboscore is the sum of the meiboscore of both eyelids (0-6). 
MGL: Meibomian gland loss 
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The results from the tables of the next sections are also presented in a boxplot 
graphics in order to visualize the trends appearing in the data obtained.  
 
3.2.2 Symptomatology assessment. 
 
 
Results regarding subjective symptomatology is showed in Figure 49 and Table 9. No 
statistically significant differences were found in OSDI (? = 0.385) and SPEED (? =0.506) questionnaires among different MGL groups. 
 
 
 
 
 
 
 
 
 
 
Figure 49. Symptomatology boxplots graphs from (A) OSDI questionnaire (B) SPEED 
Questionnaire 
A 
B 
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Table  9. Comparison of symptomatology scores among different MGL grades. 
Results expressed in mean±standard deviation (in bold) and median (IQR) for each  
 
 
3.2.3 Classical Clinical Parameters. 
 
 
       Classical clinical parameters result for each group are shown in Figures 50 and 51 as 
well as in Table 10. Statistically significant differences were found among groups in TFO 
(? = 0.023), corneal (? = 0.015) and conjunctival staining (? = 0.004). For TFO, there 
were statistically significant differences between group 5 and groups 1,2 and 3 (? =0.029; 	? = 0.014; 	? = 0.001, respectively). No differences were found among groups 
1, 2 and 3 (p=0.358); neither on between groups 4 and 5 (? = 0.210). For the corneal 
staining, there were statistically significant differences between group 5 and groups 1 
and 2 (? = 0.045 and 0.003, respectively). No differences were found among groups 3, 
4 and 5 (? = 0.191). Regarding conjunctival staining, there were also statistically 
significant differences between group 5 and groups 1 and 2 (? = 0.027 and 0.007, 
respectively) and between group 4 and groups 1 and 2 (? = 	0.045 and 0.014, 
MEIBOSCORE 
GROUP 
(MGL%) 
SYMPTOMATOLOGY 
 OSDI 
(0-100) 
SPEED 
(0-28) 
Group 1 
(0) 
13.60±13.75 
9.09(12.50) 
7±5 
6(6) 
Group 2 
(0-16.5) 
17.18±15.37 
12.50 (16.66) 
7±5 
7(6) 
Group 3 
(16.5-33) 
18.30±16.76 
16.60 (13.54) 
7±5 
6(5) 
Group 4 
(33-49.5) 
15.61±15.21 
12.50 (23.05) 
6±5 
5 (8) 
Group 5 
(>50) 
23.28±16.27 
20.83 (27.27) 
9±4 
8(6) 
p-value 0.385 0.506 
OSDI: The Ocular-surface-disease-index (scores); SPEED: Standard Patient Evaluation of Eye 
Dryness (scores) 
*statistically significant differences among groups; p<0.05. 
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respectively). No differences were found among groups 1 and 2 (p=0.953) neither 
among groups 3, 4 and 5 (? = 0.303). On the other hand, no statistically significant 
differences were found among the five groups for TBUT (? = 0.249) and Schirmer test (? = 0.160). 
 
 
 
 
 
Figure 50. Classical clinical parameters boxplots graphs from (A) Tear Film 
Osmolarity (B) Tear film break-up time and (C) Schirmer test. 
A 
B 
C 
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Figure 51. Classical clinical parameters boxplots graphs from (A) Corneal staining 
and (B) Conjunctival staining. 
 
 
 
 
 
 
 
A 
B 
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Table  10. Comparison of classical clinical parameters among different MGL groups. Results expressed in mean±standard deviation (in bold) 
and median (IQR) for each parameter. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TFO: tear film osmolarity (mOsms/L); TBUT: tear break-up time (seconds); Schirmer test (mm); Corneal and conjunctival staining were graded using Oxford Staining Score System. 
* statistically significant differences among groups; p<0.05.
MEIBOSCORE GROUP 
(MGL%) 
CLASSICAL CLINICAL PARAMETERS 
 TFO  TBUT  SCHIRMER CORNEAL 
STAINING 
CONJUNCTIVAL 
STAINING 
Group 1 
 (0) 
308±16 
305(21) 
4.86±2.52 
3.81(2.02) 
13±6 
12(4) 
0.76±0.70 
1.00 (1.00) 
1.19±0.68 
1.00 (1.00) 
Group 2 
 (0-16.5) 
310±19 
306 (20) 
4.85±2.57 
3.97(1.96) 
13±8 
12(7) 
0.62±0.85 
0.00(1.00) 
1.20±0.83 
1.00 (1.00) 
Group 3 
 (16.5-33) 
304±15 
302(14) 
4.04±1.46 
3.73(1.47) 
11±7 
10(6) 
0.98±0.86 
1.00 (1.00) 
1.67±1.02 
1.50 (1.00) 
Group 4 
 (33-49.5) 
312±12 
314(14) 
3.96±1.22 
3.77(1.67) 
10±7 
9(6) 
0.85±0.67 
1.00 (1.00) 
1.75±0.79 
2.00 (1.00 
Group 5 
 (>50) 
326±18 
320(30) 
3.64±1.51 
3.54(1.53) 
11±4 
11(6) 
1.47±1.23 
1.00 (1.00) 
1.88±0.93 
2.00 (1.00) 
p-value 0.023* 0.249 0.160 0.015* 0.004* 
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3.2.4 Keratograph 5M Automated Measurements 
 
 Figures 52 and 53 as well as Table 11 show the automated measurements 
obtained by K5M for each group. Statistically significant differences in BR were found 
between groups 5 and 1 (" = 0.043) and groups 5 and 2 (" = 0.010). On the 
contrary, no statistically significant differences were found among groups for TMHk (" = 0.405), LR (" = 0.063), NIKBUT-first (" = 0.213) and NIKBUT-avg (" =0.427).	Furthermore, no statistically significant differences were found among MGL 
groups and LLP (see Table 12).  
 A 
B 
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Figure 53. K5M automated measurements (A) NIKBUT-first(B) NIKBUT-avg. 
 
Figure 52. K5M automated measurements (A) Tear Meniscus Height (B) 
Bulbar Redness (C) Limbal Redness. 
C 
A 
B 
 Table  11. Comparison of K5M automated measurements among different MGL groups. Results expressed in mean±standard deviation (in 
bold) and median (IQR) for each parameter. 
 
 
 
 
 
 
 
 
 
 
 
 
TMHk: tear meniscus height (mm); Bulbar (BR) and limbal redness (LR) were graded automatically by K5M software; NIKBUT-first: first rupture non-invasive Keratograph tear 
film break-up time (seconds); NIKBUT-avg: average of non-invasive Keratograph tear film break-up time (seconds). 
*statistically significant differences among groups; p<0.05. 
 
 
 
 
 
MEIBOSCORE GROUP 
(MGL%) 
AUTOMATED MEASUREMENTS BY K5M 
 TMHk BR 
 
LR NIKBUT-first NIKBUT-avg 
Group 1 
 (0) 
0.23±0.05 
0.23(0.04) 
1.00±0.46 
0.90(0.53) 
0.68±0.35 
0.47(0.40) 
11.23±6.82 
7.77(7.84) 
13.81±6.15 
13.42 (7.42) 
Group 2 
 (0-16.5) 
0.26±0.07 
0.24(0.09) 
0.99±0.44 
0.90 (0.45) 
0.62±0.32 
0.58(0.36) 
8.79±5.12 
7.01(6.61) 
11.80±5.02 
10.26 (8.05) 
Group 3 
 (16.5-33) 
0.27±0.09 
0.26(0.08) 
1.16±0.55 
1.07(0.67) 
0.70±0.40 
0.63(0.53) 
8.83±4.95 
8.11(6.92) 
12.32±4.97 
11.92(7.72) 
Group 4 
 (33-49.5) 
0.26±0.80 
0.25(0.11) 
1.25±0.53 
1.33(0.78) 
0.76±0.37 
0.70 (0.72) 
10.19±5.96 
8.59(7.36) 
12.48±5.52 
12.98 (9.15) 
Group 5 
 (>50) 
0.28±0.10 
0.26(0.15) 
1.30±0.41 
1.40(0.57) 
0.92±0.41 
0.85(0.37) 
6.76±4.08 
5.59(4.96) 
10.07±4.95 
10.30(5.30) 
p-value 0.405 0.040* 0.063 0.213 0.427 
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Table  12. Comparison of lipid layer patterns among different MGL groups. Results expressed in n (%). 
 
 
 
 
 
 
 
 
 
 
 
L
ipid Layer Patterns (Guillon): 0= None or not visible; 1= Meshwork (open/tight); 2= Wave (Meshwork and Wave); 3= Amorphous (Wave and Amorphous) 
and 4= Colours (Wave and Colours/ Amorphous and Colours and Colours). 
*statistically significant differences among groups; p<0.05. 
 
MEIBOSCORE GROUP  
(MGL%) 
 
LIPID LAYER 
PATTERNS 
Group 1 
(0) 
Group 2 
(0-16.5) 
Group 3 
(16.5-33) 
Group 4 
(33-49.5) 
Group 5 
(>50) 
Total 
0 1(4.8) 2(3.4) 2(4.5) 0(0) 1(5.9) 6 (3.7) 
1 5(23.8) 6(10.2) 7(15.9) 3(15) 1(5.9) 22(13.7) 
2 4(19) 9(15.3) 5(11.4) 6(30) 3(7.6) 27(16.8) 
3 8(38.1) 31(52.2) 19(43.2) 9(45.0) 8(47.1) 75(46.6) 
4 3(14.3) 11(18.6) 11(25) 2(10) 4(23.5) 31(19.3) 
Total 21 59 44 20 17        161 
p-value 0.858 
 As aforementioned, the age is a relevant factor in MG morphology and it has been 
demonstrated in the Study I, it is also relevant on the ocular surface. Therefore, Table 13 shows 
the relationship between the MGL and several ocular surface parameters. It is also included other 
analysis of the relationship taking the age into account age as a covariant.  
 
Table  13. Correlation coefficients of MGL and ocular surface parameter and same coefficient 
correlations applying age as a covariant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 MGL 
(Covariant: Age) 
 Correlation 
coefficient 
p 
DED Questionnaires 
OSDI 0.011 0.914 
SPEED 0.012 0.904 
K5M Parameters 
TMHk 0.059 0.563 
BR -0.003 0.969 
LR -0.044 0.668 
NIKBUT-fr -0.095 0.345 
NIKBUT-avg -0.054 0.597 
Lipid Layer 
Patterns 
-0.041 0.611 
Classical Clinical Parameters 
TFO 0.088 0.393 
Corneal staining 0.208 0.041* 
Conjunctival 
staining 
-0.004 0.966 
TBUT -0.163 0.112 
Schirmer test -0.065 0.527 
MG Features 
MG quality 
secretion 
0.044 0.587 
Functional MG 0.145 0.074 
 
TFO: Tear film osmolarity (mOsms/L); TMHk: Tear meniscus height (mm); 
Bulbar and limbal redness (BR and LR) were graded automatically by K5M 
software (scores); NIKBUT-first: first rupture non-invasive Keratograph tear 
film break-up time (seconds); NIKBUT-avg: average of non-invasive 
Keratograph tear film break-up time (seconds); MGL: Meibomian gland loss 
graded with meiboscore scale; LLP: Lipid layer patterns; TBUT: Tear break-
up time(seconds); OSDI: The Ocular-surface-disease-index (scores); SPEED: 
Standard Patient Evaluation of Eye Dryness (scores). 
 
(r, Pearson and Spearman correlations) 
*statistically significant; p-value<0.05.  
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Study III 
 
Relationship between new objective MG morphological parameters and the 
ocular surface parameters 
 
 
The results of this study are divided into two sections: 
• 1º section: It shows the relationship between objective MG morphological parameters and the 
most relevant ocular surface clinical parameters.  
• 2º section: It shows the relationship between objective MG irregularity and the most relevant 
ocular surface clinical parameters in a group of participants that showed a MGL <32%.  
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3.3.1 Relationship between objective MG morphological parameters and the 
most relevant ocular surface clinical parameters. 
 
The automated algorithm processed successfully 149 (out of 161) meibography images from 
the UL. Table 14, 15 and 16 show the demographic data (general information, MG features and 
clinical parameters, respectively) of the sample evaluated.  
Table 14. General information of the sample evaluated. 
 
 
 
 
 
 
 
 
 
 
 
Table  15. MG morphological features of the sample evaluated. 
 
 
MG Morphological Features 
 Automated and Objective Parameters Slit-lamp Assessment 
 Objective 
MGL 
(%) 
Mean 
Width 
(mm) 
Mean 
Length 
(mm) 
Numbe
r of 
glands 
Quality of 
secretion 
(score) 
Functional 
MG 
(score) 
Mean±SD 
Median(IQR) 
20.32 ± 13.95 
17.50(17.00) 
0.39 ± 0.07 
0.39(0.08) 
2.55 ± 0.60 
2.57 (0.84) 
24 ± 7 
24(8) 
0.97± 0.81 
1 (2) 
0.51± 0.70 
0 (1) 
MG: Meibomian glands; MGL: Meibomian gland loss; SD: Standard deviation; IQR: Interquartile rang
  
N 149 
AGE 
(years) 
42± 17 
40 (28) 
SEX 
(Female /Male) 
80/69 
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Table  16. Clinical parameters of the sample evaluated. 
 
 
 
SD: Standard deviation; IQR: Interquartile range; OSDI: The Ocular-surface-disease-index; SPEED: Standard Patient Evaluation of Eye Dryness ; TFO: Tear film osmolarity; BR: Bulbar redness was graded automatically by 
K5M software; TMHk: Tear meniscus height; NIKBUT-avg: average of non-invasive Keratograph tear film break-up time; TBUT: Tear break-up time; LWE UL: Lid wiper epitheliopathy severity of the upper eyelid. 
 
 
 
 
 
 
In order to know the relationship between the new MG morphology parameters and the most relevant ocular surface parameters, the 
correlation coefficients were obtained (see Table 17). As well, the correlation coefficients of those MG morphology parameters which 
demonstrated to be significantly influenced by age were obtained where age was included as a covariant (see Table 18).  
 
 
 
Ocular Surface Parameters  
 
OSDI 
(score) 
SPEED 
(score) 
TFO 
(mOsms/L) 
BR 
(score) 
TMHk 
(mm) 
NIBUT-
AVG 
(seconds) 
 
 
TBUT 
(seconds) 
 
 
SCHIR
MER 
(mm) 
 
 
LWE UL 
(score) 
 
Corneal 
Staining 
(score) 
 
Conjuncti
val 
Staining 
(score) 
Mean±S
D 
Median 
 (IQR) 
16.84±14.96 
14.11(16.42) 
7± 5 
6(6) 
310±18 
306 (21) 
1.10±0.45 
1.03 
(0.63) 
0.26±0.08 
0.25 (0.09) 
12.00±5.18 
11.37 (7.97) 
4.44±2.11 
3.94 (1.93) 
12± 7 
11 (7) 
1.01±0.66 
1 (0) 
0.8 ±0.9 
1(1) 
1.47± 0.90 
1 (1) 
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Table  17. Correlation coefficients of objective MG morphological parameters and ocular surface parameters. 
 
DED: Dry eye disease; OSDI: The Ocular-surface-disease-index (score); SPEED: Standard Patient Evaluation of Eye Dryness (score) ;TFO: Tear film osmolarity (mOsms/L); TMHk: Tear meniscus height (mm); BR: Bulbar redness was graded 
automatically by K5M software; NIKBUT-avg: average of non-invasive Keratograph tear film break-up time (seconds); LWE UL: Lid wiper epitheliopathy severity of the upper eyelid (severity score); TBUT: Tear break-up time(seconds); 
MG: Meibomian glands.  
(r, Pearson and Spearman) 
*statistically significant; p<0.05. 
 Objective MGL Mean Length  Mean Width 
 
Number of Glands 
 Correlation 
coefficient 
p Correlation 
coefficient 
p Correlation 
coefficient 
p Correlation 
coefficient 
p 
AGE 0.253 0.002* -0.214 0.009* -0.196 0.017* -0.114 0.168 
SEX -0.034 0.680 0.158 0.056 -0.068 0.414 -0.062 0.454 
DED Questionnaires 
OSDI 0.062 0.451 0.012 0.880 -0.092 0.266 0.029 0.720 
SPEED 0.006 0.934 0.037 0.653 -0.030 0.717 -0.034 0.681 
Tear Film Osmolarity 
TFO -0.078 0.459 0.014 0.890 0.039 0.705 -0.094 0.369 
Keratograph 5M 
TMHk 0.274 0.0008* -0.172 0.037* -0.038 0.642 -0.029 0.722 
BR 0.177 0.032* -0.214 0.0095* -0.119 0.152 -0.140 0.092 
NIKBUT-avg 0.076 0.360 -0.042 0.613 0.097 0.239 -0.147 0.075 
ClassicalClinical Parameters 
Corneal Staining 0.049 0.554 -0.009 0.907 -0.080 0.332 -0.010 0.894 
Conjunctival Staining 0.133 0.105 -0.139 0.091 -0.130 0.113 -0.071 0.388 
LWE UL 0.000 0.991 -0.049 0.551 -0.017 0.830 -0.084 0.312 
TBUT -0.110 0.180 0.156 0.057 0.210 0.010* 0.082 0.319 
Schirmer test -0.027 0.741 0.038 0.644 -0.018 0.820 -0.027 0.735 
MG Features 
MG quality secretion 0.100 0.226 -0.125 0.129 -0.048 0.562 -0.127 0.124 
Functional MG 0.106 0.199 -0.056 0.500 -0.001 0.562 -0.071 0.392 
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Table  18. Correlation coefficients of objective MG morphological parameters and ocular surface parameters applying age as a covariant.  
DED: Dry eye disease; OSDI: The Ocular-surface-disease-index (score); SPEED: Standard Patient Evaluation of Eye Dryness (score) ;TFO: Tear film osmolarity (mOsms/L); TMHk: Tear meniscus height (mm); BR: Bulbar redness was graded 
automatically by K5M software; NIKBUT-avg: average of non-invasive Keratograph tear film break-up time (seconds); LWE UL: Lid wiper epitheliopathy severity of the upper eyelid (severity score); TBUT: Tear break-up time(seconds); 
MG: Meibomian glands 
(r, Spearman correlation) 
*statistically significant; p<0.05.
 Objective MGL 
(Covariant: AGE) 
Mean Length  
(Covariant: AGE) 
Mean Width 
(Covariant: AGE) 
 
 Correlation 
coefficient 
p Correlation 
coefficient 
p Correlation 
coefficient 
p 
DED Questionnaires 
OSDI 0.017 0.878 0.058 0.605 -0.147 0.185 
SPEED -0.047 0.671 0.047 0.676 -0.103 0.353 
Tear Film Osmolarity 
TFO 0.005 0.967 -0.006 0.956 0.028 0.800 
Keratograph 5M 
TMHk 0.119 0.285 -0.030 0.786 -0.086 0.440 
BR -0.142 0.199 0.121 0.313 0.159 0.152 
NIKBUT-avg -0.032 0.771 0.075 0.500 -0.045 0.687 
Classical Clinical Parameters 
Corneal Staining -0.050 0.654 0.153 0.169 0.054 0.630 
Conjunctival Staining -0.178 0.108 0.119 0.286 0.080 0.470 
LWE UL -0.047 0.672 0.060 0.588 0.067 0.560 
TBUT -0.081 0.468 -0.008 0.945 0.210 0.057 
Schirmer test -0.050 0.655 0.046 0.679 0.013 0.909 
MG Features 
MG quality secretion -0.098 0.380 0.136 0.219 0.063 0.569 
Functional MG 0.144 0.195 -0.058 0.605 -0.013 0.910 
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3.3.2 Relationship between objective MG irregularity and the most relevant 
ocular surface clinical parameters. 
 
The objective MG irregularity was assessed in a group of participants with a MGL < 32% since 
it is a morphological feature only observed when the MG are still present. A total of 122 
participants (out of 161) showed a MGL < 32%. Table 19, 20 and 21 show the demographic data 
(general information, MG features and clinical parameters, respectively) of the sample evaluated.  
 
Table  19. General information of the sample evaluated. Results expressed in mean±SD and 
median and IQR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MGL: Meibomian gland losss 
 
 
Table  20. MG morphological features of the sample evaluated. Results expressed in mean±SD 
and median and IQR. 
 
MG: Meibomian glands; MGL: Meibomian gland loss; SD: Standard deviation; IQR: Interquartile range
 < 32% Objective 
MGL  
N 122 
AGE 
(years) 
40 ± 17 
36 (25) 
SEX 
(Female/Male) 
64/58 
MG Morphological Features 
 Automated and Objective Parameters Slit-Lamp 
Assessment 
 Irregularity Objective 
MGL 
(%) 
Mean 
Width 
(mm) 
Mean 
Length 
(mm) 
Number 
of glands 
Quality of 
secretion 
(score) 
Mean±SD 
Median(IQR) 
22.11 ± 40.56 
5.30(29.16) 
15.39 ± 8.44 
  15.00(13.75) 
0.41 ± 0.06 
0.40(0.08) 
2.71 ± 0.52 
2.68 (0.59) 
26 ± 6 
25(7) 
2.71 ± 0.52 
2.68 (0.59) 
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Table  21.  Clinical parameters of the sample evaluated. Results expressed in mean±SD and median and IQR. 
 
SD: Standard deviation; IQR: Interquartile range; OSDI: The Ocular-surface-disease-index; TFO: Tear film osmolarity; BR: Bulbar redness was graded automatically by K5M software; TMHk: Tear meniscus height; NIKBUT-
avg: average of non-invasive Keratograph tear film break-up time; TBUT: Tear break-up time; LWE UL: Lid wiper epitheliopathy severity of the upper eyeli
Ocular Surface Parameters 
  
 
OSDI 
(score) 
 
 
TFO 
(mOsms/L) 
 
 
BR 
(score) 
 
 
TMHk 
(mm) 
 
 
NIBUT-AVG 
(seconds) 
 
 
TBUT 
(seconds) 
 
 
SCHIRMER 
(mm) 
 
 
LWE UL 
(score) 
 
Corneal 
Staining 
(score) 
Mean±SD 
Median (IQR) 
16.31±14.62 
12.50(16.26) 
309.8 ± 17.8 
306.0 (21.5) 
1.06 ± 0.45 
0.97(0.53) 
0.25 ± 0.07 
0.24(0.08) 
12.02 ± 0.52 
2.68 (0.59) 
4.56 ± 2.23 
3.97 (1.90) 
12 ± 8 
11(7) 
1.0 ± 0.7 
1(0) 
0.8 ± 0.9 
1(1) 
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Table  22. Correlation coefficients of objective MG irregularity and MG morphological features and 
ocular surface parameters. 
 
Objective MG Irregularity 
 Correlation 
Coefficient 
p 
AGE -0.117 0.198 
SEX 0.010 0.916 
MG Morphological Features 
Objective MGL -0.073 0.421 
Mean Width 0.516 <0.0001* 
Mean Length 0.211 0.020* 
Number of glands 0.009 0.922 
Quality of secretion -0.026 0.778 
Ocular Surface Parameters 
OSDI 0.015 0.874 
TFO -0.064 0.578 
BR -0.045 0.626 
TMHk 0.008 0.928 
NIBUT AVG 0.068 0.458 
TBUT 0.108 0.234 
SCHIRMER 0.090 0.322 
LWE UL -0.078 0.398 
Corneal  
Staining 
-0.071 0.436 
 
OSDI: The Ocular-surface-disease-index (score);TFO: Tear film osmolarity (mOsms/L); BR: Bulbar redness was graded automatically by K5M 
software;  TMHk: Tear meniscus height (mm); NIKBUT-avg: average of non-invasive Keratograph tear film break-up time (seconds); LWE UL: Lid 
wiper epitheliopathy severity of the upper eyelid (severity score); TBUT: Tear break-up time(seconds); MG: Meibomian glands; MGL: Meibomian 
gland loss. 
(r, Spearman correlation) 
*statistically significant; p- value < 0.05 
 
 
 
In the light of these results, the participants were classified according to three different levels 
of MG irregularity as follow: low, medium and high. These groups who showed different 
irregularity were compared (see Table 23) and afterward, the relationship between each level of 
MG irregularity and the ocular surface parameters were obtained (see Table 24).
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Table  23. Demographic data from the three different levels of MG irregularity and its 
comparison. Results expressed in mean±SD and median and IQR. 
 
 
SD: Standard deviation; IQR: Interquartile range; OSDI: The Ocular-surface-disease-index; TFO: Tear film osmolarity; BR: Bulbar redness was graded 
automatically by K5M software; TMHk: Tear meniscus height; NIKBUT-avg: average of non-invasive Keratograph tear film break-up time; TBUT: Tear 
break-up time; LWE UL: Lid wiper epitheliopathy severity of the upper eyelid. 
*statistically significant among groups; p- value < 0.05 
 
  LOW  
(G1) 
MEDIUM 
(G2) 
HIGH 
(G3) 
 
N  78 22 22 p 
AGE 
(years) 
Mean±SD 
Median(IQR) 
42 ± 18 
36(28) 
37 ± 12 
34(14) 
38 ± 16 
41(22) 
0.580 
SEX 
Female/Males 
 40/30 12/10 12/10 0.942 
MG Morphological Features 
Objective MGL 
(%) 
Mean±SD 
Median(IQR) 
15.79 ± 8.40 
14.50(12.75) 
14.00± 8.45 
11.50(13.75) 
15.36 ± 8.82 
16.50(14.50) 
0.674 
Mean Width 
(mm) 
Mean±SD 
Median(IQR) 
0.39 ± 0.05 
0.38(0.07) 
0.43± 0.06 
0.43(0.09) 
0.46± 0.06 
0.44(0.07) 
<0.001* 
Mean Length 
(mm) 
Mean±SD 
Median(IQR) 
2.65 ± 0.51 
2.65(0.55) 
2.70± 0.40 
2.69(0.43) 
2.91 ± 0.60 
3.03(0.97) 
0.117 
Number of Glands Mean±SD 
Median(IQR) 
26 ± 6 
25(7) 
27± 7 
27(9) 
24 ± 6 
24(10) 
0.353 
Quality of Secretion 
(score) 
Mean±SD 
Median(IQR) 
0.51 ± 0.73 
0(1) 
0.41 ± 0.59 
0(1) 
0.32 ± 0.57 
0(1) 
0.511 
Ocular Surface Parameters 
OSDI 
(score) 
Mean±SD 
Median(IQR) 
17.14 ± 14.58 
14.58(16.47) 
18.41 ± 18.47 
11.46(18.23) 
11.35 ± 8.89 
9.37(15.34) 
0.307 
TFO 
(mOsms/L) 
Mean±SD 
Median(IQR) 
308 ± 15 
306(21) 
320 ± 30 
309(31) 
307 ± 15 
306(22) 
0.666 
BR 
(score) 
Mean±SD 
Median(IQR) 
1.09 ± 0.47 
1.00(0.64) 
0.91 ± 0.39 
0.87(0.50) 
1.09± 0.41 
1.03(0.67) 
0.301 
TMHk 
(mm) 
Mean±SD 
Median(IQR) 
0.25 ± 0.08 
0.24(0.09) 
0.25 ± 0.06 
0.24(0.10) 
0.25 ± 0.06 
0.25(0.08) 
0.894 
NIKBUT AVG 
(seconds) 
Mean±SD 
Median(IQR) 
11.35 ± 5.19 
10.13(6.79) 
13.31 ± 4.97 
15.11(7.71) 
13.12 ± 5.46 
13(7.46) 
0.125 
TBUT 
(seconds) 
Mean±SD 
Median(IQR) 
4.27 ± 2.00 
3.90(1.55) 
5.44 ± 2.20 
5.11(3.05) 
4.71 ± 2.83 
4.03(1.46) 
0.037* 
SCHIRMER 
(mm) 
Mean±SD 
Median(IQR) 
11.87 ± 6.64 
11(6.50) 
13.68 ± 10.39 
10.50(8.50) 
13.68 ± 7.74 
11(7.50) 
0.666 
LWE UL 
(score) 
Mean±SD 
Median(IQR) 
0.97 ± 0.65 
1(0) 
0.91 ± 0.75 
1(1) 
1.05 ± 0.72 
1(1.25) 
0.687 
Corneal Staining 
(score) 
Mean±SD 
Median(IQR) 
0.81 ± 0.87 
1(1) 
0.73 ± 0.98 
0.50(1) 
0.68 ± 0.72 
1(1) 
0.666 
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Statistically significant differences were found among groups in mean width (! < 0.001) and 
TBUT (! = 0.037). Regarding mean width, there were statistically significant differences between 
group 1 and groups 2 and 3 (! = 	0.01	,-.	! = 0.006)	but no differences were found between 
groups 2 and 3 (! = 0.663). In the case of TBUT, there were statistically significant differences 
between group 1 and 2 (! = 0.014) but no differences were found between groups 1 and 3 (! =0.474) as well as groups 2 and 3 (! = 0.069). 
 
Table  24. Correlation coefficients of different levels of MG irregularity and the most relevant 
ocular surface parameters. 
 
OSDI: The Ocular-surface-disease-index (score);TFO: Tear film osmolarity (mOsms/L); BR: Bulbar redness was graded automatically by K5M 
software;  TMHk: Tear meniscus height (mm); NIKBUT-avg: average of non-invasive Keratograph tear film break-up time (seconds); LWE UL: Lid 
wiper epitheliopathy severity of the upper eyelid (severity score); TBUT: Tear break-up time(seconds); MG: Meibomian glands; MGL: Meibomian 
gland loss. (r, Spearman correlation) 
*statistically significant; p- value <0.05.
MG Irregularity 
 
GROUP 
 
N 
G1  
LOW  
 
78 
 G2 
MEDIUM 
 
22 
 G3 
HIGH 
 
22 
 
 Correlation 
Coefficient 
p Correlation 
Coefficient 
p Correlation 
Coefficient 
p 
AGE -0.087 0.447 -0.134 0.552 -0.052 0.818 
SEX -0.029 0.801 -0.014 0.949 -0.144 0.523 
MG Morphological Features 
Objective MGL -0.108 0.345 0.122 0.590 0.148 0.511 
Mean Width 0.313 0.005* 0.024 0.914 0.251 0.260 
Mean Length 0.134 0.243 -0.196 0.382 0.162 0.471 
Number of 
glands 
0.167 0.143 -0.230 0.303 -0.224 0.316 
Quality of 
secretion 
0.112 0.332 0.204 0.364 0.294 0.184 
Ocular Surface Parameters 
OSDI 0.287 0.011* 0.154 0.494 -0.141 0.532 
TFO -0.192 0.177 -0.162 0.620 0.120 0.646 
BR -0.039 0.732 0.065 0.780 0.341 0.121 
TMHk -0.059 0.608 -0.057 0.800 0.207 0.355 
NIBUT AVG -0.207 0.069 0.114 0.613 -0.159 0.479 
TBUT -0.049 0.667 0.071 0.755 0.160 0.477 
SCHIRMER 0.079 0.491 -0.003 0.990 0.003 0.990 
LWE UL -0.177 0.123 -0.237 0.287 -0.140 0.534 
Corneal  
Staining 
-0.057 0.621 0.122 0.588 -0.096 0.671 
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Study IV 
 
Ocular surface temperature in DED and healthy eyes using infrared 
thermography 
 
A total of 86 participants were enrolled in this study. Demographic data by groups are shown 
in Table 25 and 26. 
Table  25. Demographic data from the control and DED group. Results expressed in mean±SD and 
median and IQR. 
 
 
 
 
 
 
 
 
 
 
 
 
Table  26. Demographic data from DED group. Results expressed in mean±SD and median and IQR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CONTROL DED 
N 48 38 
AGE 
 (years) 
39±12 
40(17) 
49±19 
50(33) 
Corporal 
Temperature (°C) 
35.7±0.7 
35.8(0.7) 
35.9±0.5 
35.9(0.7) 
SEX 
(Male/Female) 
  14/24 25/13 
DED: Dry eye disease 
 
DED group 
 ADDE EDE 
N        16        22 
AGE 
(years) 
54±20 
60 (36) 
46±18 
42 (29) 
Corporal 
Temperature 
(°C) 
36.0±0.4 
35.9(0.4) 
35.8±0.4 
35.6(0.6) 
SEX 
(Male/Female) 
6/10 8/14 
ADDE: Aqueous-deficient dry eye; EDE: Evaporative dry eye 
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No statistically significant differences were found in blink rate between healthy eyes and DED 
(! = 	0.1; 11 ± 4 and 13 ± 5, respectively). Also, no statistically significant differences were found 
in the duration of the first and last complete IBI between healthy eyes and DED (! = 0.1; 4 ± 4 
and 5 ± 4	seconds, respectively).  
3.4.1 DED versus CONTROL 
 
No statistically significant differences were found in MOST along 40 seconds of recording 
between DED and control group (! = 0.1; 34.74±0.78°5 and 34.99±0.65°5, respectively). In 
addition, no statistically significant differences were found in MOST at the start between DED and 
control group (! = 0.1; 34.78±0.75°5 and 35.00±0.63°5, respectively) as well as at the end 
between both groups (! = 0.1; 34.72±0.77°5 and 34.97±0.67°5, respectively). Regarding mean 
TER, there was no statistically significant difference between DED	(49.8±39.6 x10-7 g/cm2/s) and 
control (48.4±38.6 x10-7 g/cm2/s) group (! = 0.1; 49.8±39.6 x10-7 and 48.4±38.6x10-7 g/cm2/s, 
respectively). 
Table 27 shows the comparison between DED and control group for GAP and GAP recovery in 
the first and the last complete IBI. There were statistically significant differences in GAP between 
first and the last complete IBI in the DED group (! = 0.004) and between DED and control group 
in the last complete IBI (! = 0.004).	 
Table  27. Comparison of GAP and GAP recovery between DED and control group in the first and last 
complete IBI. Results expressed in mean±SD and median and IQR. 
 
  First IBI Last complete IBI p-value 
 
GAP 
DED 
Mean±SD 
Median(IQR) 
 
0.02±0.23 
0.02(0.16) 
 
 
0.16±0.25 
0.12(0.25) 
 
 
0.004g 
CONTROL 
Mean±SD 
Median(IQR) 
 
-0.03±0.18 
-0.01(0.12) 
 
 
0.01±0.19 
0.02(0.20) 
 
 
0.4g 
p-value  
DED vs CONTROL 
0.2g 0.004s  
 
GAP Recovery 
DED 
Mean±SD 
Median(IQR) 
 
0.00±0.14 
0.00(0.14) 
 
 
0.02±0.27 
0.01(0.17) 
 
 
0.7g 
CONTROL 
Mean±SD 
Median(IQR) 
 
0.01±0.21 
-0.01(0.20) 
 
 
-0.03±0.22 
-0.01(0.21) 
 
 
0.8g 
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Figures 54 and 55 show the comparison between DED and control group in the first IBI. 
There were statistically significant differences in MOST at the start (! = 0.03) and at the end (! =0.01) and in MOST of the IBI (! = 0.02) between DED and control group.  
 Regarding mean TER, there was no statistically significant difference between DED and 
control group in the first IBI (! = 0.3; 49.3±48.5x10-7 and 48.5±35.7x10-7 g/cm2/s, respectively) 
 
MOST: Mean OST of the ROI (°C). MIN: Minimum temperature of ROI (°C). MAX: Maximum temperature of ROI (°C). 
Figure 54. Comparison between DED and control group in the first IBI. 
 
 
 
p-value  
DED vs CONTROL 
0.8g 0.5g  
SD: Standard deviation; IQR: Interquartile range; DED: Dry eye disease. IBI: Inter- blink interval. GAP: OST difference between the end of one 
IBI and the beginning of the next IBI (ºC). GAP recovery: OST difference between the beginning of two consecutive IBIs in the ROI (ºC). 
*differences statistically significant: p-value<0.05 
s : parametric test 
g: non-parametric test 
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SD: Standard deviation (°C). 
Figure 55. Comparison of standard deviations between DED and control in the first IBI. 
 
Figures 56 and 57 show the comparison of between DED and control group in the last 
complete IBI. There were statistically significant differences in MOST at the start (! = 0.03) and 
at the end (! = 0.001), MIN at the start (! = 0.04) and at the end (! = 0.02) and in MOST of the 
IBI (! = 0.006) between DED and control group. 
Regarding mean TER, there was no statistically significant difference between DED and control 
group in the last complete IBI (! = 0.2; 50.0±47.7 x10-7 and 48.6±35.4x10-7 g/cm2/s, respectively).  
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MOST: Mean OST of the ROI (°C). MIN: Minimum temperature of ROI (°C). MAX: Maximum temperature of ROI (°C). 
 
 
Figure 56.  Comparison between DED and control group in the last complete IBI. 
 
 
 
 
 
SD: Standard deviation (°C). 
Figure 57. Comparison of standard deviations between DED and control in the last complete 
IBI. 
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3.4.2 ADDE versus EDE 
 
No statistically significant differences were found in MOST along 40 seconds of recording 
between ADDE and EDE group (! = 0.1; 34.55±0.86°C and 34.99±0.65°C, respectively). In 
addition, no statistically significant differences were found in MOST at the start between ADDE 
and EDE (! = 0.2; 34.62±0.84°C and 34.90±0.68°C) as well as at the end of the recording between 
both groups (! = 	0.1; 34.53±	0.85°5 and 34.86±0.69°5, respectively).  
Regarding mean TER, there was no statistically significant difference between ADDE and EDE 
group (! = 0.2; 50.3± 47.5x10-7 and 49.6± 33.8x10-7 g/cm2/s, respectively). 
Table 28 shows the comparison between ADDE and EDE group for GAP and GAP recovery in 
the first and last complete IBI. There were statistically significant differences in GAP between first 
and last complete IBI in the EDE group (! = 0.02) and between ADDE and EDE group in the last 
complete IBI (! = 0.008).  
Table  28. Comparison of GAP and GAP recovery between ADDE and EDE group in the first and 
last complete IBI. Results expressed in mean±SD and median and IQR. 
 
  First IBI Last Complete IBI p-value 
 
GAP 
ADDE 
Mean±SD 
Median(IQR) 
 
0.06±0.12 
0.06(0.17) 
 
0.11±0.12 
0.09(0.17) 
 
 
0.1s  
EDE 
Mean±SD 
Median(IQR) 
 
-0.02±0.28 
0.02(0.16) 
 
0.20±0.32 
0.20(0.35) 
 
 
0.02s 
p-value 
ADDE vs EDE 
0.2g 0.008s  
 
GAP Recovery 
ADDE 
Mean±SD 
Median(IQR) 
 
-0.01±0.12 
-0.01(0.10) 
 
0.00±0.16 
0.00(0.14) 
 
 
0.2g 
EDE 
Mean±SD 
Median(IQR) 
 
0.00±0.16 
0.01(0.17) 
 
 
0.03±0.33 
0.01(0.20) 
 
 
0.8g 
p-value 
ADDE vs EDE 
0.8g 0.7g  
SD: Standard deviation; IQR: Interquartile range; IBI: Inter- blink interval; ADDE: Aqueous-deficient dry eye; EDE: Evaporative dry eye 
GAP: OST difference between the end of one IBI and the beginning of the next IBI (°C). GAP recovery: OST difference between the beginning of two 
consecutive IBIs in the ROI (°C). 
differences statistically significant: p-value<0.05 
s : parametric test 
g: non-parametric test 
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Figures 58 and 59show the comparison between ADDE and EDE group in the first IBI. There 
were statistically significant differences in MOST at the end (! = 0.02), MIN at the start (! =0.04), MAX at the end (! = 0.01) and MOST of the IBI (! = 0.02) between ADDE and EDE group. 
In addition, a statistically significant difference was found in standard deviation at the start(! =0.03) but not at the end (! = 0.5) between both groups in the first IBI (Figure 60). 
Regarding mean TER, there was no statistically significant difference between ADDE and 
EDE in the first IBI (! = 0.5; 49.5±63.3x10-7 and 49.1±34.1x10-7 g/cm2/s, respectively).  
 
 
 
MOST: Mean OST of the ROI (°C). MIN: Minimum temperature of ROI (°C). MAX: Maximum temperature of ROI (°C). 
Figure 58.  Comparison between ADDE and EDE group in the first IBI. 
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SD: Standard deviation (°C). 
Figure 59. Comparison of standard deviations between ADDE and EDE in the first IBI. 
 
 
Figures 60 and 61 show the comparison between ADDE and EDE in the last complete IBI. There 
were statistically significant differences in MOST at the start (! = 0.03) and at the end (! =0.003), MIN at the end (! = 0.02) and MOST of the IBI (! = 0.008) between ADDE and EDE 
group. In addition, statistically significant differences were found in standard deviation at the start (! = 0.04) and at the end (! = 0.03) between both groups in the last complete IBI (Figure 60). 
Regarding mean TER, there was no statistically significant difference between ADDE and EDE in 
the last complete IBI (! = 0.3; 50.0±63.0x10-7and 49.8±32.9x10-7 g/cm2/s, respectively).  
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MOST: Mean OST of the ROI (°C). MIN: Minimum temperature of ROI (°C). MAX: Maximum temperature of ROI (°C). 
Figure 60. Comparison between ADDE and EDE group in the last complete IBI. 
 
 
SD: Standard deviation (°C). 
Figure 61. Comparison of standard deviations between ADDE and EDE in the last complete IBI. 
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 Chapter 4 
Discussion and Conclusion 
Study I 
 
The effect of ageing on the ocular surface parameters 
 
 
Our study findings suggest that elderly population present ocular surface changes when 
compared to a young population. Although the majority of the ocular surface parameters studied 
presented a fair correlation with age, these results give us relevant information of the ageing of 
the ocular surface and how it could affect the DED diagnosis. Additionally, women from this study 
showed more changes due to ageing than men who presented better ocular surface conditions 
than those of their age-matched group. 
In the present research study, moderate and positive correlations (BR, LR, Corneal and 
conjunctival staining and TMHk, respectively) and negative correlations (TBUT and Schirmer test, 
respectively) were found with age. These results are in agreement with other research studies 
reported in the literature. Woods [283] found an increase in tear retention in patients older than 
40 years that could be explained by the problems in lacrimal drainage and changes in the lid 
margin. Additionally, a reduction in tear secretion and TBUT have been reported in elderly patients 
[284,285]. Andres et al.[286] established the TBUT as predictive factor of DED problems. As well, 
Guillon et al.[287] found higher tear film evaporation in older patients (more in women than men) 
suggesting that it may be a significant contributing factor to DED in female population. Similarly, 
Maissa et al.[288]found that the tear film characteristics worsening with age. Another study 
conducted by Yeotikar et al.[196] found statistically significant associations between age and 
TMHk, TBUT, palpebral redness and roughness, and conjunctival staining where 185 participants 
(aged 25 to 66 years) were evaluated. Conversely, they found a significant negative association 
between TFO and age that is not in agreement with the results of our study. In addition, they did 
not find significant effect of age on NIBUT, tear volume (measured with phenol red) and LWE. 
These differences in the results might be due to the different measurements techniques, clinical 
devices used and the characteristics of the sample.  
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Likewise, MGL and MG function showed a moderate and positive correlation with age. The 
great amount of MGL in elderly patients and the reduction in the quality of the MG secretion are 
well-known and documented by several studies [178,191,289]. Moreover, an increase in lower 
eyelid margin thickness and in the LWE severity was observed with age. The eyelid laxity, more 
common in older individuals, has been reported to be associated with DED symptoms and 
abnormal tear parameters. It has impact on tear function that lead to a greater exposure and 
increased irritation [290,291], which could explain our findings regarding the increased ocular 
redness with age.  
As highlighted by the experts of the DEWS II, there is an association between ageing and an 
increase in positive DED signs [22,23]. In addition, it has been reported that this increase by 
decade is greater with clinical DED signs compared with symptoms. Despite this, the experts 
suggest being cautious with the DED signs since the signs may not always be an intrinsic feature of 
the DED and may reflect normal ageing or other ocular surface conditions. Indeed, it is not clear 
how the pathological thresholds from different clinical signs could be adjusted to age [30]. 
Regarding subjective questionnaires, our findings showed a weak correlation (OSDI and MQ 
questionnaires) or no correlation (SPEED, DEQ-5 and SANDE questionnaires) with aging. Previous 
studies have already shown the lack of association between DED symptoms, ocular surface 
signs[292] and age[293]. Reduction of the tear secretion in DED patients induce inflammation and 
peripheral nerve damage [294]. This leads to sensitization of polymodal and mechanonociceptor 
nerve endings and an abnormal increase in cold thermoreceptor activity, evoking dryness 
sensations and pain. Prolongation of disturbances in ocular sensory pathways (molecular, 
structural or functional) eventually leads to dysestesias and neuropathic pain related to the eye 
surface[64].For example, Acosta et al.[295] conducted a study in rats and they found that the cold 
trigeminal neurons gradually die with aging. In the case of the human eye, a possible cause of 
absence or reduced dryness sensations could be explained by the aforementioned changes, 
justifying the lack of the association between these variables [196]. Our study findings showed 
that higher scores were obtained by elderly patients, but it is not consistent between 
questionnaires. These differences could be explained by different symptoms evaluated in each 
questionnaire and also by the nature of each instrument. The complexity of both central and 
peripheral neural mechanisms associated with ocular surface sensations and tissue homeostasis in 
relation to DED is still not entirely understood[64]. 
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When the age groups were compared, statistically significant differences were found in 
most of the parameters assessed. These major differences were between group A (< 42 years) 
with B (42 − 	65 years) and C (< 	65 years), whereas the upper age groups (B and C) showed 
similar DED signs and symptoms. These findings highlight the differences between both age 
populations.  
All these changes could have impact on the DED diagnosis but also in the success of several 
optical correction alternatives for presbyopia, such as intraocular lenses (IOLs) implantation and 
multifocal contact lenses (MCLs). MCLs demonstrated to be a good choice as they provide good 
visual quality [296–298] the desired independency from spectacles and, no less important, the 
aesthetic benefit (desirable mostly by women). Despite all the reported benefits, the prescription 
rate is still quite low. Studies as conducted by Sivardeen et al.[299] tried to determine the utility of 
clinical and non-clinical indicators to aid the initial selection of the optimum presbyopic CL. 
However, the features studied have been demonstrated to be poor indicators of the preferred 
MCLs type. Most of the research studies conducted about MCLs focus on visual performance and 
only a few of them focus on the CL interaction with the ocular surface[293]. Concerning this issue, 
contact lens discomfort (CLD) is one of the major issues related to CL dropout in CL wearers of all 
ages [300]. It is important to mention that the materials of the MCLs are the same as those that fit 
in young CL wearers. We believe our results about ocular surface ageing changes will provide 
relevant information in order to understand better the CL interaction with the eye in each 
population and even how these changes could impact on surgical therapies as IOLs implants or 
MCLs fitting. In addition, all these changes on the ocular surface would have an effect on the 
optical quality of the eye determined by the stability of the tear film. Consequently, it could 
impact on visual quality outcomes after IOL implantation or MCLs. It has also been reported that 
the variability in the keratometry readings is higher in patients with TFO value higher than 316 
mOsm/L that could have relevant influence on the IOL power calculation [301]. 
Ocular surface differences between women and men were also assessed. Females had a worse 
ocular surface condition than men (NIKBUT-fr, NIKBUT-avg, corneal and conjunctival staining, 
TBUT and all questionnaires performed). A study conducted by Maissa et al.[288]found that the 
changes in tear film stability and lipid layer characteristics are more marked in women than men. 
Such a finding and the higher evaporation rate in older women aforementioned could lead to a 
higher corneal and conjunctival damage by environmental exposure and therefore partly explain 
the higher symptomatology reported by women.  
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In summary, this study confirms the decline in tear film with ageing and that the ocular surface 
of women is more affected than men.  The study also demonstrated that age is a relevant factor 
that is needed to take into account. This is because the DED signs that are observed may not 
always be intrinsic features of the DED and could reflect normal ageing or another ocular surface 
conditions.  
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  Study II 
 
Relationship between MGL assessed by NIM and the ocular surface 
parameters and symptomatology 
 
 
NIM has been proven to be a useful technique for non-invasive observation of  MG 
morphology in order to help physicians improve DED diagnosis and treatments [169,178,302]. The 
aim of the study is to assess the correlation between MGL and important ocular surface 
parameters and it has to be determined if one or both (UL and LL) eyelid should be included for 
MGL assessment. This matter is quite controversial since different studies with different aims have 
considered both or only one eyelid. Routinely, LL is the most commonly assessed due to its 
accessibility which provokes less discomfort to the patient. It is believed that comparable outcome 
can be expected for MGL assessment choosing one or two eyelids, as UL and LL MGL seem to be 
significantly correlated [190]. Dogan et al.[303] assessed meibography images of 30 patients and 
proposed to evaluate only the UL for MGL assessment because of its correlation with TBUT and 
better inter-examiner agreement on MGL. On the other hand, Finis et al.[226] performed a 
retrospective analysis of 128 patients and found a strong correlation between meiboscores of the 
UL and the LL as well as with the total meiboscore. This suggests that MGL assessment based on 
the evaluation of the LL might be enough for the clinical routine. In the present study a positive 
and fair statistically significant correlation between MGL of UL and LL was found. However, there 
was no agreement as revealed by the Kappa statistic, suggesting that, despite there exist a 
relationship between MGL of both eyelids there is a bias in their meiboscore.  
Our results are in accordance with the study done by Pult et al.[190], who suggested the 
MGL assessment of both eyelids. Therefore, in our study both eyelids were taken into account in 
order to assess MGL and participants were classified into five groups according to the total 
meiboscore [178]. 
DED symptomatology was evaluated using OSDI and SPEED questionnaires in the current 
study. No statistically significant differences were found in DED questionnaires among different 
MGL groups. However, as Table 4 shows, the symptomatology score for group 5, in both 
questionnaires, is clinically higher than for the other groups. It has been reported that an MGL of 
>32% is likely to be accompanied with associated detectable clinical symptoms [179]. Similarly,  
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several studies have found correlation between MGL and OSDI scores [196,304]. However, other 
studies have not found any correlation between MGL and OSDI scores [303,305] or SPEED 
questionnaire [306]. 
Regarding MGL and its correlation with other clinical parameters, statistically significant 
differences were found in TFO between group 5 and groups 1,2 and 3. Besides, statistically 
significant differences were found in corneal staining as well as conjunctival staining between 
group 5 and groups 1 and 2. These results are in agreement with those obtained by Feng et 
al.[305] who found a positive correlation between corneal staining and MGL in DED patients. 
Previous studies have suggested that when the amount of MG reduced, the secretion of MG 
decreases. This might induce tear film homeostasis loss and greater tear film evaporation which 
could lead to surface epithelial damage, and disturbance of the glycocalyx and goblet cell mucins 
[307]. In the present study no differences were found in TBUT and Schirmer test among different 
MGL groups. These findings are in accordance with other studies that did not find any correlation 
between MGL and the  tear film parameters [308] or a low correlation was found [305]. 
Nevertheless, Arita et al. [309] studied a population with MGD and found that Schirmer test was 
positively correlated with the meiboscore. Thus, patients with less amount or damaged MG would 
have an increase of fluid that may compensate the decreased function of the lipid layer. These 
findings suggest that these ocular surface parameters could be affected by MGL in patients who 
suffer from MGD. The glandular loss may exacerbate the signs of MGD in comparison with those 
who only present MGL without other ocular condition. No statistically significant differences were 
found in any of the 5KM parameters among MGL groups except for BR. Recently, Ji et al.[310] 
found a correlation between MGL grade and NIKBUT-avg, NIKBUT and LLT in patients with DED 
and MGD. This discrepancy between studies could be due to the study population including only 
subjects with DED and MGD.  
Our findings suggest that a MGL higher than 50% is accompanied by signs of increased 
osmolarity, redness and staining of the ocular surface. However, it is important to highlight that in 
our study the mean age of the participants was higher in the groups with higher MGL. Therefore, it 
is not possible to ascertain if these signs in ocular surface parameters are due to MGL or to age. 
The great influence of aging on MG morphology and function is well-known and documented in 
the literature [178,190,308,311]. In order to address this point, the relationship between MGL and 
the ocular surface parameters was assessed considering age as a covariant. When it was 
performed, only the corneal staining was correlated with MGL. These results emphasize the 
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influence of ageing in the MG morphology but also in several ocular surface parameters such as 
corneal staining, LLT or tear volume among others [288,311]. The importance of participants age 
when performing research studies focused on the ocular surface has been previously reported 
[311] and pointed out. Thus, in order to assess the real impact or influence of the MGL on the 
ocular surface parameters (which are influenced by age), it would be necessary to compare 
matched age groups. For example, MGL has been found to be positively correlated with meibum 
quality suggesting an impaired MG function when MGL increase [141,310,312]. The present study 
has shown that when age is covariant, the relationship between MGL and meibum quality is 
absent, indicating that meibum quality could be decreased either because of a higher amount of 
MGL or because it is naturally decreased with aging. These findings suggest that different 
thresholds for defining abnormal ocular and tear film surface parameters should be considered 
according with the age. Next steps should be focused on determining the normal values of 
different parameters for each age range. 
In summary, this study suggests that a MGL higher than 50% is accompanied by signs in the 
ocular surface. In the light of the findings, future studies must consider age due to its great 
influence on the MG morphology. Also, to compare age-matched groups in order to know the 
contribution of the MGL on the ocular surface as well as establishing valid cut-off values for DED 
diagnosis. 
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Study III 
 
Relationship between new objective MG morphological parameters and the 
ocular surface parameters 
 
         The assessment of the MG morphology is currently receiving much attention due to the 
impact of the DED and, particularly of the MGD worldwide. Since the introduction of the NIM 
[178] in the clinical setting, both researchers and eye care practitioners have been able to obtain 
useful information of the MG morphology in a fast and patient-friendly way in order to perform a 
better DED diagnosis. As previously explained, MGL has been the most reported MG feature 
observed through NIM [166] which has served as indicator of severity of the condition. Typically, it 
has been graded subjectively by researchers and eye care practitioners but, in the last few years 
more objective methods have been suggested. Nowadays, the MG morphology assessment is 
advancing towards to an automatic approach due to its numerous benefits. One of these 
advantages is obtain more reliable information because the measurement is not dependent of the 
user and, on the other hand, it gives the possibility to assess other morphological features apart 
from the MGL (such as the length, width, shape, contour and tortuosity) [169,179,313]. Despite 
this, the automatic analysis of the meibography images based on imaging processing appear to be 
challenging. Many factors can influence this analysis such as specular reflections, low contrast, 
artefacts, defocused areas and as well, non-uniform illumination[314]. To date, several automated 
algorithms based on image processing have been proposed to assess MG morphology. In 2012, 
Koh et al.[192] introduced a computational method to detect the length and width of the MG 
without requiring any input from the user. They classified a total of 55 meibography images as 
healthy and non-healthy, obtaining a specificity of 96% and a sensitivity of 98%. Despite this, the 
algorithm failed to classify the images, which considered as “intermediate”. According to the 
authors, it is necessary to evaluate additional morphological features such as MG distortion. Later 
on, in 2013, Celik et al. [314]developed an automated method that allowed the identification of 
gland and inter-gland regions (two-class segmentation) of 131 meibography images.  As well, it 
allowed the classification of the meibography images into healthy, intermediate and unhealth with 
an accuracy of 88%. However, this was designed to analyse only the UL. More recently, in 2016, 
Koprowski et al.[194,195] proposed a full automated algorithm tested with a total of 172 
meibography images (from the UL and LL) of 55 DED and 31 healthy subjects which were 
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compared with the results of an expert clinician. The subjects of this work were classified into 
three groups: healthy, at-risk and affected. The study showed reproducible results obtaining a 
sensitivity of 99.3% and specificity of 97.5% in the MG diagnosis.   
           The automated algorithm used in the present study provides a three-class classification and 
it is able to differentiate between gland, inter-gland and areas of MGL. Indeed, it provides an 
objective estimation of the MGL area and as well, other morphological parameters of MG such as 
mean length, mean width, number of glands and especially, the irregularity. To the extent of our 
knowledge, this is the first attempt to quantify the irregularity of the MG using an automated 
method. The assessment of this morphological parameter in particular could provide valuable 
information about the progression of the MGD [141,180]. 
            Currently, limited information is available regarding the relationship between objective MG 
morphological parameters and the ocular surface. For example, Ban et al.[191] conducted a 
morphometric assessment using NIM and studied the relationship between the MG morphology 
and the ocular surface. In order to accomplish this, they evaluated the mean length of the MG 
ducts (five central MG ducts), percentage area of MG acini and number of glands dropouts of 37 
healthy subjects (both eyelids) analysed semi-automatically with ImageJ software. Both mean MG 
duct length and percent area of MG acini were negatively correlated with age (: = 	−0.485 and : = 	−0592, respectively) while the number of gland dropouts showed positive correlation with 
age (: = 0.518). As well as previous studies, the age is a relevant factor regarding the MG 
morphology, having an impact also in the length and the percentage of MG acini in this study 
[178,304]. In addition, they found that the mean length of the MG ducts in the UL and LL showed 
negative correlations with the meibum secretion and the corneal staining score. As well, the 
percent area of MG acini in the UL showed a positive correlation with TBUT and negative 
correlations with the tear film lipid layer interferometry and meibum secretion. Instead, the 
present study found significant positive correlations between THMk and BR with the objective 
MGL and negative correlations with the objective mean length of the MG. This finding makes 
sense as the objective MGL and length are related (reduced MG length may indicate that part of 
the MG disappears). Arita et al.[309] previously reported that an increased tear fluid could 
compensate the decreased function of the lipid layer. Additionally, this change in the tear film 
could lead to an inflammation of the ocular surface, represented by the ocular redness. 
Despite the previous results, it is important to note that the majority of the objective MG 
morphology parameters (objective MGL, mean width and mean length) showed a significant 
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correlation with age and no correlation with sex. Indeed, when age included as a covariant, it is 
observed that there is no relationship between these three objective MG morphology parameters 
and the most relevant ocular surface parameters. In other words, the influence of these MG 
morphological parameters on the ocular surface parameters could be smaller in comparison to the 
influence provided by age. Therefore, these findings highlight the relevance of the age as a factor 
to study the influence of MG morphology on the ocular surface integrity. 
Beyond the MG morphological parameters aforementioned, the other morphological 
parameter to analyse in this study was the irregularity of the MG (most commonly named as 
tortuosity or distortion). According to Mathers et al.[157], MG distortion appears in the first stage 
of morphological changes of the MG. In fact, it has been observed in patients with perennial AC 
[212] as well as in patients with CL-related allergic conjunctivitis (CLAC) [315]. In the first case, 
patients with perennial AC who presented MG distortion showed higher meibum score in 
comparison to those with perennial AC that no showed MG distortion. Similarly, in the second 
case, CL wearers with CLAC showed impaired MG function in comparison to CL wearers without 
CLAC. These findings suggest the influence of the MG distortion upon seeing the MG function 
diminished.  According to the authors, it is suggested that the AC, not the CL wear, is associated 
with MG distortion. Indeed, it is believed that the MG distortion could be due to inflammatory 
changes in the conjunctival tissue that might induce pressure on the MG in the tarsus [316,317]. 
On the other hand, MG distortion has been observed in CL wearers (both soft and rigid CL) [206] 
and the reason behind it is thought to be the chronic friction provoked by the CL. Due to the lack 
of information about the MG distortion, more investigations are needed about its origin.  It is 
relevant to mention that both MGL and MG distortion make reference to different aspects of the 
MG morphology, so it is expected not to find a relationship between them (the first one reflects 
the loss of area and the second the changes in shape) [178]. Indeed, in the present study, these 
two MG morphology features are not well related between irregularity, number of glands and 
quality secretion. On the other hand, the irregularity showed a positive correlation with the length 
and the width of the MG. This indicates that when the irregularity increase, the width and the 
length increase too. This finding is interesting because it is expected or believed that when it is 
observed an increase of irregularity is led to an increase in the width and a decrease in the length 
of the MG since MG tends to shrink itself. Nevertheless, this was not observed in our study. The 
reason that these results are unknown could be related to the automatic calculation and 
mathematics principles used in the algorithm. Further studies are needed to clarify this matter.  
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As well as the MGL, the assessment of the MG distortion is performed subjectively, usually 
as “present” or “absent”[313] or even, for example,  grading it from 0 to 2 ( grade 0: no distortion 
of the MG; grade 1: 1–4 MG with distortion > 	45°; grade 2: more than five MG with distortion >	45°).[315]. 
To the best of our knowledge, this is the first study that shows an objective attempt to 
report the irregularity of the MG. In addition, it was studied its relationship with some of the most 
relevant ocular surface parameters. As observed, it had no correlation with any ocular surface 
parameter, even with DED symptomatology. For this reason, we are led to ask ourselves if 
different levels of irregularity (participants were classified into low, medium or high irregularity) 
could be related to these ocular surface parameters.  As well, no correlations were found except 
for group 1 (low) who exhibited a fair and positive correlation with OSDI and also with the width of 
the MG. Notwithstanding, the results need to be carefully interpreted since the groups of 
irregularity are not homogeneous and there is a big difference between group 1 and the other two 
groups.  
In summary, as found in the previous chapter, the majority of the objective MG 
morphology parameters obtained with the automated algorithm are highly influenced by age. The 
influence provided by those MG morphology parameters on the ocular surface could be smaller in 
comparison to the influence provided by age. Regarding MG irregularity, it may represent the 
prodromal stage before losing the MG and as long as the gland is not atrophied, it will be 
functioning, and the ocular surface will not be affected. However, this hypothesis needs to be 
confirmed with a prospective study to assess the MG irregularity changes in time and its natural 
course as well as to clarify the role of this morphometric feature on the DED context.  
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Study IV 
 
Ocular surface temperature in DED and healthy eyes using IR thermography 
 
 
          The IR thermography has been widely used during the last decades to assess non-invasively 
the tear film, both static and dynamically. First, Morgan et al.[264] emphasized the potential of 
this technology for tear film diagnosis and later on, Purslow et al.[262] demonstrated the existing 
connection between the tear film and OST. The current study provides more information about 
the OST changes (both DED and healthy eyes) and the effect of blinking by assessing several OST 
metrics and specifically the IBI. Several research studies have demonstrated that DED subjects 
present cooler OST and faster cooling rates compared to healthy subjects [257,318]. For example, 
Craig et al.[319] found that DED patients have a significantly lower temperature GCC than 
controls. Tan et al.[258] found lower temperatures in DED subjects after 5 and 10 seconds of eye-
opening (GCC, MOST, minimum and maximum temperature and different areas of the eye). 
Kamao et al.[259] also observed greater decrease in OST in DED eyes at 10 seconds after eye-
opening and, in addition, they found that eyes with a shorter TBUT are more likely to have a 
decrease in the OST. Using a remote sensor thermometry, Singh and Bhinder[320] also found 
lower mean OST value in DED eyes compared to that found in normal subjects. On the other hand, 
a study conducted by Morgan et al[264] found an increased MOST in DED patients 
(32.38±	0.69°5) in comparison to controls (31.94±0.54°5) that could be attributed to 
inflammation or increased hyperemia within the DED group participated in their study [263,321]. 
Nevertheless, other research studies reported no significant difference in MOST immediately after 
eye open between DED and normal subjects [322,323]. In the present study, DED showed a slightly 
cooler OST in comparison to the control group in MOST along 40 seconds of recording and as well 
as in MOST at the start and at the end between both groups. However, the results were not 
statistically significant. Despite this, when the IBI of both groups were assessed and compared, 
statistically significant differences were found. In the first IBI was found statistically significant 
differences in MOST at the start and at the end and MOST of the IBI. On the other hand, in the last 
complete IBI was found, apart from the aforementioned OST metrics, in the MIN at the start and 
also at the end. These findings suggest that after a period of natural blinking, the minimums 
temperatures are affected whereas the maximums temperatures remain almost stable in both 
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groups. However, these changes in the minimums temperatures between IBIs could be 
attributable to the different conditions of the measurement. The first IBI was measured just after 
the blink and after the participant remained with the eyes closed for 3-4 seconds. This 
measurement is not highly influenced by the exposure of the ocular surface and could maintain a 
warming effect of the eyelid in the last blink before opening the eye. On the other hand, the last 
complete blink could be more influenced by the ambient surrounding or by partial blinks. In fact, 
partial blink is known that affect the stability of the tear film and its distribution in the inter-blink 
period [324]. Hence, it is possible that first IBI is not a representative IBI and may provide a false-
positive. Other reason could be due to the tear film dynamic since it is known that tear film has a 
complete cycle with four different parts [325]. Indeed, the tear film is constantly changing by 
undergoing a formation (build-up) phase directly after a blink, a fairly stable inter-blink phase and 
ultimately tear film destabilisation that can lead to tear film break-up in subjects with DED or 
when the eye is left open for a long period of time. In addition, it has been reported that tear film 
lipids tend to be relatively stable from blink to blink [326], therefore, maybe we are comparing 
different parts of the blinking cycle lead to these differences. Further studies using natural blinking 
are needed in order to elucidate this point and obtain more information about the natural 
dynamic of the blink. 
Furthermore, a significant difference was found in GAP between groups in the last 
complete IBI, being higher in the DED group. It demonstrates that DED eyes cooling quicker than 
healthy eyes and thanks to the blink action the OST of the DED eyes can be restored (GAP recovery 
remains stable). Zhang et al.[327] reported that eyelids affect the OST since the eyelid provides 
thermal pulses to the ocular surface. In addition, Deng et al.[328] using theoretical models of 
thermal dynamics explored the temperature profiles during the partial blink for the tear film and 
the simulation revealed that lid motion had a significant effect on corneal temperature during the 
blinking and for a short period after the blink. In their study, the temperature GCC for a full blink 
remains periodic over multiple blink cycles. In the case of partial blinks, there is a noticeable 
reduction of the peak temperature for each in comparison to the full blinks. This finding suggests 
that the partial blink may affect the thermal stability. As previously reported by Shen[329], 
incomplete blinking is frequently found in patients with DED, therefore the blink could be more 
determinant in DED eyes.  
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The TER is a relevant parameter in the study of the tear dynamics[266]. Previously, NIBUT 
has been negatively correlated with evaporation rates[144], indicating that an increased 
evaporation causes more rapid thinning of the tear film between blinks leading to faster break-up. 
Indeed, a recent study found evidence that ocular surface cooling and tear film break-up are 
associated and suggest that a common physical force such as tear film evaporation is acting in 
both processes[330]. Several studies have reported an increased TER in subjects with DED 
[164,319,331,332] (ADDE, EDE and mixed) while others did not found the same results [270]. In 
this study, no significant differences were found in TER between DED and control groups nor 
between ADDE and EDE groups. In the literature is possible to find a wide range of TER values 
(between 0.02 to 29 x 10-7 g/cm2/s in human eyes) for healthy and DED eyes that depends on the 
ambient temperature, relative humidity and also the technology used in each study [270]. TER 
values obtained in the current study (up to 40 x 10-7 g/cm2/s) lie out of the range reported in 
previous studies but it is well-known that this parameter is highly influenced by external factors as 
ambient temperature and humidity [333,334].For example, Petznick et al.[335] measured TER 
values in healthy subjects using an infrared thermal camera at 30°5 under two different 
percentages of relative humidity (45	and 65) and found values around 13.5 and 11.8 x 10-7 
g/cm2/s, respectively. In addition, Tan et al.[266]found a TER of  25.38±5.63 x 10-7 g/cm2/s at 70% 
of relative humidity in healthy subjects. As observed, there is a great discrepancy among studies 
and the reason is unclear. However, it could be related to the environmental conditions during the 
measurements or due to small changes in the focus of the image that could introduce an error in 
the measurements since the thermography is very sensitive to the focusing. Future studies are 
needed to corroborate these findings. 
While OST differences between DED and normal subjects is well-documented, only a few 
studies have evaluated the thermal differences between different DED types[336,337]. Abreu et 
al.[336] found lower mean initial OST in ADDE patients (GCC, nasal and temporal conjunctiva) in 
comparison to EDE, SS and control. Besides, ADDE patients showed the most substantial heat loss 
over the 5 seconds of IBI (−0.97°5). On the other hand, more recently, Matteoli et al.[337] found 
that EDE patients have the maximum temperature variation (−0.75°5) and the highest average 
cooling rate. In this study, no statistically significant differences were found in MOST along 40 
seconds and MOST at the start and at the end of the recording between ADDE and EDE.  Despite 
this, when the first and the last complete IBI between both groups were assessed, statistically 
significant differences were found. Indeed, in the first IBI was observed in MOST at the end, MIN 
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at the start, MAX at the end and MOST of the IBI whereas in the last complete IBI was found in the 
MOST at the start and at the end, MIN at the end and MOST in the IBI. Our findings suggest that 
the ADDE group showed cooler OST but the OST variability was greater in the EDE group. In 
addition, EDE showed higher GAP which lead to quicker cooling in comparison to ADDE. On the 
other hand, both groups showed no significant changes in GAP recovery which could mean that 
the eyelid provides a warming effect of the ocular surface in each blink. As well as the comparison 
between DED and control, the assessment of the IBI has provide more information about the OST 
changes between groups. Apart from the methodology used to assess the OST, the inconsistences 
in the results among different studies could be also due to the different DED diagnosis criteria 
established or even to the different degree of DED severity.  
In summary, the evaluation of the thermal behaviour during the IBI could provide useful 
information about the thermal changes of the ocular surface in DED and healthy eyes.  
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Chapter 5               
  Summary  
 
 
The following is a summary of the conclusions taken from the four performed studies:  
 
1) Age is a relevant factor that is necessary to take into account when the ocular 
surface is assessed since the DED signs that are observed may not always be 
intrinsic features of the DED and could reflect normal ageing or another ocular 
surface conditions. 
 
2) The assessment of the MGL subjectively using the meiboscore showed that a MGL 
higher than 50% is accompanied by signs of increased osmolarity, redness and 
staining of the ocular surface. Despite this, when age was included as a covariant 
only the corneal staining was correlated with MGL, emphasizing the influence of 
ageing in the MG morphology but also in several ocular surface parameters. 
Overall, these findings suggest that age-matched groups should be compared in 
order to know the contribution of the MGL on the ocular surface as well as establish 
valid cut-off values for DED diagnosis. 
 
3) It is possible to obtain further information regarding the MG morphology such as 
the area of loss, length, width and irregularity from a 2-D meibography image using 
an automated algorithm based on image processing.  
 
4) The majority of the objective MG morphology parameters obtained using an 
automated algorithm were also influenced by age, thus age-matched groups should 
be compared in order to know their contribution on the ocular surface integrity.  
 
5) To the best of our knowledge, it is the first study that shows an objective attempt to report 
the irregularity of the MG as well as its relationship with relevant ocular surface 
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parameters. According to the findings, the role of the MG irregularity as a clinical 
parameter is not clear, it may represent the prodromal stage before losing the MG. 
6) The NIM is a useful tool for the assessment of the morphology of the MG. However, 
in order to study the effect of changes in the gland morphology on the ocular 
surface, it is essential to consider age. 
7) The evaluation of the IBI provided further information about the thermal changes 
on the ocular surface of healthy and DED subjects.   
 
5.1 FUTURE STUDIES 
 
 
§ The MG structure was assessed only at one point in time in the present study. Long-
term prospective serial imaging of the MG would allow further understanding of 
the natural history of MG atrophy as well as other MG morphology features such as 
MG irregularity and its time course in our natural life cycles.  
§ The influence of age on the MG morphology and the ocular surface has been 
highlighted in this work. Future studies must consider age due to its great influence 
on the MG morphology. Also, to take into account on comparing matched-age 
groups in order to know the contribution of the MGL on the ocular surface as well 
as establishing valid cut-off values for DED diagnosis. This could help clinicians in order 
to carry out a better DED diagnosis.  
§ Currently, the study of the MG morphology involves an automatic approach in 
order to obtain more reliable information and reduce the time of the clinical 
evaluation. Future studies should incorporate an automatic method to assess the 
MG morphology. In addition, to study more deeply on the information that this 
approach could give the clinicians in order to help on the early prevention of ocular 
surface diseases or conditions such as MGD or DED.   
§ The IR thermography has shown to be a promising technology to assess the tear 
film dynamics. Future studies need to incorporate this technology in order to assess 
the tear film with other ocular surface conditions. The MGD field could be 
interesting to in order to explore the temperature differences between patients 
who show a low, medium and high amount of MGL or even between different 
levels of irregularity and to study its influence on the ocular surface temperature.  
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EPILOGUE 
 
 
 
1. SCIENTIFIC DISSEMINATION 
 
 
The proposed dissertation is a far-reaching work focused on the use of IR technology for 
MG structure assessment and thermal stability of the tear film which resulted in the following 
publications carried out for this doctoral thesis: 
 
Scientific articles 
o The effect of ageing on the ocular surface parameters. 
Authors: Laura Rico-del-Viejo, Amalia Lorente-Velázquez, José Luis Hernández-Verdejo, Ricardo García-
Mata, José Manuel Benítez-del-Castillo, David Madrid-Costa. Cont Lens Anterior Eye. 2018 Feb; 41:5-12. 
doi: 10.1016/j.clae.2017.09.015. 
o The influence of Meibomian gland loss on ocular surface clinical parameters. 
Authors: Laura Rico-del-Viejo, José Manuel Benítez-del-Castillo, Fernando Javier Gómez-Sanz, María 
García-Montero, Clara Llorens-Quintana, David Madrid-Costa. Apr 10. pii: S1367-0484(18)31061-0. doi: 
10.1016/j.clae.2019.04.004 
o Interaction between presbyopia correction and dry eye disease: A review. 
Authors: Laura Rico-Del-Viejo, Irene Martínez-Alberquilla, Pablo de Gracia, Javier Ruiz- Alcocer, James 
Wolffsohn, David Madrid-Costa. J Ophthalmol. 2019 (under review in Journal of Ophthalmology).  
o Drop Out the Area: on the importance of additional parameters when assessing meibomian glands 
condition.  
Clara Llorens-Quintana, Laura Rico-del-Viejo, Piotr Syga, David Madrid-Costa, Robert Iskander. (under 
review in Cornea Journal).   
o A novel automated approach for infrared-based assessment of Meibomian gland morphology. 
Authors: Clara Llorens-Quintana, Laura Rico-del-Viejo, Piotr Syga, David Madrid-Costa, and D. Robert 
Iskander. (under review in TVST).   
o Effect of blinking rate on tear film optical quality with different contact lenses. 
Authors: María García- Montero, Laura Rico-del-Viejo, Irene Martínez-Alberquilla, José Luis Hernández-
Verdejo, Amalia Lorente-Velázquez, David Madrid-Costa. (under review in Journal of Ophthalmology). 
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o Repeatability of non-invasive Keratograph 5M measurements associated with contact lens wear.  
Authors: María García- Montero, Laura Rico-del-Viejo, Amalia Lorente-Velázquez, Irene Martínez-
Alberquilla, José Luis Hernández-Verdejo, David Madrid-Costa. Eye Contact Lens. 2019 Mar 29. doi: 
10.1097/ICL.0000000000000596.  
o Randomized crossover trial of silicone hydrogel contact lenses. 
Authors: María García-Montero, Laura Rico-del-Viejo, Clara Llorens-Quintana, Amalia Lorente-
Velázquez, José Luis Hernández-Verdejo, David Madrid-Costa. Cont Lens Anterior Eye. 2018 Dec 23. pii: 
S1367-0484(18)30943-3. doi: 10.1016/j.clae.2018.12.006. 
o Comparison of the impact of Nesofilcon A hidrogel contact lens on the ocular surface and comfort of 
presbyopes and non presbyopes wearers. 
Authors: Amalia Lorente-Velázquez, Maria García-Montero, Fernando Javier Gómez Sanz, Laura Rico-
Del-Viejo, Jose Luis Hernández-Verdejo, David Madrid-Costa. Int J Ophthalmol. 2019 Apr 18;12(4):640-
646. doi: 10.18240/ijo.2019.04.19 
o Nonsurgical Procedures for Keratoconus Management – Review.  
Authors: Laura Rico-Del-Viejo, Maria García-Montero, Jose Luis Hernández-Verdejo, Santiago García-
Lázaro, Fernando Javier Gómez Sanz, Amalia Lorente-Velázquez. J Ophthalmol. 2017; 2017:9707650. 
doi: 10.1155/2017/9707650 
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Oral Communications   
• The role of Meibomian gland atrophy on contact lens discomfort.  
Authors: Laura Rico-del-Viejo, Nina Tavberidze, María García-Montero, Amalia Lorente-Velázquez, 
José Luis Hernández- Verdejo, David Madrid-Costa 
14° International Conference of Optometry and Vision Science (CIOCV’2017). University of Minho, 
Braga, Portugal. April 22-23th, 2017 
• Meibomian gland dropout as a predictor of the success of the multifocal contact lens 
fitting: A pilot study.  
Authors: Laura Rico-del-Viejo, Nina Tavberidze, Amalia Lorente-Velázquez, José Luis Hernández- 
Verdejo, David Madrid-Costa 
40th BCLA Clinical Conference & Exhibition. ACC Liverpool, Liverpool, UK. June 9 – 11thJune 2017 
• Impact of a daily hydrogel contact lens with higher water content on the ocular surface 
of non-presbyopic and presbyopic population. 
Authors: Laura Rico-del-Viejo, Nina Tavberidze, Amalia Lorente-Velázquez, José Luis Hernández- 
Verdejo, David Madrid-Costa 
40th BCLA Clinical Conference & Exhibition. ACC Liverpool, Liverpool, UK. June 9 – 11thJune 2017 
• Impacto de la pérdida de glándulas de meibomio (drop-out) en la película lagrimal y la 
superficie ocular.  
Authors: Laura Rico-del-Viejo, Nina Tavberidze, María García-Montero, Fernando Gómez- Sanz, 
Amalia Lorente-Velázquez, José Luis Hernández-Verdejo, David Madrid-Costa. 
 25° Congreso Internacional de Optometría, Contactología y Óptica Oftálmica (OPTOM) Madrid, 
Spain. April 13-15th, 2018 
• Envejecimiento y género, ¿Cómo influyen en la superficie ocular?  
Authors: Laura Rico-del-Viejo, Nina Tavberidze, María García-Montero, Fernando Gómez- Sanz, 
Amalia Lorente-Velázquez, José Luis Hernández-Verdejo, David Madrid-Costa. 
 25°  Congreso Internacional de Optometría, Contactología y Óptica Oftálmica (OPTOM) Madrid, 
Spain. April 13-15th, 2018 
• Meibomian glands integrity and its relationship with the ocular surface. 
Authors: Laura Rico-del-Viejo, Irene Martínez-Alberquilla, María García-Montero, Fernando 
Gómez- Sanz, Amalia Lorente-Velázquez, David Madrid-Costa. 
VI International Congress of Research in Retina and Vision. Inst. Investigaciones Oftalmológicas 
Ramón Castro Viejo, Madrid, Spain. June 29-30th, 2018  
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• Addition and pupil size effect on the visual performance of a novel extended-depth-of-
focus contact lens and a center-near design 
Authors: Javier Ruiz-Alcocer, Irene Martínez- Alberquilla, Laura Rico-del-Viejo, David Madrid-Costa.  
16° International Conference of Optometry and Vision Science CIOCV’2018. Altice Forum Braga, 
Braga, Portugal. May 4-5th 
 
• Ocular surface temperature in dry eye and healthy eyes using non-contact infrared 
thermography 
Authors: Javier Ruiz-Alcocer, Irene Martínez- Alberquilla, Laura Rico-del-Viejo, David Madrid-Costa.  
16° International Conference of Optometry and Vision Science CIOCV’2018. Altice Forum Braga, 
Braga, Portugal. May 4-5th 
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Poster Presentations  
• Non-contact meibography: The relevance of the assessment of the meibomian glands 
structure in the clinical setting.  
Authors: Laura Rico-del-Viejo, Nina Tavberidze, José Manuel Benítez-del- Castillo, Amalia Lorente-
Velázquez, Asunción Peral, David Madrid-Costa.  
13°  International Conference of Optometry and Vision Science (CIOCV’2016). University of Minho, 
Portugal. April 23th-24th, 2016 
• Impact on the ocular surface of a new daily hidrogel contact lens with high water 
content.  
Authors: Laura Rico-del-Viejo, Nina Tavberidze, Amalia Lorente-Velázquez, José Luis Hernández-
Verdejo, David Madrid-Costa.  
8th Tear Film & Ocular Surface Conferences (TFOS). Le Corum, Montpellier, France. September 7th- 
10th, 2016 
• Effects of contact lens wearing on tear film and ocular surface of presbyopes population.  
Authors: Laura Rico-del-Viejo, Javier Ruiz-Alcocer, Nina Tavberidze, Amalia Lorente-Velázquez, José 
Luis Hernández-Verdejo, David Madrid-Costa.  
8th Tear Film & Ocular Surface Conferences (TFOS). Le Corum, Montpellier, France. September 7th- 
10th, 2016 
 
• Infrared Meibography as a tool for Meibomian gland Dysfunction classification.  
Authors: Laura Rico-del-Viejo, Nina Tavberidze, María García-Montero, Amalia Lorente-Velázquez, 
José Luis Hernández- Verdejo, David Madrid-Costa.  
 14° International Conference of Optometry and Vision Science (CIOCV’2017). University of Minho, 
Braga, Portugal. April 22-23th, 2017 
 
• Comparison of temporal ocular surface temperature changes induced by different 
contact lens materials.  
Authors: José Luis Hernández- Verdejo, Laura Rico-del-Viejo, María García-Montero , Nina 
Tavberidze, María García-Montero, Amalia Lorente-Velázquez, José Luis Hernández- Verdejo, David 
Madrid-Costa.  
 14° International Conference of Optometry and Vision Science (CIOCV’2017). University of Minho, 
Braga, Portugal. April 22-23th, 2017 
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• Comparison of tear film optical quality dynamics in contact lens wearers.  
Authors: María García-Montero, Laura Rico-del-Viejo, Nina Tavberidze, Amalia Lorente-Velázquez,  
José Luis Hernández- Verdejo, David Madrid-Costa.  
 14° International Conference of Optometry and Vision Science (CIOCV’2017). University of Minho, 
Braga, Portugal. April 22-23th, 2017 
 
• Impact of blinking frequency on tear film optical quality dynamic in contact lens wearers.  
Authors: María García-Montero, Laura Rico-del-Viejo, Nina Tavberidze, Amalia Lorente-Velázquez, 
José Luis Hernández- Verdejo, David Madrid-Costa.  
 14°  International Conference of Optometry and Vision Science (CIOCV’2017). University of Minho, 
Braga, Portugal. April 22-23th, 2017 
 
• Impact of blinking frequency on the ocular surface temperature.  
Authors: José Luis Hernández- Verdejo, Laura Rico-del-Viejo, María García-Montero, Nina 
Tavberidze, Amalia Lorente-Velázquez, David Madrid-Costa.  
 14°  International Conference of Optometry and Vision Science (CIOCV’2017). University of Minho, 
Braga, Portugal. April 22-23th, 2017 
 
• Impact on anterior ocular surface of three different types of soft contact lenses 
materials.  
Authors: Nina Tavberidze, Amalia Lorente-Velázquez, Laura Rico-del-Viejo, María García-Montero, 
José Luis Hernández- Verdejo, David Madrid-Costa.  
 14°  International Conference of Optometry and Vision Science (CIOCV’2017). University of Minho, 
Braga, Portugal. April 22-23th, 2017 
 
• Ocular surface temperature in patients with evaporative and aqueous-deficient dry eye 
relative to normal. 
Authors: Irene Martínez-Alberquilla, Gabriela Orbezo, Álvaro Carrasco, María García- Montero, 
Clara Llorens-Quintana, Laura Rico-del-Viejo.  
VI International Congress of Research in Retina and Vision. Inst. Investigaciones Oftalmológicas 
Ramón Castro Viejo, Madrid, Spain. June 29-30th, 2018  
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• Comparison of the ocular surface temperature and evaporation among different lipid 
layer patterns.   
Authors: Gabriela Orbezo, Álvaro Carrasco, Irene Martínez-Alberquilla, María García- Montero, 
Laura Rico-del-Viejo, Clara Llorens-Quintana. 
VI International Congress of Research in Retina and Vision. Inst. Investigaciones Oftalmológicas 
Ramón Castro Viejo, Madrid, Spain. June 29-30th, 2018  
 
• Comparación de los cambios temporales de temperatura de la superficie ocular durante 
el uso de diferentes tipos de lentes de contacto. 
Authors: José Luis Hernández-Verdejo, Laura Rico-del-Viejo, María García-Montero. Fernando 
Javier Gómez-Sanz, Nina Tavberidze, Amalia Lorente- Velázquez, David Madrid-Costa. 
25° Congreso Internacional de Optometría, Contactología y Óptica Oftálmica (OPTOM) Madrid, 
Spain. April 13-15th, 2018 
• Estudio de la dinámica de la película lagrimal en la calidad óptica del ojo durante el 
parpadeo con diversos materiales de lentes de contacto blandas.  
Authors: María García-Montero, José Luis Hernández-Verdejo, Laura Rico-del-Viejo, Amalia 
Lorente- Velázquez, Nina Tavberidze, Fernando Javier Gómez-Sanz, Nina Tavberidze, Irene 
Martínez- Alberquilla, David Madrid-Costa. 
25º Congreso Internacional de Optometría, Contactología y Óptica Oftálmica (OPTOM) Madrid, 
Spain. April 13-15th, 2018 
 
• Impacto del porte de lentes de contacto en la sintomatología del usuario.  
Authors: Fernando Javier Gómez-Sanz, María García-Montero, José Luis Hernández-Verdejo, Laura 
Rico-del-Viejo, Nina Tavberidze, Amalia Lorente- Velázquez, David Madrid-Costa, Irene Martínez- 
Alberquilla.  
25° Congreso Internacional de Optometría, Contactología y Óptica Oftálmica (OPTOM) Madrid, 
Spain. April 13-15th, 2018 
• Impacto sobre la superficie ocular de una lente de contacto neofilcon A para dos 
poblaciones de sujetos: Jóvenes y Présbitas. 
Authors: Amalia Lorente- Velázquez, María García-Montero, Laura Rico-del-Viejo, José Luis 
Hernández-Verdejo, Nina Tavberidze, Fernando Javier Gómez-Sanz, David Madrid-Costa. 
25°  Congreso Internacional de Optometría, Contactología y Óptica Oftálmica (OPTOM) Madrid, 
Spain. April 13-15th, 2018 
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• Automatic and Objective assessment of Meibomian glands structure and dropout. 
Authors: Clara Llorens-Quintana, Laura Rico-del-Viejo, Piotr Syga, Cezary Sielużycki, D. Robert 
Iskander  
Annual ARVO Meeting. Hawaii Convection Center, Honolulu (Hawaii, EEUU), 29- 3rd May, 2018 
 
• The impact of two contact lenses designed for visual display terminals on the ocular 
surface of habitual contact lens wearers. 
Authors: Irene Martínez- Alberquilla, Laura Rico-del-Viejo, Fernando Javier Gómez-Sanz, Amalia 
Lorente- Velázquez, José Luis Hernández-Verdejo, María García-Montero.  
15°  International Conference of Optometry and Vision Science CIOCV’2018. University of Minho, 
Braga, Portugal. April 28-29th 
 
• How affect the contact lenses designed for “visual display terminal” in the ocular surface 
integrity? 
Authors: Irene Martínez- Alberquilla, Laura Rico-del-Viejo, Fernando Javier Gómez-Sanz, Amalia 
Lorente- Velázquez, José Luis Hernández-Verdejo, María García-Montero.  
15° International Conference of Optometry and Vision Science CIOCV’2018. University of Minho, 
Braga, Portugal. April 28-29th 
• The relationship between new morphological and objective Meibomian glands 
parameters and relevant ocular surface parameters. 
Authors: Laura Rico-del-Viejo, Clara Llorens-Quintana, Javier Ruiz-Alcocer, Irene Martínez-
Alberquilla, María García-Montero, David Madrid-Costa.  
16° International Conference of Optometry and Vision Science CIOCV’2018. Altice Forum Braga, 
Braga, Portugal. May 4-5th 
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Outreach Activities 
• Open-house day for the Erasmus+ Program ”Little Scientists” at the Faculty of Optics and 
Optometry, Complutense University of Madrid, Spain.  
Participation: Laura Rico-del-Viejo and Duygu Acar. 
• 2nd Edition “OPTOMEVISTA” (NEOUM). University of Minho, Braga, Portugal. May 21st, 
2016 
“European Dry Eye Network: The future of Dry Eye Research” 
           Authors: Laura Rico-del-Viejo and David Madrid-Costa.  
• IV Jornadas AEOPTOMETRISTAS 2017. Madrid, Spain. February 11th 2017 
“European Dry Eye Network (EDEN)”  
 Authors: Laura Rico-del-Viejo and David Madrid-Costa.  
• Summer Exhibition at the Royal Society of Science with the Project “Not a Dry Eye in the 
house”.  
Coordinator: Prof. James Wolffsohn (Aston University). London July 2-8th 2018  
• Coordinator of the second edition of “PhDAY 2018” in the Faculty of Optics and Optometry 
(November 22nd 2018), Complutense University of Madrid, Madrid, Spain.  
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Other Activities 
• Collaboration in a Multicenter DED study 
Prevalence and Risk Factors of DED 
Promotor: Aston University (Birmingham)  
Coordinator: Professor James Wolffsohn 
• Collaboration in Books 
o Superficie ocular y lentes de contacto - Fundación Salud Visual (February 2016)  
o Language: Spanish 
o  Authors: José M. González Méijome and César Villa Collar.   
o  Collaboration in: CHAPTER 7  
o Actualización en Queratocono. 
o Language: Spanish 
o  Authors: Cristina Peris Martínez and Nicolás Alejandre Alba 
o  Collaboration in: CHAPTER 10 
• Reviewer  
• Contact Lens and Anterior Eye (2017) 
• Journal of Optometry (2016-2018) 
• Journal of Ophthalmology (2018-2019) 
• Industrial sector training 
• Collaboration in R&D and Marketing Department in Mark’ennovy (Madrid, Spain). 
• Teaching and mentoring 
• Pediatric Optometry (30 hours) 
• Mentoring and supervision of MSc students.  
• Event management 
• 2° Edition PhDAY 2018, Faculty of Optics and Optometry (Madrid, Spain). November 22sd, 
2018. 
• Other activities related to EDEN: 
• Collaboration in the EDEN website 
• Collaboration in the editing of EDEN videos  
EDEN training courses:  
• Complutense University of Madrid, Spain  
• Aston University, Birmingham, UK  
• WUST, Wroclaw, Poland  
• Mid-term meeting with EU Commitee, Madrid 
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2. PARTICIPANT INFORMATION SHEET AND INFORMED CONSENT 
 
 
                            HOJA DE INFORMACIÓN AL PARTICIPANTE 
 
 
Título del Estudio: “Evaluación de la estructura de las glándulas de meibomio mediante 
tecnología infrarroja” 
 
Título del Estudio (original): “Infrared Imaging of Meibomian Gland Structure” 
 
 
INVESTIGADORES: José Manuel Benítez del Castillo1 
                                    David Madrid Costa2 
                                    Laura Rico del Viejo2 
1. Unidad de Superficie Ocular (Oftalmología) del Hospital Universitario Clínico San Carlos, Madrid.  
2. Departamento de  Óptica II: Optometría y Visión, Facultad de Óptica y Optometría, UCM 
 
LOCALIZACIÓN DEL ESTUDIO: Facultad de Óptica y Optometría 
C. Arcos de Jalón Nº 118 
28037 MADRID 
 
INTRODUCCIÓN 
 
 
Estimado Paciente, 
 
 
Se le invita a participar en un estudio de investigación clínica cuyo objetivo principal 
es actualizar la clasificación de la disfunción de las glándulas de meibomio (DGM) basada 
en la estructura de las glándulas revelada por técnicas de imagen. 
 
Antes de decidirse a participar en este estudio, es importante que entienda por qué 
se realiza el estudio y lo que implicará. Por favor, tómese su tiempo para leer con 
detenimiento la siguiente información y pregunte al responsable del estudio si hay algo 
que no está claro o si desea más información.  
 
Este estudio cumple con la legislación vigente: Declaración de Helsinki, Convenio 
de Oviedo, Ley 274/2002 de autonomía del paciente, Ley orgánica de protección de datos 
15/1999 (consultar artículos sobre derechos de acceso, rectificación, cancelación y 
oposición explicados en el anexo de este documento) y Ley 14/2007 de investigación 
biomédica. 
 
 
Su participación en este estudio es totalmente voluntaria y puede decidir no 
participar o cambiar su decisión en cualquier momento, sin que por ello se produzca 
perjuicio alguno. Del mismo modo, puede esperar a consultar con otra profesional antes 
de tomar la decisión de participar en el estudio. La participación en el estudio no le 
supondrá coste alguno. No hay remuneración económica para usted ni para los 
investigadores. La recogida de datos para este estudio no implica ningún riesgo para 
usted. La información recogida será únicamente empleada para investigación clínica. 
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 Todos sus datos serán reconocidos mediante un código y sólo los investigadores 
podrán relacionar dichos datos con usted. Conforme a las disposiciones legales, usted 
tiene derecho a conocer los datos del estudio que sobre usted se recojan, a obtener una 
copia, y a conocer el uso que puedan darse a los mismos. Dicha información le será 
suministrada por el investigador. En el caso de que con los datos del estudio se realizará 
alguna publicación científica su identidad será totalmente confidencial. 
 
 
Si posteriormente desea hacer alguna pregunta o revocar el consentimiento, se pondrá 
en contacto con los investigadores:  
 
- Dr. David Madrid Costa      correo electrónico: damadrid@ucm.es  
- Laura Rico del Viejo           correo electrónico: larico@ucm.es  
 
 
 
DESCRIPCIÓN DEL ESTUDIO 
 
Los lípidos producidos por las glándulas de meibomio son el componente principal de 
la capa lipídica de la película lagrimal. Es sabido que la capa lipídica protege contra la 
evaporación de la fase acuosa, proporciona lubricación y también ayuda a estabilizar la 
película lagrimal. Por esta razón, los lípidos secretados por las glándulas de meibomio 
son esenciales para el mantenimiento de la superficie ocular[147].La disfunción de las 
glándulas de Meibomio (DGM) es la anomalía más común en la práctica 
oftalmológica[338] y la principal causa de ojo seco. En 2011, Tear Film and Ocular 
Surface Society (TFOS) definió la DGM como una anomalía crónica de las glándulas de 
meibomio que se caracteriza por la obstrucción del conducto terminal o cambios 
cualitativos o cuantitativos en la secreción glandular[158]. Esto puede resultar en una 
alteración de la película lagrimal, síntomas de irritación ocular, inflamación clínicamente 
aparente y enfermedad de la superficie ocular[158]. A pesar de que esta condición influye 
en la salud y en el bienestar de millones de personas, no existe un consenso general 
respecto a la definición, clasificación, diagnóstico o terapia de la DGM. Gran parte de este 
desconocimiento se debe a la ausencia de un método de observación clínico que sea 
práctico para el diagnóstico ocular. 
La Meibografía de no contacto es una tecnología reciente que proporciona la 
evaluación "in vivo" de la morfología de las glándulas y ha demostrado ser útil en el 
diagnóstico de la DGM[169,178] Esta tecnología utiliza luz infrarroja (IR) para trans-
iluminar el párpado y con la ayuda de una cámara CCD registra imágenes de las 
glándulas de meibomio de ambos párpados superior e inferior[157]. La pérdida de tejido 
glandular (comúnmente denominado dropout) se refiere a la pérdida parcial o total de las 
glándulas[166]. Esta pérdida aumenta con la edad en sujetos normales, pero no 
necesariamente debido a la presencia de DGM obstructiva[339]. Se ha postulado que la 
creciente evaporación de la capa acuosa de la película lagrimal está relacionada con la 
extensión de pérdida glandular existente[340]. 
 Otra tecnología utilizada para evaluar las glándulas de meibomio es la Microscopía 
Confocal Láser. Esta herramienta no invasiva permite obtener imágenes de alta 
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resolución de los tejidos vivos a nivel celular, proporcionando imágenes comparables a los 
métodos histoquímicos[341]. Particularmente aplicado a la observación de las glándulas, 
proporciona información sobre la densidad y el diámetro de los acinos, la reflectividad de 
la secreción, la inflamación periglandula y las características de orificio.  
 
Los cambios producidos en las distintas estructuras de las glándulas en pacientes de 
ojo seco y otras condiciones oculares han sido observados en varios estudios científicos 
con esta tecnología[89,198] 
 
OBJETIVO DEL ESTUDIO 
 
El objetivo de este estudio es la actualización de la clasificación de la DGM basada 
en la estructura de las glándulas de meibomio revelada por técnicas de imagen. Las 
tecnologías antes mencionadas se utilizarán para identificar los cambios en la estructura 
de las glándulas de meibomio que nos ayudan a predecir la evolución de esta disfunción.  
 
BENEFICIOS DEL ESTUDIO 
 
 La participación en este estudio puede aportar al voluntario información valiosa 
sobre el estado de su superficie ocular y la obtención de recomendaciones personalizadas 
por parte de los profesionales de la visión que trabajan en este proyecto para mejorar su 
salud ocular. La información que se obtendrá con este estudio será de gran relevancia 
para los médicos oftalmólogos ya que la clasificación que se pretende realizar ayudará al 
clínico a realizar un mejor diagnóstico de la disfunción de las glándulas de meibomio, 
siendo esta la anomalía más frecuente en las consultas de oftalmología de todo el mundo. 
 
DURACIÓN TOTAL DE SU PARTICIPACIÓN 
 
La duración esperada del estudio es de 1 día. 
 
LOS EXÁMENES CLÍNICOS  
 
Durante el estudio, el responsable del estudio le realizará una serie de exámenes 
que se describirán a continuación. Los exámenes que se realizarán en el marco del 
estudio serán de dos tipos: aquéllos que se basen en determinar su función ocular (como 
funciona su vista y que signos o síntomas presenta) y los exámenes relacionados con la 
observación y medida de la morfología de las glándulas de meibomio. 
Primero se realizará una anamnesis en profundidad a cada participante en la que 
se incluirán preguntas relevantes para el estudio y para los criterios de inclusión del 
mismo. A continuación se les realizará  un cuestionario subjetivo para cuantificar la 
posible sintomatología asociada con el ojo seco. 
 
Después de esta primera parte, se procederá a realizar toda la batería de exámenes 
clínicos.  
 
 
1º Evaluación de la sintomatología de ojo seco. 
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La evaluación de la sintomatología juega un papel fundamental en el diagnóstico clínico 
del ojo seco. Por este motivo, los participantes tendrán que rellenar varios cuestionarios 
sobre ojo seco validados para conocer la sintomatología en cada caso.  
 
 
2º Osmolaridad de la película lagrima. 
 
La evaluación de la osmolaridad lagrimal es especialmente importante ya que 
actualmente es posiblemente la medida objetiva más fiable para diagnosticar el ojo seco. 
Se procederá a la evaluación de la osmolaridad lagrimal de cada ojo del paciente 
utilizando un dispositivo para dicho propósito.  
 
 
3º Evaluación de la superficie ocular con el dispositivo Keratograph 5M. 
 
Conocer el estado de la integridad de la superficie ocular es importante a la hora de 
determinar la gravedad del ojo seco. Para ello, nuevos dispositivos han sido desarrollados 
para realizar una evaluación no invasiva de todos los componentes importantes de la 
superficie ocular. Se procederá a evaluar los parámetros de la superficie ocular con el 
Keratograph 5M, un topógrafo corneal avanzado.  
 
4º Evaluación de la temperatura de la superficie ocular mediante termografía infrarroja. 
 
La termografía infrarroja es una tecnología que ha cobrado mucha importancia en el 
campo de la oftalmología. Se procederá al registro de la temperatura ocular del 
participante mediante una cámara térmica infrarroja. Esta evaluación es no invasiva y se 
realizará en condiciones naturales de parpadeo del participante.  
 
5º Evaluación de las estructuras de las superficie ocular con lámpara de hendidura.  
 
Como se ha mencionado anteriormente, conocer el estado de la integridad de la superficie 
ocular es importante a la hora de determinar la gravedad del ojo seco. Por ello, la 
evaluación exhaustiva de las estructuras se realizará mediante lámpara de hendidura. 
También se procederá a aplicar fluoresceína y verde lisamina (tintes oculares) para 
evaluar el estado de los tejidos oculares sin ningún tipo de repercusión para la visión del 
participante. 
 
6º Evaluación de la morfología de las glándulas de meibomio mediante meibografía 
infrarroja. 
 
 
La integridad de las glándulas de meibomio es importante para mantener la homeostasis 
de la superficie ocular ya que de ellas dependen la producción de los lípidos que forman 
parte de la capa lipídica de la película lagrimal. Por este motivo, se procederá a realizar 
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meibografía de no contacto para la observación de la morfología de las glándulas de 
meibomio. También se graduarán con escalas subjetivas la expresibilidad de las 
glándulas, la calidad de la secreción y la tortuosidad que presentan las glándulas. 
 
 
7º Evaluación de la producción lagrimal mediante el test de Schirmer. 
 
La evaluación de la secreción lagrimal nos aporta información sobre la producción 
acuosa. 
Este test consisten en la inserción de una tira de papel en el borde temporal del párpado 
inferior. Tras su inserción, se deberá medir la longitud de tira o hilo mojada por la película 
lagrimal en un determinado periodo de tiempo.  
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ANEXO 
 
Ley orgánica de protección de datos 15/1999: 
 
• Artículo 15: Derechos de acceso 
 
1. El interesado tendrá derecho a solicitar y obtener gratuitamente información de sus datos de 
carácter personal sometidos a tratamiento, el origen de dichos datos, así como las comunicaciones 
realizadas o que se prevén hacer de los mismos. 
2. La información podrá obtenerse mediante la mera consulta de los datos por medio de su 
visualización, o la indicación de los datos que son objeto de tratamiento mediante escrito, copia, 
telecopia o fotocopia, certificada o no, en forma legible e inteligible, sin utilizar claves o códigos que 
requieran el uso de dispositivos mecánicos específicos. 
3. El derecho de acceso a que se refiere este artículo sólo podrá ser ejercitado a intervalos no 
inferiores a doce meses, salvo que el interesado acredite un interés legítimo al efecto, en cuyo caso 
podrán ejercitarlo antes. 
• Artículo 16: Derecho de rectificación y cancelación 
1. El responsable del tratamiento tendrá la obligación de hacer efectivo el derecho de rectificación o 
cancelación del interesado en el plazo de diez días. 
2. Serán rectificados o cancelados, en su caso, los datos de carácter personal cuyo tratamiento no 
se ajuste a lo dispuesto en la presente Ley y, en particular, cuando tales datos resulten inexactos o 
incompletos. 
3. La cancelación dará lugar al bloqueo de los datos, conservándose únicamente a disposición de 
las Administraciones públicas, Jueces y Tribunales, para la atención de las posibles 
responsabilidades nacidas del tratamiento, durante el plazo de prescripción de éstas. Cumplido el 
citado plazo deberá procederse a la supresión. 
4. Si los datos rectificados o cancelados hubieran sido comunicados previamente, el responsable 
del tratamiento deberá notificar la rectificación o cancelación efectuada a quien se hayan 
comunicado, en el caso de que se mantenga el tratamiento por este último, que deberá también 
proceder a la cancelación. 
5. Los datos de carácter personal deberán ser conservados durante los plazos previstos en las 
disposiciones aplicables o, en su caso, en las relaciones contractuales entre la persona o entidad 
responsable del tratamiento y el interesado. 
Artículo 17: Procedimiento de oposición, acceso, rectificación o cancelación 
1. Los procedimientos para ejercitar el derecho de oposición, acceso, así como los de rectificación y 
cancelación serán establecidos reglamentariamente. 
2. No se exigirá contra prestación alguna por el ejercicio de los derechos de oposición, acceso, 
rectificación o cancelación. 
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CONSENTIMIENTO INFORMADO 
(COPIA PARA INVESTIGADOR) 
 
Código de identificación del paciente: ________________ 
 
 
 
 
 
 
 
 
 
I
n
t
r
o
d
u
z
ca sus iniciales en los recuadros ↓ 
 
1. Confirmo que he leído y entendido la información del presente estudio dada el día ………………… 
y que he tenido oportunidad de realizar preguntas sobre el mismo.     
 
2. Comprendo que mi participación en el estudio es voluntaria y que este no niega la necesidad de  
un examen ocular periódico.  
 
3. Comprendo que puedo retirarme del estudio cuando quiera y sin repercusión a mis derechos legales.  
 
4. Presto libremente mi conformidad para participar en el estudio. 
 
________________________ ________________ ____________________ 
Nombre del participante Fecha Firma 
 
_________________________ ________________ ____________________ 
Nombre del investigador Fecha Firma 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Título del Estudio: “Evaluación de la estructura de las glándulas de meibomio mediante tecnología infrarroja” 
 
INVESTIGADORES David Madrid Costa1 
Laura Rico del Viejo1 
José Manuel Benítez del Castillo2 
1.Departamento de  Óptica II: Optometría y Visión, Facultad de Óptica y Optometría, UCM 
2. Unidad de Superficie Ocular (Oftalmología) del Hospital Universitario Clínico San Carlos, 
Madrid. 
 
 
LOCALIZACIÓN DEL 
ESTUDIO 
Facultad de Óptica y Optometría 
Calle  Arcos de Jalón Nº 118 
CP 28037 MADRID 
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CONSENTIMIENTO INFORMADO 
(COPIA PARA PARTICIPANTE) 
 
Código de identificación del paciente: ________________ 
 
 
 
 
Título del Estudio: “Evaluación de la estructura de las glándulas de meibomio mediante tecnología infrarroja” 
 
INVESTIGADORES David Madrid Costa1 
Laura Rico del Viejo1 
José Manuel Benítez del Castillo2 
1.Departamento de  Óptica II: Optometría y Visión, Facultad de Óptica y Optometría, UCM 
2. Unidad de Superficie Ocular (Oftalmología) del Hospital Universitario Clínico San Carlos, 
Madrid. 
 
LOCALIZACIÓN DEL 
ESTUDIO 
Facultad de Óptica y Optometría 
Calle  Arcos de Jalón Nº 118 
CP 28037 MADRID 
 
 
 
      Introduzca sus iniciales en los recuadros ↓ 
 
1. Confirmo que he leído y entendido la información del presente estudio dada el día ………………… 
y que he tenido oportunidad de realizar preguntas sobre el mismo.     
 
2. Comprendo que mi participación en el estudio es voluntaria y que este no niega la necesidad de  
un examen ocular periódico.  
 
3. Comprendo que puedo retirarme del estudio cuando quiera y sin repercusión a mis derechos legales.  
 
4. Presto libremente mi conformidad para participar en el estudio. 
 
________________________ ________________ ____________________ 
Nombre del participante Fecha Firma 
 
_________________________ ________________ ____________________ 
Nombre del investigador Fecha Firma 
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3. CLINICAL SHEET 
 
 
Ficha Clínica 
 
 
Fecha:  
Hora:                                                                                                                 Paciente: 
 
Nombre y Apellidos: ______________________________________________ 
Sexo: M F  
Fecha de nacimiento:_________________________________ Edad: _______ 
 
Profesión: ________________________________________________________ 
 
Ø ¿Consentimiento informado?   Si       
 
Anamnesis 
Salud general (tache lo que proceda) 
 
1. Tiene o ha padecido:  
o anemia, o  diabetes, o infecciones frecuentes de oído o garganta, o sinusitis, o artritis, o reumatismo, 
o trastorno de la tiroides, o hipertensión arterial,  o enfermedades de la piel,  o enfermedades del 
colágeno, o asma, o bronquitis, oenfisema 
2. ¿Es fumador? SIo    NOo      Número de cigarrillos al día: ____  
3. ¿Padece alguna alergia?    oSI   oNO     ¿Cuál?____________ 
4. ¿Toma normalmente o está tomando alguna medicación? (aunque no sea para los ojos)  
oSI   oNO    ¿Cuál?            ¿Para qué?  ¿Desde cuándo? 
5. ¿Usa lágrimas artificiales?  oSI   oNO    ¿Cuántas veces al día? ____ 
   ¿A qué hora se ha puesto la última gota? _____ 
6. Si es mujer, ¿está tomando anticonceptivos orales? oSI   oNO 
                           ¿Desde cuándo? _______ 
7. ¿Está embarazada? oSI   oNO    
 
Historial Visual 
8. ¿A qué edad empezó a usar gafas/ LC?    Última revisión: 
9. ¿Ha tenido o tiene alguno de los siguientes procesos oculares? (tache lo que proceda) 
  
 
 
                                                     Ojo Derecho                  Ojo Izquierdo    ¿Hace cuánto tiempo? 
 186 
 
Ojo vago o o ........................ 
Estrabismo o o ........................ 
Enfermedad de retina o o ........................ 
Úlcera corneal o o ........................ 
Conjuntivitis frecuentes o o ........................ 
Defecto epitelial recurrente o o ........................ 
Queratocono o o ........................ 
Ojo seco severo o o ........................ 
Enfermedad superficie ocular o o ........................ 
Glaucoma o o ........................ 
Cataratas o o ........................ 
Cirugía ocular (especificar) o o ........................ 
Otros (especificar) o o ........................ 
 
10. ¿Alguien de su familia ha tenido alguno de los procesos oculares anteriormente descritos? (especificar) 
 
 
 
 
 
 
Tratamientos ( pasados y presentes) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Información adicional a tener en cuenta: 
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Pruebas Clínicas  
 
 
v Osmolaridad de la película lagrimal  
 
 
OD   OI    
 
 
Ojo escogido:  OD    /      OI       Motivo:   
 
 
v Parámetros del Keratograph  
 
Altura del menisco lagrimal (x3) 
 
1.  .    mm    
2.  .    mm    
3.  .    mm    
 
Enrojecimiento ocular (x3)     
 
                                     Bulbar  
 
 
 
 
1.   Temporal .   Nasal  .      
                       Limbal        
Temporal  .      Nasal   .  
 
                       Bulbar 
 
2.   Temporal .   Nasal  .      
                         Limbal        
  Temporal  .      Nasal   .  
 
                       Bulbar 
 
3.   Temporal .   Nasal  .      
                         Limbal        
  Temporal  .      Nasal   .  
 
 
Capa lipídica (vídeo) (x1)      
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Viscosidad de la película lagrimal (vídeo) (x1)  
 
NIKBUT (x3) 
 
FR: 
 
1)  .      2)  .     3)  .        
 
 
AVG: 
 
 
1)  .      2)  .     3)  .        
 
 
 
v Evaluación de la temperatura de la superficie ocular 
 
Ø Párpados  
Ø Córnea y Conjuntiva 
Ø Dinámica de la película lagrimal (registro de 40 segundos -parpadeo normal) 
 
 
v Evaluación de la superficie ocular (Lámpara de Hendidura) 
 
 
- CÓRNEA, CONJUNTIVA y PÁRPADOS (Luz Difusa) (Evaluación General) 
 
Observaciones:_____________________________________________________________
__________________________________________________________________________
__________________________________________________________________________ 
 
 
- PÁRPADOS  
 
Borde del párpado 
 
Grosor del borde libre 0-5                                                       _______ 
Irregularidad del margen  0-1                                                  _______ 
Telangiectasias 0-1                                                                  _______ 
Distiquiasis  0-1                                                                       _______ 
Madarosis 0-1                                                                           _______ 
Malposición 0-1                                                                       _______ 
Unión cutaneomucosa (línea de Marx): posicionamiento posterior  
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(0-3)                                                                                      _________ 
 
Orificios glandulares 
 
Pouting: sobreelevación del orificio  0-1                                     _____ 
Capping: cúpula grasa queratinizada sobre el orificio 0-1          ______ 
Pérdida de definición de bordes  0-1                                            ______ 
Invasión vascular 0-1                                                                    ______ 
Estrechamiento del orificio 0-1                                                    ______ 
Posicionamiento posterior a la línea de Marx   0-1                      ______ 
Acinos glandulares 
 
Facilidad de visualización  0-3                                                      ______ 
Dilataciones quísticas  0-3                                                             ______ 
Concreciones   0-3                                                                         ______ 
Chalazión  0-3                                                                               _______ 
 Secreción 
 
Espumosa  0-1                                                                               ______ 
Volumen 
 Calidad 0-3                                                                     _______ 
Facilidad de expresión   0-3                                                       _______ 
Ausencia de secreción  0-1                                                        _______ 
 
 
Observaciones:___________________________________________________________________
________________________________________________________________________________
______________________________________________________________________________ 
 
 
 
-  TINCIÓN CORNEAL  (Fluoresceína)  
• Escala OXFORD  
(Evaluar tinción a los 2 minutos de la instilación de fluoresceína) 
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*Hacemos TBUT durante ese tiempo 
 
 
 
 (Escala Oxford)  
OD  0    1   2  3   4 
OI  0    1   2  3   4 
• TBUT  
1. ________s 
2. ________s 
3. ________s 
 
Observaciones: 
__________________________________________________________________________
__________________________________________________________________________
__________________________________________________________________________ 
 
*REGISTRO EN FOTOS (KERATOGRAPH) DE FLUORESCEÍNA ( POSICIÓN 
PRIMARIA DE MIRADA, OTRAS POSICIONES Y BORDE PÁRPADO INFERIOR) 
 
 
 
- TINCIÓN VERDE LISAMINA  
Escala OXFORD 
 
 
 
(Escala Oxford)  
OD  0    1   2  3   4 
OI  0    1   2  3   4 
 
Observaciones: 
________________________________________________________________________________
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________________________________________________________________________________
_____________________________________________________ 
 
*REGISTRO EN FOTOS (KERATOGRAPH) VERDE LISAMINA ( POSICIÓN 
PRIMARIA DE MIRADA, OTRAS POSICIONES Y LID WIPER SUPERIOR E 
INFERIOR) 
 
ü Limpiados el ojo con solución salina. 
 
*Esperamos 10 minutos para dejar recuperar ( Tiempo para cuestionarios subjetivos 
en el caso de que no se hayan completado anteriormente). 
 
 
v Meibografía Infrarroja 
 
 
Párpado superior                          Párpado inferior  
 
DROPOUT (0-3): __________ 
 
 Observaciones:_______________________________________________________________ 
 
 
 
v Test de Schirmer ( 5 minutos con anestésico tópico).       oSI            oNO 
 
Volumen: _________________________ 
 
Observaciones:__________________________________________________________
__________________________________________________________________________ 
 
 
: The Ocular-surface-disease-index (OSDI)[72], Mcmonnies (MQ)[83], the standard patient 
evaluation of eye dryness (SPEED)[82], the Symptom Assessment in Dry Eye (SANDE)[76] and the 
Dry Eye Questionnaire (DEQ-5; short version)[78]. 
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4. DED QUESTIONNAIRES 
 
 
1. The Ocular Surface Disease Index (OSDI) 
 
 
 
 
 
 
 
 
 
 
 
OCULAR SURFACE DISEASE INDEXâ 
 
El Test OSDI (ocular surface disease index) es un test sencillo creado para establecer una 
gravedad y clasificación del ojo seco según su sintomatología. 
 
 
Apellidos y Nombre: ___________________________, _________________ 
 
Fecha: _____/_____/_______         Código y Grupo:______________ 
 
Conteste a las siguientes preguntas marcando la casilla que mejor represente su respuesta.  
¿Ha experimentado alguna de las siguientes alteraciones durante la última 
semana? 
 En todo 
momento 
Casi en 
todo 
momento 
El 50% 
del 
tiempo 
Casi en 
ningún 
momento 
En ningún 
momento 
1. Sensibilidad a la 
luz 
     
2. Sensación de 
arenilla en los ojos 
     
3. Dolor de ojos      
4. Visión borrosa      
5. Mala visión      
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¿Ha tenido problemas en los ojos que le han limitado o impedido realizar alguna 
de las siguientes actividades durante la última semana? 
 
 
 
¿Ha sentido incomodidad en los ojos en alguna de las siguientes situaciones 
durante la última semana? 
 
 
 
 
 
 
 
 En todo 
momento 
Casi en 
todo 
momento 
El 50% 
del 
tiempo 
Casi en 
ningún 
momento 
En 
ningún 
momento 
 
N/A 
6. Leer       
7. Conducir de 
noche  
      
8. Trabajar con un 
ordenador o 
utilizar un 
cajero 
automático  
      
9. Ver la televisión       
 En todo 
momento 
Casi en 
todo 
momento 
El 50% 
del 
tiempo 
Casi en 
ningún 
momento 
En 
ningún 
momento 
 
N/A 
10. Viento       
11. Lugares con baja 
humedad (muy 
secos) 
      
12. Zonas con aire 
acondicionado 
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2. Symptom Assessment in Dry Eye 
(SANDE) 
 
 
 
 
 
 
 
 
                                 
 
 
CUESTIONARIO SANDE 
 
Por favor, complete las siguientes preguntas sobre la frecuencia y la severidad de los síntomas 
del ojo seco: 
 
1. FRECUENCIA de los síntomas: 
 
Por favor, coloque una X sobre la línea indicando como es de frecuente, en promedio, siente 
sus ojos secos y/o irritados:  
 
 
 
         ________________________________________________ 
 
            Raramente                                                                             Todo el tiempo 
 
 
 
2. SEVERIDAD de los síntomas: 
 
Por favor, coloque una X sobre la línea indicando como es de severo, en promedio, los 
síntomas de sequedad y/o irritación:  
 
 
 
         ________________________________________________ 
 
             Muy suave                                                                                 Muy severo 
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3. Standard Patient Evaluation of Eye Dryness (SPEED) 
 
 
 
 
 
 
CUESTIONARIO SPEED II 
Apellidos y Nombre: ___________________________, _________________ 
Fecha: _____/_____/_______ Fecha de nacimiento: ______/______/_______  
Código y Grupo:____________________ 
 
El síndrome de ojo seco es la razón más frecuente por la que los pacientes visitan 
al oftalmólogo. Por lo tanto, pedimos que se tome un momento y complete 
cuidadosamente el siguiente cuestionario: 
 
Indique la FRECUENCIA de los síntomas que usted experimenta marcando nunca, a veces, a 
menudo o constante a continuación: 
 
0 = Nunca , 1 = A veces , 2 = A menudo , 3 = Constante 
 
Síntomas 0 1 2 3 
Sequedad, Sensación de arenilla o 
Picazón 
    
Dolor o Irritación     
Ardor y Lagrimeo     
Fatiga Ocular     
 
 
Indique la SEVERIDAD de los síntomas que usted experimenta usando la lista que se presenta a 
continuación: 
 
0= No tengo problemas 
1= Tolerable- No es perfecto pero no resulta incómodo 
2= Incómodo- Es irritante pero no interfiere en mi día a día 
3= Molesto- Es irritante e interfiere en mi día a día 
4= Intolerable- Incapaz de realizar mis tareas diarias 
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Síntomas 0 1 2 3 4 
Sequedad, Sensación de arenilla o 
Picazón 
     
Dolor o Irritación      
Ardor y Lagrimeo      
Fatiga Ocular      
 
 
Por favor, marque con una X si ha experimentado estos síntomas: 
 
1. Hoy_____ 
2. En las últimas 72 horas_____ 
3. En los pasados 3 meses_____ 
 
 
Ø ¿Utiliza lágrimas artificiales o pomada?            SI / NO 
 
En caso afirmativo, ¿Cual utiliza?___________________________ 
 
Ø ¿Le han dicho que tiene blefaritis o ha sido tratado por un orzuelo? 
 Blefaritis:    SI/NO 
 Orzuelo:      SI/NO 
 
Ø ¿Ha experimentado fluctuación de la visión? (Que puede mejorar con el parpadeo) 
 
1. Nunca_____ 
2. A veces____ 
3. Frecuentemente____ 
4. Mucho/Siempre_____ 
 
 
 
 
 
Puntuación Total (Frecuencia + Severidad) =_______ 
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4. McMonnies (MQ) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cuestionario de evaluación de ojo seco de McMonnies 
Apellidos y Nombre: ___________________________, _________________ 
 
Fecha: _____/_____/_______         Código y Grupo:______________ 
 
Responda a las siguientes preguntas subrayando las respuestas que le parezcan más 
apropiadas:  
Mujer / Hombre. 
Edad: menos de 25 años / 25–45 años / más de 45 años.  
Actualmente: no llevo lentes de contacto / lentes de contacto rígidas / lentes de contacto blandas.  
1. ¿Le han recetado alguna vez un colirio u otro tratamiento para ojo seco?  
Sí / No / No lo sé 
2. ¿En algún momento ha experimentado alguno de los siguientes síntomas oculares? (subraye 
los que se le apliquen).  
Dolor / Picor / Sequedad / Arenilla / Escozor 	 
3. ¿Con qué frecuencia experimenta estos síntomas? (subrayar) 
 Nunca / A veces / A menudo/  Constantemente  
4. ¿Son sus ojos inusitadamente sensibles al humo del tabaco, la contaminación, el aire 
acondicionado o la calefacción central?  
 Sí / No / A veces 
5. ¿Sus ojos se ponen muy rojos e irritados al nadar? 
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 No aplicable / Sí  / No / A veces	 
6. ¿Se le secan e irritan los ojos después de beber alcohol? 
 No aplicable / Sí / No / A veces  	 
7. ¿Toma (subraye, por favor) comprimidos de antihistamínicos o utiliza colirio antihistamínico, 
diuréticos (comprimidos fluidos), píldoras para dormir, tranquilizantes, anticonceptivos 
orales, medicación para la úlcera duodenal, problemas digestivos, alta tensión , 
antidepresivos o ...?  
(escriba cualquier medicación que esté tomando y no aparezca en la lista). 	
 
8. ¿Padece artritis?  Sí / No / No lo sé 	 
9. ¿Experimenta sequedad de nariz, boca, garganta, pecho o vagina?  Nunca / A veces / A 
menudo / Constantemente 
10. ¿Padece alteraciones tiroideas? Sí / No / No lo sé  
11. ¿Sabe que duerme con los ojos parcialmente abiertos?  Sí  / No / A veces 	 
12. ¿Se levanta con los ojos irritados después de dormir?  Sí / No  / A veces  

Puntuaciones: Normal (< 10) Ojo seco marginal (10–20) Ojo seco patológico (>20) 	 
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5. Dry Eye Questionnaire (DEQ-5; short version) 
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5. PERSONAL IMAGES PERMISSIONS 
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Yo, Alejandro Martinez Aguila, con DNI 46888086X, autorizo a Laura Rico del Viejo para usar en 
su tesis doctoral las fotos obtenidas durante las pruebas que me realizaron. 
Y para que conste, firmo la presente 
Madrid, a 17 de octubre de 2018 
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Permiso para uso de imagenes 
Yo, IRENE MARTINEZ ALBERQUILLA , con DNI 53990797E doy permiso a 
LAURA RICO DEL VIEJO , con DNI 80063778L para utilizar las imagenes en su tesis 
doctoral, siendo solo para uso privado y academico. 
Firmado, 
Fecha: 17/10/2018 
 203 
 
6. DESCRIPTION OF THE METHODOLOGY TO OBTAIN THE MG MORPHOLOGY 
PARAMETERS BY THE AUTOMATIC ALGORITHM 
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